0000908259 2025-01-01 2025-09-30 0000908259 dei:BusinessContactMember 2025-01-01 2025-09-30 0000908259 2025-09-30 0000908259 2024-12-31 0000908259 us-gaap:RelatedPartyMember 2025-09-30 0000908259 us-gaap:RelatedPartyMember 2024-12-31 0000908259 us-gaap:NonrelatedPartyMember 2025-09-30 0000908259 us-gaap:NonrelatedPartyMember 2024-12-31 0000908259 2023-12-31 0000908259 us-gaap:RelatedPartyMember 2023-12-31 0000908259 us-gaap:NonrelatedPartyMember 2023-12-31 0000908259 us-gaap:ServiceMember 2025-07-01 2025-09-30 0000908259 us-gaap:ServiceMember 2024-07-01 2024-09-30 0000908259 us-gaap:ServiceMember 2025-01-01 2025-09-30 0000908259 us-gaap:ServiceMember 2024-01-01 2024-09-30 0000908259 2025-07-01 2025-09-30 0000908259 2024-07-01 2024-09-30 0000908259 2024-01-01 2024-09-30 0000908259 us-gaap:ServiceMember 2024-01-01 2024-12-31 0000908259 us-gaap:ServiceMember 2023-01-01 2023-12-31 0000908259 2024-01-01 2024-12-31 0000908259 2023-01-01 2023-12-31 0000908259 us-gaap:PreferredStockMember 2024-12-31 0000908259 us-gaap:CommonStockMember 2024-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000908259 us-gaap:RetainedEarningsMember 2024-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2024-12-31 0000908259 us-gaap:PreferredStockMember 2025-03-31 0000908259 us-gaap:CommonStockMember 2025-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000908259 us-gaap:RetainedEarningsMember 2025-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-03-31 0000908259 2025-03-31 0000908259 us-gaap:PreferredStockMember 2025-06-30 0000908259 us-gaap:CommonStockMember 2025-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000908259 us-gaap:RetainedEarningsMember 2025-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-06-30 0000908259 2025-06-30 0000908259 us-gaap:PreferredStockMember 2023-12-31 0000908259 us-gaap:CommonStockMember 2023-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000908259 us-gaap:RetainedEarningsMember 2023-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2023-12-31 0000908259 us-gaap:PreferredStockMember 2024-03-31 0000908259 us-gaap:CommonStockMember 2024-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000908259 us-gaap:RetainedEarningsMember 2024-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2024-03-31 0000908259 2024-03-31 0000908259 us-gaap:PreferredStockMember 2024-06-30 0000908259 us-gaap:CommonStockMember 2024-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000908259 us-gaap:RetainedEarningsMember 2024-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2024-06-30 0000908259 2024-06-30 0000908259 us-gaap:PreferredStockMember 2022-12-31 0000908259 us-gaap:CommonStockMember 2022-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000908259 us-gaap:RetainedEarningsMember 2022-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2022-12-31 0000908259 2022-12-31 0000908259 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0000908259 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000908259 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0000908259 2025-01-01 2025-03-31 0000908259 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0000908259 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000908259 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000908259 2025-04-01 2025-06-30 0000908259 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0000908259 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000908259 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0000908259 us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0000908259 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000908259 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000908259 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000908259 2024-01-01 2024-03-31 0000908259 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000908259 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000908259 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000908259 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0000908259 2024-04-01 2024-06-30 0000908259 us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0000908259 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000908259 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0000908259 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0000908259 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0000908259 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0000908259 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0000908259 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000908259 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000908259 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000908259 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0000908259 us-gaap:PreferredStockMember 2025-09-30 0000908259 us-gaap:CommonStockMember 2025-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000908259 us-gaap:RetainedEarningsMember 2025-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2025-09-30 0000908259 us-gaap:PreferredStockMember 2024-09-30 0000908259 us-gaap:CommonStockMember 2024-09-30 0000908259 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000908259 us-gaap:RetainedEarningsMember 2024-09-30 0000908259 us-gaap:NoncontrollingInterestMember 2024-09-30 0000908259 2024-09-30 0000908259 OTLC:GMPBioMember 2025-09-30 0000908259 OTLC:GMPBioMember 2025-01-01 2025-09-30 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2024-01-01 2024-01-31 0000908259 OTLC:EquityPurchaseAgreementMember OTLC:PeakOneOpportunityFundLPMember 2021-05-01 2021-05-31 0000908259 OTLC:EquityPurchaseAgreementMember OTLC:PeakOneOpportunityFundLPMember 2021-05-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2022-03-31 0000908259 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2022-05-31 0000908259 us-gaap:CommonStockMember OTLC:SecuritiesPurchaseAgreementMember 2025-01-01 2025-09-30 0000908259 OTLC:SecuritiesPurchaseAgreementMember 2022-06-30 0000908259 OTLC:SecuritiesPurchaseAgreementMember 2024-01-01 2024-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember 2025-07-31 0000908259 OTLC:IndependentContractorAgreementMember 2025-08-06 0000908259 OTLC:IndependentContractorAgreementMember 2025-08-06 2025-08-06 0000908259 us-gaap:CommonStockMember OTLC:IndependentContractorAgreementMember 2025-08-06 2025-08-06 0000908259 OTLC:SecuritiesPurchaseAgreementAndPurchaseAgreementMember OTLC:GoldenMountainPartnersMember 2022-01-31 0000908259 OTLC:SinceInceptionDateMember 2025-01-01 2025-09-30 0000908259 OTLC:PointRMergerAgreementMember 2025-09-30 0000908259 OTLC:AutotelicIncMember 2025-01-01 2025-09-30 0000908259 OTLC:AutotelicIncMember 2025-09-30 0000908259 OTLC:AmitShahMember 2025-09-30 0000908259 OTLC:SupplementalAgreementMember OTLC:GoldenMountainPartnersLLCMember 2024-01-01 2024-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2023-09-01 2023-09-30 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2023-10-01 2023-10-31 0000908259 OTLC:AdditionallyAccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2024-01-01 2024-01-31 0000908259 OTLC:OncotelicWarrantMember 2022-02-28 0000908259 2022-01-01 2022-12-31 0000908259 us-gaap:WarrantMember 2024-03-31 0000908259 OTLC:NotePurchaseAgreementsMember OTLC:AutotelicIncMember 2021-08-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2021-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2021-12-01 2021-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementsMember 2022-06-01 2022-06-30 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FourthManLLCMember 2023-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember OTLC:FourthManLLCMember 2023-01-01 2023-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember 2022-06-01 2022-06-30 0000908259 OTLC:SecuritiesPurchaseAgreementAndPurchaseAgreementMember OTLC:GoldenMountainPartnersMember 2020-06-30 0000908259 OTLC:MosaicImmunoEngineeringIncMember 2024-04-01 2024-04-30 0000908259 OTLC:SinceInceptionDateMember 2024-01-01 2024-12-31 0000908259 OTLC:PointRMergerAgreementMember 2024-12-31 0000908259 OTLC:AutotelicIncMember 2024-01-01 2024-12-31 0000908259 OTLC:VuongTrieuMember 2024-01-01 2024-12-31 0000908259 us-gaap:FairValueInputsLevel3Member OTLC:PointRMember 2024-01-01 2024-12-31 0000908259 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2024-12-31 0000908259 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2023-12-31 0000908259 us-gaap:AccountingStandardsUpdate202006Member 2024-12-31 0000908259 OTLC:GMPBioMember 2025-09-30 0000908259 OTLC:GMPBioMember 2025-01-01 2025-09-30 0000908259 OTLC:GMPBioMember 2024-12-31 0000908259 OTLC:GMPBioMember 2024-01-01 2024-12-31 0000908259 OTLC:GMPBioMember 2023-12-31 0000908259 OTLC:GMPBioMember 2023-01-01 2023-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2025-09-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2025-09-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2024-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2024-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember 2025-01-01 2025-09-30 0000908259 us-gaap:MeasurementInputExpectedTermMember 2024-01-01 2024-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0000908259 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0000908259 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2025-09-30 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2024-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputSharePriceMember 2023-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember 2023-01-01 2023-12-31 0000908259 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000908259 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0000908259 us-gaap:MeasurementInputExpectedDividendRateMember 2023-12-31 0000908259 OTLC:MergerAgreementMember 2019-04-30 0000908259 OTLC:MergerAgreementMember 2019-04-01 2019-04-30 0000908259 OTLC:PointRMember OTLC:MergerAgreementMember 2019-11-30 0000908259 OTLC:PointRMember OTLC:MergerAgreementMember 2022-01-01 2022-12-31 0000908259 us-gaap:InProcessResearchAndDevelopmentMember 2024-12-31 0000908259 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember 2025-09-30 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember 2024-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember 2025-09-30 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember 2024-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember 2025-09-30 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember 2024-12-31 0000908259 OTLC:ConvertibleDebenturesMember 2025-09-30 0000908259 OTLC:ConvertibleDebenturesMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableStephenBoeschMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableStephenBoeschMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableRelatedPartyMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableRelatedPartyMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2024-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember 2025-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember 2024-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteBridgeInvestorsMember 2025-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteBridgeInvestorsMember 2024-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember 2025-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember 2024-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2025-09-30 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2024-12-31 0000908259 OTLC:MarchTwentyTwentyTwoNotesMember OTLC:SixteenPercentConvertibleNoteAccreditedInvestorsMember 2025-09-30 0000908259 OTLC:MarchTwentyTwentyTwoNotesMember OTLC:SixteenPercentConvertibleNoteAccreditedInvestorsMember 2024-12-31 0000908259 OTLC:DebtClinicalTrialsGMPMember OTLC:TwoPercentageConvertibleNotesForeverProsperityMember 2025-09-30 0000908259 OTLC:DebtClinicalTrialsGMPMember OTLC:TwoPercentageConvertibleNotesForeverProsperityMember 2024-12-31 0000908259 OTLC:MayAndJuneTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2025-09-30 0000908259 OTLC:MayAndJuneTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2024-12-31 0000908259 OTLC:JulyTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2025-09-30 0000908259 OTLC:JulyTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2024-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2025-09-30 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2024-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SixteenPercentageConvertibleNotesCEORelatedPartyMember 2025-09-30 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SixteenPercentageConvertibleNotesCEORelatedPartyMember 2024-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember 2025-09-30 0000908259 OTLC:JHDarbiePPMTwoDebtMember 2024-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtBridgeInvestorsMember 2025-09-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtBridgeInvestorsMember 2024-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCFOMember 2025-09-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCFOMember 2024-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAutotelicIncRelatedPartyMember 2025-09-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAutotelicIncRelatedPartyMember 2024-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCEOMember 2025-09-30 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCEOMember 2024-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember 2023-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember 2023-12-31 0000908259 OTLC:ConvertibleDebenturesMember OTLC:TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember 2023-12-31 0000908259 OTLC:ConvertibleDebenturesMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableStephenBoeschMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableRelatedPartyMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableDrSanjayJhaMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:FivePercentConvertibleNotePayableBridgeInvestorsMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember 2023-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteAutotelicIncRelatedPartyMember 2023-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteBridgeInvestorsMember 2023-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember OTLC:FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember 2023-12-31 0000908259 OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2023-12-31 0000908259 OTLC:JHDarbiePPMDebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2024-12-31 0000908259 OTLC:JHDarbiePPMDebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2023-12-31 0000908259 OTLC:JHDarbiePPMDebtMember 2024-12-31 0000908259 OTLC:JHDarbiePPMDebtMember 2023-12-31 0000908259 OTLC:NovemberDecemberTwoThousandTwentyOneAndMarchTwoThousandTwentyTwoNotesMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2024-12-31 0000908259 OTLC:NovemberDecemberTwoThousandTwentyOneAndMarchTwoThousandTwentyTwoNotesMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2023-12-31 0000908259 OTLC:DebtClinicalTrialsGMPMember OTLC:TwoPercentageConvertibleNotesForeverProsperityMember 2023-12-31 0000908259 OTLC:MayAndJuneTwoThousandTwentyTwoNoteMember OTLC:SixteenPercentageConvertibleNotesAccreditedInvestorsMember 2023-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2023-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember OTLC:SixteenPercentageConvertibleNotesCEORelatedPartyMember 2023-12-31 0000908259 OTLC:JHDarbiePPMTwoDebtMember 2023-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtBridgeInvestorsMember 2023-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCFOMember 2023-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtAutotelicIncRelatedPartyMember 2023-12-31 0000908259 OTLC:OtherDebtMember OTLC:ShortTermDebtFromCEOMember 2023-12-31 0000908259 OTLC:JHDarbiePPM2DebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2024-12-31 0000908259 OTLC:JHDarbiePPM2DebtMember OTLC:SixteenPercentageConvertibleNotesNonRelatedPartiesMember 2023-12-31 0000908259 OTLC:JHDarbiePPM2DebtMember OTLC:SixteenPercentageConvertibleNotesCEORelatedPartyMember 2024-12-31 0000908259 OTLC:JHDarbiePPM2DebtMember OTLC:SixteenPercentageConvertibleNotesCEORelatedPartyMember 2023-12-31 0000908259 OTLC:JHDarbiePPM2DebtMember 2024-12-31 0000908259 OTLC:JHDarbiePPM2DebtMember 2023-12-31 0000908259 OTLC:BridgeInvestorMember OTLC:ConvertibleDebenturesMember 2025-09-30 0000908259 OTLC:ConvertibleDebenturesMember 2025-09-30 0000908259 OTLC:ConvertibleDebenturesMember 2024-12-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:FallTwoThousandNineteenDebtFinancingMember 2019-12-01 2019-12-31 0000908259 OTLC:FallTwoThousandNineteenDebtFinancingMember 2019-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-01 2019-12-31 0000908259 OTLC:DrSanjayJhaMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:DrVuongTrieuMember OTLC:FallTwoThousandNineteenNotesMember us-gaap:RelatedPartyMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:ChulhoParkMember OTLC:FallTwoThousandNineteenNotesMember us-gaap:RelatedPartyMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:AmitShahMember OTLC:FallTwoThousandNineteenNotesMember us-gaap:RelatedPartyMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:TwoAccreditedInvestorsMember OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2019-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2025-01-01 2025-09-30 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2024-01-01 2024-09-30 0000908259 OTLC:GMPNoteMember 2020-06-30 0000908259 OTLC:GMPNoteTwoMember 2021-09-30 0000908259 OTLC:ConvertiblePromissoryNoteMember OTLC:OctoberPurchaseAgreementMember 2021-10-31 0000908259 OTLC:ConvertiblePromissoryNoteMember OTLC:JanuaryPurchaseAgreementMember 2021-10-31 0000908259 OTLC:UnsecuredConvertibleNotePurchaseAgreementsMember 2022-01-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-09-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2024-12-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2025-01-01 2025-09-30 0000908259 OTLC:GoldenMountainPartnersLLCMember 2024-01-01 2024-09-30 0000908259 OTLC:NotePurchaseAgreementMember 2021-08-31 0000908259 OTLC:NotePurchaseAgreementMember 2021-08-01 2021-08-31 0000908259 OTLC:NotePurchaseAgreementMember 2025-07-01 2025-09-30 0000908259 OTLC:NotePurchaseAgreementMember 2025-01-01 2025-09-30 0000908259 OTLC:AugustTwoThousandTwentyOneInvestorsNotesMember us-gaap:RelatedPartyMember 2024-07-01 2024-09-30 0000908259 OTLC:AugustTwoThousandTwentyOneInvestorsNotesMember us-gaap:RelatedPartyMember 2024-01-01 2024-09-30 0000908259 OTLC:NotePurchaseAgreementMember 2025-09-30 0000908259 OTLC:NotePurchaseAgreementMember 2024-12-31 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2022-03-31 0000908259 OTLC:FiveInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2022-03-31 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2022-12-31 0000908259 OTLC:FourthManLLCMember us-gaap:SubsequentEventMember OTLC:SecuritiesPurchaseAgreementMember 2025-10-01 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2025-01-01 2025-09-30 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2025-09-30 0000908259 OTLC:BlueLakeMember OTLC:SecuritiesPurchaseAgreementMember 2025-09-30 0000908259 OTLC:FourthManLLCMember 2025-01-01 2025-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2025-07-01 2025-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2025-01-01 2025-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2024-07-01 2024-09-30 0000908259 OTLC:FourthManConvertibleNoteMember 2024-01-01 2024-09-30 0000908259 OTLC:MastHillFundMember OTLC:SecuritiesPurchaseAgreementMember 2022-05-31 0000908259 OTLC:MastHillFundMember us-gaap:SubsequentEventMember OTLC:SecuritiesPurchaseAgreementMember 2025-10-01 0000908259 OTLC:MastHillFundMember OTLC:SecuritiesPurchaseAgreementMember 2022-05-01 2022-05-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastNoteMember 2025-09-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2025-09-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2024-01-01 2024-09-30 0000908259 OTLC:BlueLakePartnersLLCMember OTLC:SecuritiesPurchaseAgreementMember 2022-06-30 0000908259 OTLC:PlacementAgentMember OTLC:BlueLakePartnersLLCMember 2022-06-01 2022-06-30 0000908259 OTLC:BlueLakePartnersLLCMember OTLC:SecuritiesPurchaseAgreementMember 2024-05-31 0000908259 OTLC:BlueLakePartnersLLCMember OTLC:SecuritiesPurchaseAgreementMember 2024-05-01 2024-05-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember OTLC:SecuritiesPurchaseAgreementMember 2025-07-31 0000908259 us-gaap:WarrantMember 2025-07-31 0000908259 2025-07-31 2025-07-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2025-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2024-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2025-01-01 2025-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMember 2024-01-01 2024-09-30 0000908259 OTLC:AutotelicMember 2024-01-01 2024-01-01 0000908259 OTLC:AutotelicMember 2024-12-31 0000908259 OTLC:AutotelicMember 2025-09-30 0000908259 OTLC:AutotelicMember 2025-01-01 2025-09-30 0000908259 OTLC:CFOMember 2024-01-01 2024-01-31 0000908259 OTLC:CFOMember 2024-01-01 2024-12-31 0000908259 OTLC:CFOMember 2025-01-01 2025-09-30 0000908259 srt:ChiefExecutiveOfficerMember 2023-12-01 2023-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0000908259 OTLC:BridgeInvestorMember 2025-01-01 2025-09-30 0000908259 OTLC:BridgeInvestorMember OTLC:ConvertibleDebenturesMember 2024-12-31 0000908259 OTLC:BridgeInvestorMember 2024-12-31 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2019-04-01 2019-04-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2023-12-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-04-01 2019-04-30 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-01-01 2023-12-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2023-12-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-08-01 2019-08-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-01-01 2023-12-31 0000908259 OTLC:BridgeInvestorMember us-gaap:ConvertibleDebtMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2023-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2024-12-31 0000908259 OTLC:FallTwoThousandNineteenNotesMember OTLC:NotePurchaseAgreementsMember 2023-01-01 2023-12-31 0000908259 srt:MaximumMember OTLC:ThirdPartyMember OTLC:GMPNoteMember 2024-12-31 0000908259 OTLC:ThirdPartyMember OTLC:GMPNoteMember 2024-12-31 0000908259 OTLC:DebtFinancingMember OTLC:GoldenMountainPartnersLLCMember 2024-01-01 2024-12-31 0000908259 OTLC:ConvertiblePromissoryNoteMember OTLC:JanuaryPurchaseAgreementMember 2022-01-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2023-12-31 0000908259 OTLC:GoldenMountainPartnersLLCMember 2023-01-01 2023-12-31 0000908259 OTLC:NotePurchaseAgreementsMember 2021-08-31 0000908259 OTLC:NotePurchaseAgreementsMember 2021-08-01 2021-08-31 0000908259 OTLC:NotePurchaseAgreementMember 2023-01-01 2023-12-31 0000908259 OTLC:AugustTwoThousandTwentyOneInvestorsNotesMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0000908259 OTLC:NotePurchaseAgreementMember 2023-12-31 0000908259 OTLC:FivePercentConvertibleNoteMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2024-12-31 0000908259 OTLC:FivePercentConvertibleNoteMember OTLC:AugustTwentyTwentyOneConvertibleNotesMember 2023-12-31 0000908259 OTLC:FiveInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2021-12-31 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2021-12-01 2021-12-31 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2021-12-31 0000908259 OTLC:FourthManLLCMember OTLC:SecuritiesPurchaseAgreementMember 2024-12-31 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2024-01-01 2024-12-31 0000908259 OTLC:BlueLakeMember 2023-12-31 0000908259 OTLC:BlueLakeMember 2023-01-01 2023-12-31 0000908259 OTLC:FourthManMember 2023-12-31 0000908259 OTLC:FourthManMember 2023-01-01 2023-12-31 0000908259 OTLC:FourthManConvertibleNoteMember 2024-12-31 0000908259 OTLC:FourthManConvertibleNoteMember 2023-12-31 0000908259 OTLC:BlueLakeMember OTLC:SecuritiesPurchaseAgreementMember 2024-12-31 0000908259 OTLC:SecuritiesPurchaseAgreementMember 2024-12-31 0000908259 OTLC:FourthManConvertibleNoteMember 2024-01-01 2024-12-31 0000908259 OTLC:FourthManConvertibleNoteMember 2023-01-01 2023-12-31 0000908259 us-gaap:AccountingStandardsUpdate202006Member 2023-01-01 0000908259 OTLC:OneInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2022-05-31 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2022-05-01 2022-05-31 0000908259 OTLC:MayTwoThousandAndTwentyThreeMember OTLC:MastHillFundLPMember 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2023-12-31 0000908259 us-gaap:ConvertibleDebtMember OTLC:MayTwoThousandAndTwentyTwoMember 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2024-01-01 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember 2023-01-01 2023-12-31 0000908259 us-gaap:AccountingStandardsUpdate202006Member OTLC:MayTwoThousandAndTwentyThreeMember 2023-01-01 0000908259 OTLC:OneInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2022-06-30 0000908259 OTLC:PlacementAgentMember OTLC:SecuritiesPurchaseAgreementMember 2022-06-01 2022-06-30 0000908259 OTLC:OneInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2021-12-31 0000908259 OTLC:OneInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2024-05-31 0000908259 OTLC:OneInstitutionalInvestorsMember OTLC:SecuritiesPurchaseAgreementMember 2024-05-31 2024-05-31 0000908259 OTLC:JuneTwoThousandAndTwentyThreeMember 2024-01-01 2024-12-31 0000908259 OTLC:JuneTwoThousandAndTwentyThreeMember 2023-01-01 2023-12-31 0000908259 us-gaap:AccountingStandardsUpdate202006Member OTLC:JuneTwoThousandAndTwentyThreeMember 2023-01-01 0000908259 srt:ChiefExecutiveOfficerMember us-gaap:RelatedPartyMember 2021-05-31 0000908259 OTLC:AutotelicMember 2022-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2023-12-31 0000908259 OTLC:AutotelicMember 2024-01-01 2024-12-31 0000908259 OTLC:CFOMember 2022-01-01 2022-12-31 0000908259 OTLC:CFOMember 2023-01-01 2023-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2023-01-01 2023-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2024-01-01 2024-12-31 0000908259 OTLC:BridgeInvestorMember 2023-01-01 2023-12-31 0000908259 OTLC:RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember OTLC:AugustTwoThousandAndTwentyOneMember 2025-09-30 0000908259 OTLC:RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember OTLC:AugustTwoThousandAndTwentyOneMember 2024-12-31 0000908259 OTLC:AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember OTLC:AugustTwoThousandAndTwentyOneMember 2025-09-30 0000908259 OTLC:AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember OTLC:AugustTwoThousandAndTwentyOneMember 2024-12-31 0000908259 OTLC:ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2025-09-30 0000908259 OTLC:ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2024-12-31 0000908259 OTLC:AugustTwoThousandAndTwentyOneMember 2025-09-30 0000908259 OTLC:AugustTwoThousandAndTwentyOneMember 2024-12-31 0000908259 OTLC:FourthManLLCMember OTLC:SixteenPercentCouponMarchTwoThousandTwentyThreeMember 2025-09-30 0000908259 OTLC:FourthManLLCMember OTLC:SixteenPercentCouponMarchTwoThousandTwentyThreeMember 2024-12-31 0000908259 OTLC:FourthManLLCMember 2025-09-30 0000908259 OTLC:FourthManLLCMember 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastHillFunMember OTLC:MastHillMember 2025-09-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastHillFunMember OTLC:MastHillMember 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastHillFunMember 2025-09-30 0000908259 OTLC:MayTwoThousandAndTwentyTwoMastHillFunMember 2024-12-31 0000908259 OTLC:RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2024-12-31 0000908259 OTLC:RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2023-12-31 0000908259 OTLC:ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2023-12-31 0000908259 OTLC:AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2024-12-31 0000908259 OTLC:AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember OTLC:AugustTwoThousandAndTwentyOneMember 2023-12-31 0000908259 OTLC:AugustTwoThousandAndTwentyOneMember 2023-12-31 0000908259 OTLC:SixteenPercentCouponMarchTwoThousandTwentyThreeMember OTLC:MarchTwoThousandTwentyTwoMember 2024-12-31 0000908259 OTLC:SixteenPercentCouponMarchTwoThousandTwentyThreeMember OTLC:MarchTwoThousandTwentyTwoMember 2023-12-31 0000908259 OTLC:MarchTwoThousandTwentyTwoMember 2024-12-31 0000908259 OTLC:MarchTwoThousandTwentyTwoMember 2023-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember OTLC:MastHillMember 2024-12-31 0000908259 OTLC:MayTwoThousandAndTwentyTwoMember OTLC:MastHillMember 2023-12-31 0000908259 OTLC:JuneTwoThousandAndTwentyTwoMember OTLC:BlueLakePartnersLLCMember 2024-12-31 0000908259 OTLC:JuneTwoThousandAndTwentyTwoMember OTLC:BlueLakePartnersLLCMember 2023-12-31 0000908259 OTLC:JuneTwoThousandAndTwentyTwoMember 2024-12-31 0000908259 OTLC:JuneTwoThousandAndTwentyTwoMember 2023-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember OTLC:TenPercentCouponAugustTwoThousandTwentySixMember 2025-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember OTLC:TenPercentCouponAugustTwoThousandTwentySixMember 2024-12-31 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember 2025-09-30 0000908259 OTLC:JulyTwoThousandAndTwentyFiveMastNoteMember 2024-12-31 0000908259 srt:ChiefFinancialOfficerMember OTLC:OtherShortTermAdvancesMember 2025-09-30 0000908259 srt:ChiefFinancialOfficerMember OTLC:OtherShortTermAdvancesMember 2024-12-31 0000908259 srt:ChiefExecutiveOfficerMember OTLC:OtherShortTermAdvancesMember 2025-09-30 0000908259 srt:ChiefExecutiveOfficerMember OTLC:OtherShortTermAdvancesMember 2024-12-31 0000908259 OTLC:BridgeInvestorMember OTLC:OtherShortTermAdvancesMember 2025-09-30 0000908259 OTLC:BridgeInvestorMember OTLC:OtherShortTermAdvancesMember 2024-12-31 0000908259 OTLC:AutotelicMember OTLC:OtherShortTermAdvancesMember 2025-09-30 0000908259 OTLC:AutotelicMember OTLC:OtherShortTermAdvancesMember 2024-12-31 0000908259 OTLC:OtherShortTermAdvancesMember 2025-09-30 0000908259 OTLC:OtherShortTermAdvancesMember 2024-12-31 0000908259 srt:ChiefFinancialOfficerMember 2024-12-31 0000908259 srt:ChiefFinancialOfficerMember 2023-12-31 0000908259 srt:ChiefExecutiveOfficerMember 2024-12-31 0000908259 OTLC:BridgeInvestorMember 2024-12-31 0000908259 OTLC:BridgeInvestorMember 2023-12-31 0000908259 OTLC:AutotelicMember 2024-12-31 0000908259 OTLC:AutotelicMember 2023-12-31 0000908259 OTLC:JVMember 2023-12-31 0000908259 OTLC:JVMember 2025-09-30 0000908259 OTLC:GMPBioMember 2025-09-30 0000908259 OTLC:DragonOverseasMember 2025-09-30 0000908259 OTLC:GMPBioMember 2024-09-30 0000908259 OTLC:GMPBioMember 2023-12-31 0000908259 OTLC:GMPBioMember 2023-01-01 2023-12-31 0000908259 OTLC:JVMember 2024-12-31 0000908259 OTLC:GMPBioMember 2024-12-31 0000908259 OTLC:DragonOverseasMember 2024-12-31 0000908259 OTLC:GMPBioMember 2023-12-31 0000908259 OTLC:AccreditedInvestorsMember us-gaap:WarrantMember 2024-01-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementTwoMember 2023-07-01 2024-01-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbiePlacementAgreementMember 2024-01-31 0000908259 srt:MinimumMember OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 srt:MaximumMember OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 OTLC:JHDarbiePlacementAgreementMember 2023-07-01 2024-01-31 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2025-09-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2025-01-01 2025-09-30 0000908259 us-gaap:CommonStockMember OTLC:JHDarbiePlacementAgreementTwoMember 2025-09-30 0000908259 us-gaap:CommonStockMember OTLC:JHDarbiePlacementAgreementTwoMember 2025-01-01 2025-09-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2024-07-01 2024-09-30 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-01 2024-09-30 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbiePlacementAgreementTwoMember 2025-01-01 2025-09-30 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-01 2024-09-30 0000908259 OTLC:JHDarbiePlacementMember 2023-07-01 2024-01-31 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2024-12-31 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-01 2024-12-31 0000908259 us-gaap:CommonStockMember OTLC:JHDarbiePlacementAgreementTwoMember 2024-12-31 0000908259 us-gaap:CommonStockMember OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-01 2024-12-31 0000908259 OTLC:JHDarbiePlacementAgreementTwoMember 2023-01-01 2023-12-31 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbiePlacementAgreementTwoMember 2024-01-01 2024-12-31 0000908259 us-gaap:ConvertibleDebtMember OTLC:JHDarbiePlacementAgreementTwoMember 2023-01-01 2023-12-31 0000908259 OTLC:AccreditedInvestorsMember us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsTwoMember 2025-09-30 0000908259 OTLC:AccreditedInvestorsMember us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsTwoMember 2024-12-31 0000908259 OTLC:SubscriptionAgreementsTwoMember 2025-09-30 0000908259 OTLC:SubscriptionAgreementsTwoMember 2024-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:SubscriptionAgreementsMember 2024-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:SubscriptionAgreementsMember 2023-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsMember 2024-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:SubscriptionAgreementsMember 2023-12-31 0000908259 OTLC:SubscriptionAgreementsMember 2024-12-31 0000908259 OTLC:SubscriptionAgreementsMember 2023-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:SubscriptionAgreementsTwoMember 2024-12-31 0000908259 OTLC:AccreditedInvestorsMember OTLC:SubscriptionAgreementsTwoMember 2023-12-31 0000908259 OTLC:SubscriptionAgreementsTwoMember 2023-12-31 0000908259 us-gaap:MeasurementInputExpectedTermMember 2025-09-30 0000908259 us-gaap:MeasurementInputPriceVolatilityMember 2025-09-30 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-09-30 0000908259 us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0000908259 us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0000908259 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2025-07-01 2025-09-30 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2024-01-01 2024-09-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:VuongTrieuMember OTLC:SecuritiesPurchaseAgreementMember 2019-04-30 0000908259 OTLC:VuongTrieuMember us-gaap:ConvertibleDebtMember 2019-04-30 0000908259 OTLC:VuongTrieuMember OTLC:FallTwoThousandAndNineteenNoteMember 2019-04-01 2019-04-30 0000908259 OTLC:VuongTrieuMember 2020-01-01 2020-12-31 0000908259 OTLC:VuongTrieuMember 2023-12-31 0000908259 OTLC:VuongTrieuMember 2024-09-30 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2024-01-01 0000908259 OTLC:AutotelicIncMember 2024-12-31 0000908259 OTLC:AutotelicIncMember 2025-09-30 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2025-09-30 0000908259 us-gaap:SubsequentEventMember 2025-10-01 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2024-01-01 2024-09-30 0000908259 OTLC:StevenKingMember OTLC:TermSheetAgreementMember 2024-04-01 2024-04-01 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2024-01-01 2024-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:MasterServiceAgreementMember OTLC:AutotelicIncMember 2023-01-01 2023-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:AutotelicIncMember 2023-01-01 2023-12-31 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2021-05-01 2021-05-31 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2022-12-31 0000908259 OTLC:AutotelicIncMember 2023-12-31 0000908259 OTLC:AugustTwoThousandAndTwentyOneNoteMember OTLC:AutotelicIncMember 2024-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:ArtiusConsultingAgreementMember 2023-01-01 2023-12-31 0000908259 us-gaap:RelatedPartyMember OTLC:MosaicConsultingAgreementMember 2024-07-01 2024-07-31 0000908259 us-gaap:RelatedPartyMember OTLC:MosaicConsultingAgreementMember 2023-01-01 2023-12-31 0000908259 OTLC:DrMaidaMember us-gaap:RelatedPartyMember OTLC:MaidaConsultingAgreementMember 2023-01-01 2023-12-31 0000908259 us-gaap:WarrantMember 2025-08-01 2025-08-31 0000908259 us-gaap:InvestorMember us-gaap:WarrantMember OTLC:EquityPurchaseAgreementMember 2025-08-01 2025-08-31 0000908259 us-gaap:WarrantMember OTLC:EquityPurchaseAgreementMember 2025-08-01 2025-08-31 0000908259 2025-08-01 0000908259 2025-08-31 0000908259 OTLC:FourthManLLCMember 2025-03-01 2025-03-31 0000908259 2025-07-01 2025-07-31 0000908259 OTLC:JeffersonCapitalMember 2025-08-01 2025-08-31 0000908259 OTLC:ValorNationMember 2025-08-01 2025-08-31 0000908259 OTLC:FourthManLLCMember 2025-08-01 2025-08-31 0000908259 2025-09-01 2025-09-30 0000908259 OTLC:FourthManLLCMember 2024-02-01 2024-02-29 0000908259 OTLC:BlueLakeMember 2024-05-01 2024-05-31 0000908259 OTLC:BlueLakeMember 2023-02-01 2023-02-28 0000908259 OTLC:BlueLakeMember 2023-06-01 2023-06-30 0000908259 OTLC:FourthManLLCMember 2023-06-01 2023-06-30 0000908259 OTLC:FourthManLLCMember 2023-07-01 2023-07-31 0000908259 OTLC:FourthManLLCMember 2023-10-01 2023-10-31 0000908259 srt:MaximumMember OTLC:TwoThousandSeventeenEquityIncentivePlanMember 2025-01-01 2025-09-30 0000908259 srt:MaximumMember OTLC:TwoThousandFifteenAndTwoThousandFiveEquityIncentivePlanMember 2025-01-01 2025-09-30 0000908259 2022-01-01 2022-09-30 0000908259 srt:MaximumMember OTLC:TwoThousandSeventeenEquityIncentivePlanMember 2024-01-01 2024-12-31 0000908259 srt:MaximumMember OTLC:TwoThousandFifteenAndTwoThousandFiveEquityIncentivePlanMember 2024-01-01 2024-12-31 0000908259 OTLC:ExercisePriceOneMember 2025-01-01 2025-09-30 0000908259 OTLC:ExercisePriceOneMember 2025-09-30 0000908259 OTLC:ExercisePriceTwoMember 2025-01-01 2025-09-30 0000908259 OTLC:ExercisePriceTwoMember 2025-09-30 0000908259 OTLC:ExercisePriceThreeMember 2025-01-01 2025-09-30 0000908259 OTLC:ExercisePriceThreeMember 2025-09-30 0000908259 OTLC:ExercisePriceFourMember 2025-01-01 2025-09-30 0000908259 OTLC:ExercisePriceFourMember 2025-09-30 0000908259 OTLC:ExercisePriceOneMember 2024-01-01 2024-12-31 0000908259 OTLC:ExercisePriceOneMember 2024-12-31 0000908259 OTLC:ExercisePriceTwoMember 2024-01-01 2024-12-31 0000908259 OTLC:ExercisePriceTwoMember 2024-12-31 0000908259 OTLC:ExercisePriceThreeMember 2024-01-01 2024-12-31 0000908259 OTLC:ExercisePriceThreeMember 2024-12-31 0000908259 OTLC:ExercisePriceFourMember 2024-01-01 2024-12-31 0000908259 OTLC:ExercisePriceFourMember 2024-12-31 0000908259 OTLC:ExercisePriceFiveMember 2024-01-01 2024-12-31 0000908259 OTLC:ExercisePriceFiveMember 2024-12-31 0000908259 OTLC:ExercisePriceOneMember us-gaap:WarrantMember 2025-09-30 0000908259 OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2025-09-30 0000908259 srt:MinimumMember OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2025-09-30 0000908259 srt:MaximumMember OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2025-09-30 0000908259 OTLC:ExercisePriceThreeMember us-gaap:WarrantMember 2025-09-30 0000908259 srt:MaximumMember OTLC:ExercisePriceThreeMember us-gaap:WarrantMember 2025-09-30 0000908259 OTLC:ExercisePriceFourMember us-gaap:WarrantMember 2025-09-30 0000908259 OTLC:ExercisePriceOneMember us-gaap:WarrantMember 2024-12-31 0000908259 OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2024-12-31 0000908259 srt:MinimumMember OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2024-12-31 0000908259 srt:MaximumMember OTLC:ExercisePriceTwoMember us-gaap:WarrantMember 2024-12-31 0000908259 OTLC:ExercisePriceThreeMember us-gaap:WarrantMember 2024-12-31 0000908259 OTLC:ExercisePriceFourMember us-gaap:WarrantMember 2024-12-31 0000908259 OTLC:ExercisePriceFiveMember us-gaap:WarrantMember 2024-12-31 0000908259 OTLC:MergerAgreementMember OTLC:PointRMergerMember 2025-01-01 2025-09-30 0000908259 OTLC:MergerAgreementMember OTLC:PointRMergerMember 2025-09-30 0000908259 OTLC:MergerAgreementMember OTLC:PointRMergerMember 2024-01-01 2024-12-31 0000908259 OTLC:MergerAgreementMember OTLC:PointRMergerMember 2024-12-31 0000908259 2025-10-01 2025-10-31 0000908259 OTLC:FourthManLLCMember us-gaap:SubsequentEventMember 2025-10-01 2025-10-31 0000908259 OTLC:FourthManLLCMember us-gaap:SubsequentEventMember 2025-11-01 2025-11-30 0000908259 srt:MaximumMember OTLC:SeriesAConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2025-11-17 2025-11-17 0000908259 OTLC:SeriesAConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2025-11-17 0000908259 us-gaap:PreferredStockMember 2025-07-31 0000908259 us-gaap:PreferredStockMember 2025-08-31 0000908259 us-gaap:SubsequentEventMember 2025-11-17 2025-11-17 0000908259 us-gaap:PreferredStockMember us-gaap:SubsequentEventMember 2025-11-17 2025-11-17 0000908259 us-gaap:PreferredStockMember us-gaap:SubsequentEventMember 2025-11-17 0000908259 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-11-13 2025-11-13 0000908259 us-gaap:SubsequentEventMember 2025-11-13 2025-11-13 0000908259 OTLC:AccreditedInvestorsMember OTLC:JHDarbiePlacementAgreementMember 2020-07-01 2021-03-31 0000908259 OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2020-07-01 2021-03-31 0000908259 OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2021-03-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2020-07-01 2021-03-31 0000908259 OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2021-03-31 0000908259 srt:MaximumMember OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2020-07-01 2021-03-31 0000908259 srt:MaximumMember OTLC:OneConvertiblePromissoryNoteMember OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2021-03-31 0000908259 us-gaap:WarrantMember OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2021-03-31 0000908259 OTLC:AccreditedInvestorsMember us-gaap:WarrantMember OTLC:JHDarbiePlacementAgreementMember 2024-01-31 0000908259 us-gaap:IPOMember 2024-12-31 0000908259 us-gaap:IPOMember 2024-01-01 2024-12-31 0000908259 OTLC:JHDarbiePlacementAgreementMember 2024-01-01 2024-12-31 0000908259 OTLC:JHDarbiePlacementAgreementMember 2020-07-01 2021-03-31 0000908259 srt:MaximumMember OTLC:JHDarbiePlacementAgreementMember OTLC:EdgepointAIIncMember 2021-03-31 0000908259 us-gaap:InvestorMember 2022-02-28 0000908259 us-gaap:InvestorMember 2022-02-01 2022-02-28 0000908259 us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0000908259 us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 iso4217:USD shares iso4217:USD shares pure false 0000908259

S-1 Oncotelic Therapeutics, Inc. DE 13-3679168 29397 Agoura Road, Suite 107 Agoura Hills CA 91301 (650) 635-7000 Vuong Trieu Oncotelic Therapeutics, Inc. 29397 Agoura Road, Suite 107 Agoura Hills CA 91301 (650) 635-7000 Non-accelerated Filer true false

409000

86128

20000

3976

18976

1179972

9107

1612948

134211

1101760

2788230

22653225

28156163

26677426

2565877

2437167

347598

346057

2625000

670844

703616

10328100

9790866

3542244

3297208

3542244

3297208

20079663

19199914

20079663

19199914

0.01

750000000

439446318

407289618

4394463

4072899

43765008

42219400

-39108893

-38040668

9050578

8251631

-974078

-774119

8076500

7477512

28156163

26677426

426 480 1020 1212

490547

80277

657019

343347

3200000

490973

3280757

658039

3544559

-490973

-3280757

-658039

-3544559

231338

205616

642917

655946

-22937

-392058

114722

32772

140828

-88258

-623396

-90894

-610145

-580439

-1114369

-3371651

-1268184

-4124998

-67004

-67165

-199959

-202000

-1047365

-3304486

-1068225

-3922998

-0.00

-0.01

-0.00

426435213

407289888

414315703

403428494

407289888

4072899

42219400

-38040668

-774119

7477512

1002832

10028

60170

70198

-298716

-65548

-364264

408292720

4082927

42279570

-38339384

-839667

7183446

277856

-67407

210449

408292720

4082927

42279570

-38061528

-907074

7393895

4516082

45161

270965

316126

26637516 266375 1214473 1480848

-1047365

-67004

-1114369

439446318

4394463

43765008

-39108893

-974078

8076500

399184128

3991839

41655026

-33516736

-518592

11611537

500000

5000

108029

113029

-408676

-66499

-475175

399684128.00

3996839.00

41763055.00

-33925412.00

-585091.00

11249391

7605760

76060

456345

532405

-209837

-68336

-278173

407289888

4072899

42219400

-34135249

-653427

11503623

407289888

4072899

42219400

-34135249

-653427

11503623

-3304486

-67165

-3371651

-3304486

-67165

-3371651

407289888

4072899

42219400

-37439735

-720592

8131972

407289888

4072899

42219400

-37439735

-720592

8131972

-1268184

-4124998

3200000

135573

117132

183742

32772

140828

-88258

-19407

-11320

360565

211285

1541

1444

-600128

-636387

478000

615000

445000

923000

615000

322872

-21387

106128

190405

429000

169018

285260

281260

386324 645434 1480848 -209323

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) was originally incorporated in the State of New York in 1988 as OXiGENE, Inc. The Company reincorporated in the State of Delaware in 1992, changed its name to Mateon Therapeutics, Inc. (“Mateon”) in 2016, and subsequently changed its name to Oncotelic Therapeutics, Inc. in November 2020. The Company conducts business through Oncotelic and its wholly owned subsidiaries, including Oncotelic, Inc., PointR Data, Inc. (“PointR”), Pet2DAO, Inc. (“Pet2DAO”), and EdgePoint AI, Inc. (“EdgePoint”), a consolidated subsidiary with non-controlling interests. (Collectively, “Oncotelic,” “we,” “our,” or “the Company”). Further detail on prior mergers and corporate history is provided in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on April 15, 2025. The Company is principally focused on the development of immuno-oncology therapeutics, including OT-101, a transforming growth factor-beta (TGF-β) inhibitor being advanced for difficult-to-treat cancers and viral respiratory diseases. OT-101 is being developed through our joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), affiliates of Golden Mountain Partners (“GMP”). As of September 30, 2025, the Company owns 45% of GMP Bio. During the quarter, GMP Bio completed an independent third-party valuation by Frost & Sullivan (Hong Kong), which preliminarily estimated the potential value of the drug pipeline under development at approximately $1.7 billion. This valuation is non-binding, forward-looking, and based upon a number of assumptions including the successful achievement of clinical, regulatory, and commercial milestones. The valuation should not be interpreted as a current measure of fair value under U.S. GAAP. Oncotelic is in the process of seeking a separate, ASC-compliant valuation performed under U.S. GAAP standards. The results of this valuation, or other events that indicate a change in the value of the Company’s holdings in GMP Bio will be incorporated into future reporting periods consistent with the Company’s fair value reporting under U.S. GAAP. The JV is advancing OT-101 for high-grade gliomas, pancreatic cancer, and other oncology indications, as well as for epidemic and pandemic respiratory diseases. In addition, the JV is developing five additional therapeutic candidates, which—if successfully developed and approved—are anticipated to contribute meaningful long-term value to both the JV and the Company. Separately from the JV, the Company plans to develop OT-101 for select animal-health indications and is evaluating the use of digital assets and blockchain-based technologies to support that platform. The Company has also acquired apomorphine for potential uses in Parkinson’s disease, erectile dysfunction, and female sexual dysfunction. The Company continues to evaluate advancement opportunities for OXi4503 (for acute myeloid leukemia and myelodysplastic syndromes) and CA4P (in combination with checkpoint inhibitors for metastatic melanoma). The Company’s core scientific focus is the development of its proprietary self-immunization protocol (“SIP™”), designed to stimulate a patient’s immune system to recognize and target tumors without requiring tumor extraction or antigen identification. The SIP™ platform is supported by more than three decades of RNA-based research and is being applied initially to oncology, with potential expansion to Duchenne Muscular Dystrophy (“DMD”) and other diseases driven by TGF-β overexpression. The JV continues preparing for planned Phase 2 and Phase 3 trials for OT-101 in high-grade glioma, pancreatic cancer, and other indications. The JV is also sponsoring investigator-initiated clinical studies in additional oncology applications. Under an agreement and supplemental agreement with GMP, the Company received approximately $1.2 million in service fees related to development activities for OT-101. Additional detail regarding these agreements is included in our Annual Report on Form 10-K for the year ended December 31, 2024. The Company remains committed to advancing its therapeutic pipeline, strengthening the clinical and commercial prospects of GMP Bio, and pursuing programs intended to address significant unmet medical needs in oncology and related therapeutic areas. Fundraising Private Placement 2 & JH Darbie Financing Between July 2023 and January 2024, the Company entered into a series of subscription agreements with 46 accredited investors which resulted in a conversion of a gross amount of approximately $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zp4WH4x3IMNd">2.4 million, consisting of 94 notes, under the prior JH Darbie Financing into new debt to the Company. JH Darbie and the Company are parties to a March 2023 placement agent agreement (“Agreement”) pursuant to which <span id="xdx_90E_eus-gaap--DebtConversionDescription_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zGNxNQi25Vl9">JH Darbie has the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. The subscription agreements entered between July 2023 and January 2024 fully converted JH Darbie PPM-1 notes into PPM-2 notes. For more information on the new JH Darbie Financing, refer to Note 8 of these Notes to the Consolidated Financial Statements. Equity Purchase Agreement -2021 In May 2021, the Company entered into an Equity Purchase Agreement (the “EPL”) and Registration Rights Agreement (the “Registration Rights Agreement”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company shall have the right, but not the obligation, to direct Peak One to purchase up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210501__20210531__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--PeakOneOpportunityFundLPMember_zZuIJ82AHat6">10.0 million (the “Maximum Commitment Amount”) in shares of the common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210531__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--PeakOneOpportunityFundLPMember_zrGVaBJsWfHi">0.01 per share (“Common Stock”) in multiple tranches. The Company filed a post-effective amendment for the EPL on April 15, 2025 with the SEC and the SEC has made the post-effective amendment effective on April 21, 2025. The Company filed a prospectus under rule 424b3 with the SEC on April 29, 2025. For more information on the EPL, refer to Note 10 of the Notes to the Consolidated Financial Statements. March 2022 Notes In March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $250,000, which Note is convertible into shares of the Company’s Common Stock. As of September 30, 2025, this note is in default and available for conversion into the Company’s Common Stock due to cross default provision contained in November / December 2021 Notes. During the nine months ended September 30, 2025, Fourth Man converted a portion of the March 2022 debt, including interest, and conversion fee, of approximately $116,000 for 1,658,914 shares of the Company’s Common Stock. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. May 2022 Note In May 2022, the Company entered into a Securities Purchase Agreement with Mast, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.6 million, which note is convertible into shares of the Company’s Common Stock. The May 2022 Note was extended till December 2025. During the nine months ended September 30, 2025, Mast Hill converted a portion of the May 2022 debt, including interest, and conversion fee, of approximately $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z6Jo9DlBuHV1">270,000 for <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUkLTSHPOHBl">3,860,000 shares of the Company’s Common Stock. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. June 2022 Note In June 2022, the Company entered into a Securities Purchase Agreement with Blue Lake, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of approximately $340,000, which note is convertible into shares of the Company’s Common Stock. During the year ended December 31, 2024, Blue Lake converted the balance of their debt, including accrued interest and penalty, of approximately $530,000 for approximately 7.6 million shares of the Company’s Common Stock. As of September 30, 2025, this note is fully converted. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. July 2025 Note In July 2025, the Company entered into a Securities Purchase Agreement with Mast Hill, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $560,000, which note is convertible into shares of the Company’s Common Stock, par value $0.01 per share (“Common Stock”). This note was utilized for corporate expenses. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. Mast Hill Equity Purchase Agreement In August, 2025, the Company entered into an Equity Purchase Agreement (the “Mast EPA”) and a Registration Rights Agreement (the “Mast Registration Rights Agreement”) with Mast, pursuant to which the Company shall have the right, but not the obligation, to direct Mast, to purchase up to $25 million (the “Maximum Commitment Amount”) in shares of the Company’s Common Stock in multiple tranches. The Company plans to file a registration statement with the SEC at the earliest. For more information on the Mast EPA, refer to Note 10 of the Notes to the Consolidated Financial Statements. Jefferson Capital Ventures, LLC and Valor Nation, Inc Independent Contractor Agreements In August, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into independent contractor agreements (“ICA”) with Jefferson Capital Ventures, LLC (“Jefferson”) and Valor Nation, Inc. (“Valor”) for providing certain consulting and advisory services. The ICAs call for Jefferson and Valor to provide consulting and advisory services including strategic planning meetings, coordination non-legal support for SEC compliance, balance sheet and income statement optimization strategies, shareholder and investor communication planning, liaison with investment bankers, analysts, and institutional investors, operational efficiency and cost-saving recommendations and ancillary strategic services not requiring a license, corporate planning, operations and capital markets advisory services not requiring licenses. Such services shall be provided by Jefferson and Valor for a period of 18 months from the signing of the ICA, unless terminated earlier by either party under certain predefined conditions. Jefferson has agreed to be compensated $20,000 per month in cash and issued 20,320,930 forfeitable restricted stock awards (“RSAs”) of shares of Common Stock and Valor has agreed to be compensated with <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20250806__20250806__us-gaap--TypeOfArrangementAxis__custom--IndependentContractorAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTkBahtWN4Oi">4,064,586 shares of Common Stock. While the Common Stock underlying the Jefferson and Valor RSAs will be issued as of the date of the Jefferson and Valor ICAs, Jefferson will earn the RSAs and Common Stock only when certain corporate milestones are achieved. The corporate milestones (“Milestones”), when Jefferson will earn the RSAs and Common Stock, are when the Company’s market capitalization exceeds $100 million on any single trading day’s close, the cumulative increase of at least $10 million in shareholder equity from the start of engagement and the successful uplisting to a U.S. national exchange (e.g., Nasdaq or NYSE American), with at least one full day of trading. For more information on the Jefferson and Valor ICAs, refer to our Current Report on Form 8-K filed with the SEC on August 12, 2025. Forever Prosperity (previously GMP) Note purchase agreements and unsecured notes Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling gross $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20220131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndPurchaseAgreementMember__dei--LegalEntityAxis__custom--GoldenMountainPartnersMember_ztF37EUg81Ja">4.5 million. Such notes were assigned to Forever Prosperity, LLC, an affiliated entity of GMP. For more information on the GMP debt financing, refer to Note 5 of the Notes to the Consolidated Financial Statements. Joint Venture with GMP Bio In March 2022, the Company formalized a JV, GMP Bio, with Dragon , both affiliates of GMP. Although no assurances can be given, GMP Bio currently intends to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. For more information on the JV, refer to Note 6 of the unaudited Notes to the Consolidated Financial Statements. Pet2DAO In November 2022, the Company formed a Decentralized autonomous organization (“DAO”) entity, Pet2DAO LLC (“Pet2DAO”), as a wholly owned subsidiary. For more information on Pet2DAO, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. Mosaic ImmunoEngineering, Inc. Term Sheet In April 2024, the Company entered into a binding term sheet (the “Term Sheet”) with Mosaic ImmunoEngineering, Inc. (“Mosaic”). For more information on the Term Sheet, refer to the Current Report on Form 8-K filed with the SEC on April 29, 2024. In August 2024, Mosaic and the Company mutually agreed to extend the date of the Term Sheet to expire at the earlier of (1) the signing of definitive agreements or (2) December 31, 2024. In December 2024, the Company and Mosaic further extended the term of the term-sheet to expire at the earlier of (1) the signing of definitive agreements or (2) June 30, 2025. Currently, both parties are in discussions to extend the timeline to complete the due diligence and finalize the signing of definitive agreements to a date mutually acceptable to both. Principles of Consolidation The consolidated financial statements include the accounts of Oncotelic, its wholly owned subsidiaries, Oncotelic Inc. and PointR; and Edgepoint our non-controlled interest entity. Intercompany accounts and transactions have been eliminated in consolidation. The Company’s investment in GMB Bio is recorded and reported as a minority investment in equity securities. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules of the SEC for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. The accompanying unaudited condensed consolidated financial statements should therefore be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2024 included in the Company’s 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. The unaudited condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and entities in which the Company has non-controlling interests. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim period presented. Our consolidated operations comprise a single operating segment and reporting unit. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net accumulated losses of approximately $39.1 million since inception of Oncotelic Inc., as the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Oncotelic Inc. The Company also has a negative working capital of approximately $18.5 million at September 30, 2025, of which approximately $2.6 million contingent liability of issuance of common shares of the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR Merger Agreement. The Company has negative cash flows from operations for the nine months ended September 30, 2025 of approximately $0.6 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to continue to incur significantly lower direct costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 have been, and will be, incurred by the JV, but the Company also recognizes the need to raise capital to remain viable as well as have the ability to develop its own products and achieve some of the plans to enhance shareholder value. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The Company’s long-term plans include continued development of its current pipeline of products, in addition to continue the development of OT-101 which is exclusively out-licensed to the JV and the JV will be responsible for the funding required to support the development in entirety, to generate sufficient revenues, through either technology transfer or product sales, or raise additional financing to cover its anticipated expenses. The Company has supported its operations through a combination of debt and equity financing. See Note 3, 5 and 10 below). Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments. The Company obtained short-term loans of approximately $0.45 million from Autotelic Inc., a related party, and net approximately $480,000 from Mast Hill under a secured note during the nine months ended September 30, 2025. In addition, the Company obtained a short-term loan of $10 thousand from Amit Shah, it’s CFO during the nine months ended September 30, 2025. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for 12 months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.

0.45

1700000000

1200000

2400000

JH Darbie has the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis.

10000000.0

0.01

250000

116000

1658914

600000

270000

3860000

340000

530000

7600000

560000

0.01

20000

20320930

4064586

100000000

10000000

4500000

39100000

18500000 2600000

-600000

450000

480000

10000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect and require more significant judgments and estimates used in the preparation of the financial statements, including but not limited to, the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments. Cash As of September 30, 2025, and December 31, 2024 the Company held all its cash in banks. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2025 and December 31, 2024, respectively. Restricted cash consists of certificates of deposits held at banks as collateral. Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring. Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.</td></tr> </table> The Company did not have any Level 1 or Level 2 assets and liabilities at September 30, 2025 and December 31, 2024. Investment in equity securities The following table summarizes the cumulative gross unrealized gains and losses and fair values for long-term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of September 30, 2025 and December 31, 2024: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--EquitySecuritiesInitialBookValue_iI_c20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zmirb59GBExl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zDOIobmAkkN7" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20250101__20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zl3qlO6hC2De" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zU7SBhot229g" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--EquitySecuritiesInitialBookValue_iI_c20250930_zvwioUrdoaE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20250930_zD63MaDF5Zn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20250101__20250930_z71eJKBzDsLj" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20250930_zuo4LxZAYgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zP8FYinkIoN8" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zKCg1dwq0vTj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zuieGBndYfHa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zqJKhSYKoyTe" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231_z8FKmNV6TFxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231_zAkcxVqEWPql" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231_zfsbUbFaFl67" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231_z36BwRroH1Bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio on a negotiated value, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of September 30, 2025 and December 31, 2024. Derivative Liability The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), which consisted of conversion feature derivatives at September 30, 2025 and December 31, 2024, are Level 3 fair value measurements. <p id="xdx_89C_ecustom--SummaryOfChangesInFairValueOfDerivativeLiabilitiesTableTextBlock_zswS5BpWx7p" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2025 and December 31, 2024: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250101__20250930_zJoPFyx2KuB1" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025 Conversion Feature</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_z0EFvnputsm8" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024 Conversion Feature</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zUMdwfjYxZbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">703,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">423,214</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zBjtJdevEqo1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(32,772</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zgkwt1EZvNAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">670,844</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2025, and December 31, 2024, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2025 and December 31, 2024, respectively: SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">September 30, 2025</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">December 31, 2024</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Key</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Key</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Assumptions</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Assumptions</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">for fair value</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">for fair value</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">of conversions</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">of conversions</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zodEkuAQpCoe">3.68% - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zB4e9ODxt2uf">4.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zlDizkPVDqre">3.98%-<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zZSkm5QUDFD4">5.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Market price of share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zTDFKBjhkRY8">0.04 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zuHKcmXQnFLf">0.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zxZD9p3aUmmd">0.02 – <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zBnyDFasF5cb">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Life of instrument in years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxA1taj3SOg8">136.4% - <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z8yQ9jsj7oW">139.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zirsN6m6Nlp9">138.38%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zOq56iGm2Gv3">226.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> A contingent consideration of $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMember_zwQRlDFuZPsj">2,625,000 for shares of the Company, issuable to PointR shareholders recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic as well as other AI technologies. As such, the Company did not record any change to the valuation during the nine months ended September 30, 2025 or 2024, respectively. If, and when, the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended September 30, 2025 and 2024, respectively, there were no transfers of financial assets or financial liabilities between the hierarchy levels. Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. For the three and nine months ended September 30, 2025 and 2024, no equivalent shares of the Common Stock were included as the Company has incurred a loss in each of the periods, and addition of such stock equivalents in the computation would have been anti-dilutive. Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations. For stock options issued to employees and members of the Board of Directors (the “Board”) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If, however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital. For shares issued in connection with provision of services, the Company estimates the cost of the shares at a price of the Company’s stock on the date of issuance and records that cost as a stock based compensation cost. Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and nine months ended September 30, 2025 and 2024, respectively, there were no impairment losses recognized for long-lived assets. Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the nine months ended September 30, 2025 and September 30, 2024, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the three and nine months ended September 30, 2025; and three months ended September 30, 2024, no impairment was recognized towards goodwill. For the nine months ended September 30, 2024, we recorded an impairment loss of approximately $3.2 million, based on the difference between the carrying value of our goodwill as against the market capitalization of the Company. For more information on goodwill and impairment, refer to Note 3 to these Notes to the Consolidated Financial Statements. Derivative Financial Instruments Indexed to the Company’s Common Stock We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Consolidated Statement of Income. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability. Variable Interest Entity (VIE) Accounting The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At September 30, 2025 and December 31, 2024, the Company identified EdgePoint to be the Company’s sole VIE. At September 30, 2025 and December 31, 2024, the Company’s ownership percentage of EdgePoint was 29% each, respectively. The VIE’s net assets were less than $0.1 million at September 30, 2025 and December 31, 2024, respectively. Investments - Equity Method The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the Consolidated Financial Statements. Joint Venture agreement We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture. We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination. To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non-managing entity and the inability of the non-managing entity to remove us from our role as the managing entity. We use the equity method of accounting for those arrangements where we exercise significant influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our consolidated balance sheet. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss. When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value. The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the company. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (Topic 606). Under Topic 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company anticipates generating revenues from rendering services to other third-party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either upon achievement of certain pre-defined milestones, when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized. Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred. Recent Accounting Pronouncements All newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect and require more significant judgments and estimates used in the preparation of the financial statements, including but not limited to, the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.

Cash As of September 30, 2025, and December 31, 2024 the Company held all its cash in banks. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of September 30, 2025 and December 31, 2024, respectively. Restricted cash consists of certificates of deposits held at banks as collateral.

Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring.

Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.</td></tr> </table> The Company did not have any Level 1 or Level 2 assets and liabilities at September 30, 2025 and December 31, 2024.

Investment in equity securities The following table summarizes the cumulative gross unrealized gains and losses and fair values for long-term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of September 30, 2025 and December 31, 2024: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--EquitySecuritiesInitialBookValue_iI_c20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zmirb59GBExl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zDOIobmAkkN7" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20250101__20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zl3qlO6hC2De" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zU7SBhot229g" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--EquitySecuritiesInitialBookValue_iI_c20250930_zvwioUrdoaE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20250930_zD63MaDF5Zn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20250101__20250930_z71eJKBzDsLj" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20250930_zuo4LxZAYgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zP8FYinkIoN8" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zKCg1dwq0vTj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zuieGBndYfHa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zqJKhSYKoyTe" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231_z8FKmNV6TFxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231_zAkcxVqEWPql" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231_zfsbUbFaFl67" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231_z36BwRroH1Bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio on a negotiated value, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of September 30, 2025 and December 31, 2024.

The following table summarizes the cumulative gross unrealized gains and losses and fair values for long-term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of September 30, 2025 and December 31, 2024: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">September 30, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--EquitySecuritiesInitialBookValue_iI_c20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zmirb59GBExl" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zDOIobmAkkN7" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20250101__20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zl3qlO6hC2De" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20250930__us-gaap--AwardTypeAxis__custom--GMPBioMember_zU7SBhot229g" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--EquitySecuritiesInitialBookValue_iI_c20250930_zvwioUrdoaE6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20250101__20250930_zD63MaDF5Zn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20250101__20250930_z71eJKBzDsLj" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20250930_zuo4LxZAYgi1" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zP8FYinkIoN8" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zKCg1dwq0vTj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zuieGBndYfHa" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zqJKhSYKoyTe" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231_z8FKmNV6TFxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231_zAkcxVqEWPql" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231_zfsbUbFaFl67" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231_z36BwRroH1Bg" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 22653225

22653225

Derivative Liability The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), which consisted of conversion feature derivatives at September 30, 2025 and December 31, 2024, are Level 3 fair value measurements. <p id="xdx_89C_ecustom--SummaryOfChangesInFairValueOfDerivativeLiabilitiesTableTextBlock_zswS5BpWx7p" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2025 and December 31, 2024: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250101__20250930_zJoPFyx2KuB1" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025 Conversion Feature</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_z0EFvnputsm8" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024 Conversion Feature</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zUMdwfjYxZbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">703,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">423,214</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zBjtJdevEqo1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(32,772</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zgkwt1EZvNAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">670,844</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2025, and December 31, 2024, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of September 30, 2025 and December 31, 2024, respectively: SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">September 30, 2025</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">December 31, 2024</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Key</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Key</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Assumptions</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Assumptions</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">for fair value</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">for fair value</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">of conversions</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">of conversions</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zodEkuAQpCoe">3.68% - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zB4e9ODxt2uf">4.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zlDizkPVDqre">3.98%-<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zZSkm5QUDFD4">5.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Market price of share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zTDFKBjhkRY8">0.04 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zuHKcmXQnFLf">0.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zxZD9p3aUmmd">0.02 – <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zBnyDFasF5cb">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Life of instrument in years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxA1taj3SOg8">136.4% - <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z8yQ9jsj7oW">139.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zirsN6m6Nlp9">138.38%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zOq56iGm2Gv3">226.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table> A contingent consideration of $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMember_zwQRlDFuZPsj">2,625,000 for shares of the Company, issuable to PointR shareholders recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic as well as other AI technologies. As such, the Company did not record any change to the valuation during the nine months ended September 30, 2025 or 2024, respectively. If, and when, the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended September 30, 2025 and 2024, respectively, there were no transfers of financial assets or financial liabilities between the hierarchy levels. <p id="xdx_89C_ecustom--SummaryOfChangesInFairValueOfDerivativeLiabilitiesTableTextBlock_zswS5BpWx7p" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of September 30, 2025 and December 31, 2024: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250101__20250930_zJoPFyx2KuB1" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025 Conversion Feature</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_z0EFvnputsm8" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024 Conversion Feature</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zUMdwfjYxZbh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">703,616</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">423,214</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zBjtJdevEqo1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(32,772</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zgkwt1EZvNAh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">670,844</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

703616

423214

-32772

280402

670844

703616

SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">September 30, 2025</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">December 31, 2024</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Key</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Key</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Assumptions</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Assumptions</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">for fair value</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">for fair value</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">of conversions</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">of conversions</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zodEkuAQpCoe">3.68% - <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zB4e9ODxt2uf">4.03</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zlDizkPVDqre">3.98%-<span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zZSkm5QUDFD4">5.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Market price of share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zTDFKBjhkRY8">0.04 - <span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zuHKcmXQnFLf">0.08</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">$ <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zxZD9p3aUmmd">0.02 – <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zBnyDFasF5cb">0.04</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Life of instrument in years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">0.01</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zxA1taj3SOg8">136.4% - <span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_z8yQ9jsj7oW">139.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zirsN6m6Nlp9">138.38%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zOq56iGm2Gv3">226.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table>

3.68

4.03

3.98

5.09

0.04

0.08

0.02

0.04

P0Y3D P0Y3D

136.4

139.5

138.38

226.9

2625000

Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. For the three and nine months ended September 30, 2025 and 2024, no equivalent shares of the Common Stock were included as the Company has incurred a loss in each of the periods, and addition of such stock equivalents in the computation would have been anti-dilutive.

Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees, including employee stock options, in the statements of operations. For stock options issued to employees and members of the Board of Directors (the “Board”) for their services, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If, however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital. For shares issued in connection with provision of services, the Company estimates the cost of the shares at a price of the Company’s stock on the date of issuance and records that cost as a stock based compensation cost.

Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the three and nine months ended September 30, 2025 and 2024, respectively, there were no impairment losses recognized for long-lived assets.

Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the nine months ended September 30, 2025 and September 30, 2024, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed.

Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. For the three and nine months ended September 30, 2025; and three months ended September 30, 2024, no impairment was recognized towards goodwill. For the nine months ended September 30, 2024, we recorded an impairment loss of approximately $3.2 million, based on the difference between the carrying value of our goodwill as against the market capitalization of the Company. For more information on goodwill and impairment, refer to Note 3 to these Notes to the Consolidated Financial Statements.

3200000

Derivative Financial Instruments Indexed to the Company’s Common Stock We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Consolidated Statement of Income.

Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

Variable Interest Entity (VIE) Accounting The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At September 30, 2025 and December 31, 2024, the Company identified EdgePoint to be the Company’s sole VIE. At September 30, 2025 and December 31, 2024, the Company’s ownership percentage of EdgePoint was 29% each, respectively. The VIE’s net assets were less than $0.1 million at September 30, 2025 and December 31, 2024, respectively.

0.29

100000

Investments - Equity Method The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the Consolidated Financial Statements.

Joint Venture agreement We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture. We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination. To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non-managing entity and the inability of the non-managing entity to remove us from our role as the managing entity. We use the equity method of accounting for those arrangements where we exercise significant influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our consolidated balance sheet. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss. When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value. The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the company.

Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (Topic 606). Under Topic 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company anticipates generating revenues from rendering services to other third-party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either upon achievement of certain pre-defined milestones, when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.

Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

Recent Accounting Pronouncements All newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

NOTE 3 - INTANGIBLE ASSETS AND GOODWILL Goodwill from 2019 Reverse Merger with Oncotelic and PointR The Company completed the reverse merger with Oncotelic Inc. (“Merger”) in April 2019. The Company completed the merger with PointR Data Inc (“PointR Merger”) in November 2019. For more details on the two mergers, refer to our 2020 Annual Report on Form 10-K for the year ended December 31, 2020 filed by the Company on April 15, 2021. The Oncotelic merger gave rise to Goodwill of approximately $4.9 million. Upon the non-financial sale of our asset as contribution to our equity method investment, we derecognized the balance of the carrying value of our goodwill of approximately $4.9 million from the Oncotelic Merger in accordance with our policy and authoritative accounting guidance. Further, we added goodwill of approximately $16.2 million upon the completion of the Merger with PointR. Between the years 2022 and 2024, we recorded impairments of approximately $<span id="xdx_903_eus-gaap--AssetImpairmentCharges_pn5n6_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--BusinessAcquisitionAxis__custom--PointRMember_zunZR2Jnvc7a">13.4 million, as we observed our market capitalization being negatively impacted as compared to the book value of our net assets. We have one operating segment and reporting unit. Accordingly, our review of goodwill impairment indicators was performed at the entity-wide level. In performing our annual impairment assessment, we determined if we should qualitatively assess whether it was more likely than not the fair value of goodwill was less than its carrying amount (the qualitative impairment test). The factors we considered in the assessment included our market capitalization, general macroeconomic conditions, conditions specific to the industry and market and whether there had been sustained declines in our share price. If we concluded, it was more likely than not, the fair value of the reporting unit was less than its carrying amount, or elected not to use the qualitative impairment test, a quantitative impairment test would be performed. We used our market capitalization as an indicator of fair value. While we believe the fair value measurement need not be based solely on the quoted market price of an individual share of our Common Stock, and that we also could consider the impact of a control premium in measuring the fair value of its reporting unit. In the absence of any other valuation metrics, the Company believed using a control premium utilized would not be appropriate under the current circumstances. We also considered some other market comparables’ trends in our stock price as well as the industry over a period of two successive quarters and prospective quarter to evaluate whether the fair value of our reporting unit was greater than our carrying amount. As such, we performed a quantitative impairment assessment of goodwill for our single reporting unit at the end of 2024, due to a sustained decline in our market capitalization and an increase in negative economic outlook for biotech markets We estimated and reconciled the fair value of our reporting unit utilizing our market capitalization based on the stock price of our Common Stock as of December 31, 2024. Before completing our goodwill impairment test, we first tested our indefinite-lived intangible asset then our remaining long-lived assets for impairment. We concluded our indefinite-lived intangible assets were not impaired. Based on the market capitalization, we further concluded the fair value of our single reporting unit was less than its carrying value and therefore recognized an impairment charge of $3.2 million during the year ended December 31, 2024. The calculation of the impairment charge included substantial fact-based determinations and estimates. The Company evaluated if it needed to record any additional goodwill impairment as of September 30, 2025, based solely on the market capitalization of the Company and concluded that no further impairment was required to be recorded for the nine months ended September 30, 2025. A summary of our goodwill as of September 30, 2025 and December 31, 2024 is shown below: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250930_ziPPOJeLuYZg" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zUR7N9xKxR6h" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iS_zl2dDRGgLX77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,788,230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,988,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillImpairmentLoss_iN_di_z9MENur7STE1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Goodwill impairment due to market capitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,200,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iE_zYO4V9YByVCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In general, the goodwill is tested on an annual impairment date of December 31, unless we observe any further deterioration in our market capitalization in any interim periods, in which case we may, depending on the materiality of the impairment, record an impairment at the end of other reporting periods. In-Process Research & Development (“IPR&D”) Summary The IPR&D assets were acquired in the PointR Merger during the year ended December 31, 2019. Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. The balance of IPR&D as of September 30, 2025 and December 31, 2024, respectively, was $1,101,760. For more information on the IPR&D, please refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025.

4900000

16200000

13400000

3200000

A summary of our goodwill as of September 30, 2025 and December 31, 2024 is shown below: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250930_ziPPOJeLuYZg" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zUR7N9xKxR6h" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iS_zl2dDRGgLX77" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,788,230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,988,230</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillImpairmentLoss_iN_di_z9MENur7STE1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Goodwill impairment due to market capitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,200,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iE_zYO4V9YByVCa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2788230

5988230

3200000

2788230

1101760

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expense consists of the following amounts: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930_zMlnEQVNrZkl" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zrXlYbtjkAC6" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzzKQ_zQalKSqR8KMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,692,263</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,691,725</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALzzKQ_zGTbLqogI5Vj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">873,611</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">745,442</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzzKQ_z20qDkAIhwh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,565,874</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,437,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250930_zeD7IqGvwQtd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zIt7WjnG4oP7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: center"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIDZzpW6A8Pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Accounts payable – related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">347,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">346,057</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accounts payable and accrued expense consists of the following amounts: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250930_zMlnEQVNrZkl" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zrXlYbtjkAC6" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzzKQ_zQalKSqR8KMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,692,263</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,691,725</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALzzKQ_zGTbLqogI5Vj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">873,611</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">745,442</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzzKQ_z20qDkAIhwh6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,565,874</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,437,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20250930_zeD7IqGvwQtd" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231_zIt7WjnG4oP7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: center"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zIDZzpW6A8Pf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Accounts payable – related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">347,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">346,057</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1692263

1691725

873611

745442

2565874

2437167

347598

346057

NOTE 5 – CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT As of September 30, 2025 and December 31, 2024, special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts: SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250930_z6cTCy5DTztg" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zIIgboroyPli" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Current Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible debentures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zVFxPCB3to11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">10% Convertible note payable, due April 23, 2022 – Bridge Investor</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_z1TYJx1qZd59" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">10% Convertible note payable, due April 23, 2022 – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zJ2QRcMP5MKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible note payable, due August 6, 2022 – Bridge Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zOxmgZLnSFs1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Fall 2019 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableStephenBoeschMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zNhVVVRWwOVb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Stephen Boesch</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zuH8FPMxQgUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,733</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableDrSanjayJhaMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z7FpTgMEIKGb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322,628</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,253</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zvgeJSmGdEEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – CEO & CFO – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102,659</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zdCSRdwSNRK" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note payable – Bridge Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">216,622</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">210,322</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zaJb2Q90Vi7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,105,800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,073,925</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> August 2021 Convertible Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zuSL9fZttUej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note – Autotelic Inc– Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,552</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zQMJZ6UFBGmj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">451,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,075</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zUIBh9nkDQEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note – CFO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90,584</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,770</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zijjf6qLWm62" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">843,593</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">817,397</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">March 2022 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentConvertibleNoteAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zm2nzCo77kxf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">143,579</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233,687</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt for Clinical Trials – Forever Prosperity (Formerly GMP)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwoPercentageConvertibleNotesForeverProsperityMember__srt--TitleOfIndividualAxis__custom--DebtClinicalTrialsGMPMember_zJOH8QewgYac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2% Convertible Notes – Forever Prosperity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,907,562</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,840,247</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">May and June 2022 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MayAndJuneTwoThousandTwentyTwoNoteMember_zEP4LJj0Eicj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">12% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">788,863</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">993,130</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> July 2025 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JulyTwoThousandTwentyTwoNoteMember_zbTBZoZ8BYrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible Note – Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,302</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">JH Darbie PPM 2 Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zNniJe7nCHsg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">16% Convertible Notes - Non-related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,289,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,183,638</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesCEORelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zofSMdElpcl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zx1BB1m5Gcfk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,414,595</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,308,638</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Other Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zcSwxQnMfaQb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCFOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zUIGsjFQ1hkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term debt from CFO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zngpydE3T7pd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Autotelic Inc. – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,085,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCEOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zcIQlIiZjtyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short Term Debt from CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_zgIlIlObeISg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Short term debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,866,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,421,050</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DebenturesNotesAndOtherDebt_iI_zWw1IOxVrzY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total of short-term convertible debentures & notes and other debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,870,344</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,088,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Convertible Debentures As of September 30, 2025, the Company had a derivative liability of approximately $<span id="xdx_90E_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20250930__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebenturesMember_zz3sUhootpxh">670,844 and recorded a change in fair value of approximately $32,772 on the Convertible Debentures issued in 2019 to our CEO and a bridge investor. As of December 31, 2024, the Company had a derivative liability of approximately $704,000 and recorded a change in fair value of approximately $280,000 during the year ended December 31, 2024, on the Convertible Debentures issued in 2019 to our CEO and a bridge investor. Bridge Financing Notes with Officer and Bridge Investor In April 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO and the Bridge Investor with a commitment to purchase convertible notes in the aggregate of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWGDuUToTcAj">400,000. For more information on the Bridge SPA, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. In April 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. For more information on Tranche #1, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. In August 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. For more information on Tranche #2, refer to 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. Fall 2019 Debt Financing In December 2019, the Company closed its Fall 2019 Debt Financing, raising an additional $500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to $1,000,000. The Company entered into those certain Note Purchase Agreements (the “Fall 2019 Note Purchase Agreements”) with certain accredited investors and the officers of the Company for the sale of convertible promissory notes (the “Fall 2019 Notes”). The Company completed the initial closing under the Fall 2019 Note Purchase Agreements in November 2019. The Company issued Fall 2019 Notes in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_z76YauW6PLP1">250,000 to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $<span id="xdx_90E_ecustom--ProceedsFromConvertibleDebtGross_pp0p0_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zo7q6gNRXaNl">500,000. In connection with the second and final closing of the Fall 2019 Debt Financing, the Company issued Fall 2019 Notes to additional investors including $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrSanjayJhaMember_z7DmPQp4e8Ed">250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s then Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer, all related parties as Officers of the Company, and converted such amounts due into the Fall 2019 Notes. $<span id="xdx_907_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ze1L37NtPdn9">35,000 due to Dr. Vuong Trieu, $<span id="xdx_90D_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--ChulhoParkMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zdCuaWQ94lzk">27,000 due to Chulho Park and $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--AmitShahMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zOLv3kW1AOgg">20,000 due to Amit Shah were converted into convertible debt under the Fall 2019 Notes during the third quarter of 2019. The Company also issued the Fall 2019 Notes of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorsMember_z0CsRn3UcP38">168,000 to two accredited investors during the third quarter of 2019. All the Fall 2019 Notes provided for interest at the rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20250930__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember_zdVa2I3ZfTd4">5% per annum and are unsecured. For more information on the Fall 2019 Debt Financing, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. There was no activity during the nine months ended September 30, 2025 and 2024. The total unamortized principal amount of the Fall 2019 Notes was $850,000 as of September 30, 2025, and December 31, 2024. Further, the Company recorded interest expense of approximately $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zkpSiieRIwte">10,600 and $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zBFKWXa6Ju28">32,000 on these Fall 2019 Notes for the three and nine months ended September 30, 2025 and September 30, 2024, respectively. The total amount outstanding under the Fall 2019 Notes, net of discounts and including accrued interest thereon, as of September 30, 2025 and December 31, 2024, was approximately $1,106,000 and $1,073,900, respectively. Forever Prosperity (Formerly GMP) Notes In June 2020, the Company secured $2 million in debt financing, evidenced by a one-year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and was personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of the Company. In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID- 19 bearing 2% annual interest. In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “October Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $<span id="xdx_904_eus-gaap--ConvertibleDebt_iI_pn5n6_c20211031__us-gaap--TypeOfArrangementAxis__custom--OctoberPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z9e2qqI4r6Xc">0.5 million. Further, in January 2022, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “January Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_pn5n6_c20211031__us-gaap--TypeOfArrangementAxis__custom--JanuaryPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zYJPO2s7IVxh">0.5 million. Between June 2020 and January 2022, the Company entered into four Unsecured Convertible Note Purchase Agreements with Forever Prosperity, for a total amount of $4.5 million. Cumulatively, these four Notes are referred to as the “GMP Notes”. The GMP Notes carry an interest rate of 2% per annum and mature on the earlier of (a) the one- year anniversary of the date of the Purchase Agreement, or (b) the acceleration of the maturity by GMP upon occurrence of an Event of Default (as defined below). All Notes contain a voluntary conversion mechanism whereby GMP may convert the outstanding principal and accrued interest under the terms of all the GMP Notes into shares of Common Stock (the “Conversion Shares”), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion from GMP. Prepayment of the GMP Notes may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. As of September 30, 2025, the GMP Notes are in default, however Forever Prosperity has not called for the repayment of the debt. The total principal outstanding on all the GMP notes, inclusive of accrued interest, was approximately $4.9 million and $4.8 million, as of September 30, 2025, and December 31, 2024, respectively. During the three and nine months ended September 30, 2025, and 2024, the Company incurred approximately $22,700 and $67,500 of interest expense, respectively, on all the 4 notes. For a more detailed discussion on the Forever Prosperity Notes, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. August 2021 Notes In August 2021, the Company entered into Note Purchase Agreements with Autotelic - a related party, our CFO – a related party, and certain accredited investors (the “August 2021 investors”), whereby the Company issued four convertible notes in the aggregate principal amount of $698,500 convertible into Common Stock of the Company for net proceeds of approximately $691,000. The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Common Stock, at a conversion price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pip0_c20210831__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zvzv9GSFw8G7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.18. The August 2021 Note Holders has waived the default in the maturity of the August 2021 Notes and as such there is no event of default and also agreed to extend the date of maturity of the August 2021 Notes to December 31, 2025. The Company determined that the economic characteristics and risks of the embedded conversion option are not clearly and closely related to the economic characteristics and risks of the debt host instrument. Further, the Company determined that the embedded conversion feature meets the definition of a derivative but met the scope exception to the derivative accounting required under ASC 815 for certain contracts involving a reporting entity’s own equity. <p id="xdx_892_ecustom--ScheduleOfConvertibleNotesNetOfDiscountTableTextBlock_gL3SOCNNODTTB-HLNID_z6ShY5gdC8k7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2025, and December 31, 2024, the August 2021 Notes, inclusive of accrued interest, consist of the following amounts: SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250930__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zbUyCxvMSyr7" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zJ2Mwa0vf516" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember_zWY9zQRFtU31" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Autotelic Related party convertible note, 5% coupon December 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">301,927</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,552</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember_zjwZIfpwWBMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accredited investors convertible note, 5% coupon December 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">451,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,075</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zdR2b2IQFjV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">CFO Related party convertible note, 5% coupon December 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90,584</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,770</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_zU0mageELpff" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Convertible notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">843,593</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">817,397</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three and nine months ended September 30, 2025 and 2024, the Company recognized approximately $8,700 and $26,200 of interest expense on the August 2021 Investors notes of which approximately $<span id="xdx_90A_eus-gaap--InterestExpense_c20240701__20240930__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyOneInvestorsNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z7NfFocYF7wc">4,000 and $<span id="xdx_908_eus-gaap--InterestExpense_c20240101__20240930__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyOneInvestorsNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzLAPP8ijZ8d">12,190 are attributable to related parties. At September 30, 2025 and December 31, 2024, accrued interests on these convertible notes totaled approximately $145,000 and $119,000, respectively. March 2022 Financing In March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zQKQJTKjEjJe">0.25 million (the “Fourth Man Note”), convertible into Common Stock of the Company. The Fouth Man Note carries a twelve (<span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_ztBPMMntRrnj">12%) percent coupon and a default coupon of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zfQDMvZEh2xk">16% and mature at the earliest of one year from issuance or upon event of default. As of December 31, 2023, this note was in default and Fourth Man has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at an initial conversion price established at a fixed rate of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zmmTznJW9Mqa">0.10, and subsequently corrected to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLddm3ecLDYa">0.07 based on the terms of the Securities Purchase Agreement and Fourth Man Note. The Company granted a total number of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUyjQMWjrwbb">1,250,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20251001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFH5XK7cM089">0.20 up to five years after issuance. The Placement agent was also granted a total of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zT56cqpHSbA3">125,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zc29UW6WYyOj">0.20 up to five years after issuance, as part of a finder’s fee agreement. As of September 30, 2025, and December 31, 2024, the Fourth Man Note, including accrued interest and net of debt discount, consist of the following amounts: <div id="xdx_C0A_gL3SOCNNODTTB-HLNID_z34SUt4HGIfl"> <table cellpadding="0" cellspacing="0" id="xdx_300_134_zrr8a2TJMh8j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250930__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_z17QiII3XlL3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zv5MPkaH9gX4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--SixteenPercentCouponMarchTwoThousandTwentyThreeMember_zd3bisVF7o9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">143,579</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">233,687</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_z53Dw4sUBLgb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_zg2nOWLv2Qmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,579</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">233,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> During the nine months ended September 30, 2025, the Company converted approximately $62,000 in principal and approximately $54,100 in accrued interest and legal fees into 1,658,914 shares of Common Stock. The note includes a default amount calculated at <span id="xdx_902_ecustom--DebtDefaultPrincipalAndAccruedInterestPercentage_iI_pid_dp_uPure_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakeMember_zYgtokOxKpN6">125% of the unpaid principal and accrued interest. As the Company failed to repay the note at the original maturity date, The Company has recorded an estimated default penalty of approximately $70,000. As of the date of this Report, Fourth Man has cumulatively converted approximately $0.2 million of the Fourth Man Note into 1,658,914 shares of Common Stock, and as such, the remaining balance of the Fourth Man Note is approximately $45,000. The Company recognized approximately $7,100 and $23,800 during the three and nine months ended September 30, 2025. Similarly, the Company had recognized approximately $8,400 and $25,500 of interest during the three and nine months ended September 30, 2024. May 2022 Mast Financing In May 2022, the Company entered into a securities purchase agreement with Mast Hill Fund (“Mast”), whereby the Company issued one convertible note in the aggregate principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MastHillFundMember_zUxjEwnr6NG9">605,000 convertible into shares of the Company’s Common Stock (“May 2022 Mast Note”). The May 2022 Mast Note carries a twelve (<span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MastHillFundMember_zVEI43OAogUj">12%) percent coupon and a default coupon of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MastHillFundMember_z3nTpkH95hz2">16% and mature at the earliest of one year from issuance or upon event of default. Mast has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at a conversion price established at a fixed rate of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MastHillFundMember_zw88p5aVbt7a">0.10, and subsequently corrected to $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20251001__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MastHillFundMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHdBSE7ssVQ5">0.07 based on the terms of the Securities Purchase Agreement and May 2022 Mast Note. The Company granted a total number of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MastHillFundMember_zLIQaOJUEDP5">3,025,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance. The Placement agent was also granted a total amount of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220501__20220531__srt--TitleOfIndividualAxis__custom--MastHillFundMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zT83NNduhAX9">302,500 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance as part of a finder’s fee agreement. Portion of the proceeds were be used to retire some of the November/December 2021 notes. As of September 30, 2025, and December 31, 2024, the May 2022 Mast Note, net of debt discount, consist of the following amounts: <div id="xdx_C09_gL3SOCNNODTTB-HLNID_ziKUteJrwg7d"> <table cellpadding="0" cellspacing="0" id="xdx_30D_134_ziMrP4YbuCzf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250930__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMastHillFunMember_zQowTPxMYAOa" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMastHillFunMember_zjrAUbYSkIma" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_hdei--LegalEntityAxis__custom--MastHillMember_z1CIyMEktm3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, 12% coupon May 2025, inclusive of accrued interest and penalty</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">788,863</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">993,130</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleLongTermNotesPayable_iI_zRJcSsNvBD76" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">788,863</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">993,130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> During the nine months ended September 30, 2025, the Company converted approximately $268,400 in accrued interest and legal fees into 3,860,000 shares of common stock. The May 2022 Mast Note had been extended through May 27, 2025 at a cost of approximately $82,000, and which is included in the amount outstanding and payable to Mast as of September 30, 2025. Mast Hill further extended the May 2022 Mast Note to December 31, 2025 in August 2025. Accrued interest was approximately $184,000 and $388,000 as of September 30, 2025 and December 31, 2024. The Company recognized approximately $0 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants during the three and nine months ended September 30, 2025 and 2024, respectively. June 2022 Blue Lake Financing In June 2022, the Company entered into a securities purchase agreement with Blue Lake Partners, LLC (“Blue Lake”), whereby the Company issued one convertible note in the aggregate principal amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_ztKnGLkWVx1f">335,000 convertible into shares of Common Stock of the Company (“June 2022 Blue Lake Note”). The June 2022 Blue Lake Note carried a twelve (<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_zpRR53qJjro9">12%) percent coupon and a default coupon of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_zYKdDkqAfXc9">16% and mature at the earliest of one year from issuance or upon event of default. Blue Lake had the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_zuVTtQPwjUx4">0.10. The Company granted a total number of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_zqvslCI4yRsf">837,500 warrants convertible into an equivalent number of the Company common shares at a strike price of $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_znKT3mtCXvEg">0.20 up to five years after issuance. The Placement agent was also granted a total amount of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20220630__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--BlueLakePartnersLLCMember_zeuxL0U5UG1a">83,750 warrants as part of a finder’s fee agreement. In May 2024, Blue Lake converted the balance of their note of approximately $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20240531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_zLw6Bjh5wb8d">531,000 including principal, accrued interest and default penalty, into <span id="xdx_906_eus-gaap--ConversionOfStockSharesIssued1_c20240501__20240531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakePartnersLLCMember_zZJdNm5Rzb6h">7,605,760 shares of Common Stock of the Company. July 2025 Mast Financing On July 31, 2025, the Company entered into a securities purchase agreement with Mast, whereby the Company issued a secured convertible note in the aggregate principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zPSuWM3lslsc">560,000 convertible into shares of Common Stock of the Company (“July 2025 Mast Note”). The July 2025 Mast Note carries a twelve (<span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zNgsJmLr2jxk">12%) percent coupon and a default coupon of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zevvEWTxBWKf">18% and mature at the earliest of one year from issuance or upon event of default. Mast has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at a conversion price established at a fixed rate of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_ze1Uj8NqxPL2">0.07. The note is secured against the assets of the Company, excluding any assets assigned to the JV. In connection with the July 2025 Mast Note, the Company granted a total number of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zRDsjAgPuFZg">2,000,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $0.15 up to five years after issuance. The Company also issued 2,250,000 of the Company’s common stock as commitment shares to Mast. As of September 30, 2025, and December 31, 2024, July 2025 Mast Note, net of debt discount, consist of the following amounts: SCHEDULE OF NET OF DEBT DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250930__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_z7TvwknDorG8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zB4AECa1I9a6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TenPercentCouponAugustTwoThousandTwentySixMember_zULKQRjKFYR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, inclusive of accrued interest 10% coupon due August 2026</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">569,512</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherNotesPayable_iI_z5untKuGRK36" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes, gross</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">569,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_z5xRCfsrDCpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: debt discount recorded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(203,834</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zbZa5lTTJL18" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">34,624</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zlsrdlaMpLY" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">400,302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company recognized approximately $9,500 and $0 of accrued interest during the nine months ended September 30, 2025, and 2024, respectively. The Company recognized approximately $34,600 and $0 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs and fair value allocated to the warrants and the commitment shares during the nine months ended September 30, 2025. Other short-term advances As of September 30, 2025 compared to December 31, 2024, other short-term advances consist of the following amounts obtained from various employees and related parties: SCHEDULE OF SHORT-TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Other Advances</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250930__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zugksRIpfvd2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zbj5Fz2bzdif" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zhv0650KFGRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Short term advance from CFO – Related Party</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">86,050</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">76,050</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zqqrIRIoe7Zg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term advance from CEO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--BridgeInvestorMember_zcBysNwzaLpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term advances – bridge investors & others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AutotelicMember_zCqO1QAiXIL3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Short term advances – Autotelic Inc. – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,520,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,085,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_zTULriE4VOe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Short term advance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,866,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,421,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of January 1, 2024, approximately $1.5 million was outstanding and payable to Autotelic. During the year ended December 31, 2024 Autotelic Inc. provided additional short-term funding of approximately $0.6 million to the Company. During the nine months ended September 30, 2025 Autotelic Inc. provided additional short-term funding of $435,000 to the Company. As such, approximately $2.5 million was outstanding and payable to Autotelic at September 30, 2025. As of January 1, 2024, approximately $35,000 was outstanding and payable to the Company’s CFO. During the year ended December 31, 2024, the CFO provided additional short-term funding of $41,000. In the nine months ended September 30, 2025, the CFO further provided additional short-term funding of $10,000 to the Company. As such, approximately $86,000 was outstanding and payable to the Company’s CFO at September 30, 2025. In December 2023, the Company received $50,000 from the Company’s CEO. As such, $50,000 was outstanding to the Company’s CEO at September 30, 2025. As of September 30, 2025, approximately $210,000 was outstanding as short-term advances from certain bridge investors.

As of September 30, 2025 and December 31, 2024, special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts: SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250930_z6cTCy5DTztg" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20241231_zIIgboroyPli" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Current Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible debentures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zVFxPCB3to11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">10% Convertible note payable, due April 23, 2022 – Bridge Investor</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_z1TYJx1qZd59" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">10% Convertible note payable, due April 23, 2022 – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zJ2QRcMP5MKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible note payable, due August 6, 2022 – Bridge Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zOxmgZLnSFs1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Fall 2019 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableStephenBoeschMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zNhVVVRWwOVb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Stephen Boesch</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,708</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zuH8FPMxQgUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,733</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableDrSanjayJhaMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z7FpTgMEIKGb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">322,628</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,253</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zvgeJSmGdEEi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – CEO & CFO – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102,659</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zdCSRdwSNRK" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note payable – Bridge Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">216,622</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">210,322</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zaJb2Q90Vi7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,105,800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,073,925</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> August 2021 Convertible Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zuSL9fZttUej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note – Autotelic Inc– Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,927</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,552</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zQMJZ6UFBGmj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">451,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,075</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zUIBh9nkDQEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note – CFO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90,584</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,770</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zijjf6qLWm62" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">843,593</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">817,397</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">March 2022 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentConvertibleNoteAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MarchTwentyTwentyTwoNotesMember_zm2nzCo77kxf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">143,579</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233,687</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt for Clinical Trials – Forever Prosperity (Formerly GMP)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwoPercentageConvertibleNotesForeverProsperityMember__srt--TitleOfIndividualAxis__custom--DebtClinicalTrialsGMPMember_zJOH8QewgYac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">2% Convertible Notes – Forever Prosperity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,907,562</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,840,247</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold">May and June 2022 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MayAndJuneTwoThousandTwentyTwoNoteMember_zEP4LJj0Eicj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">12% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">788,863</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">993,130</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> July 2025 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--JulyTwoThousandTwentyTwoNoteMember_zbTBZoZ8BYrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible Note – Accredited Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,302</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">JH Darbie PPM 2 Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zNniJe7nCHsg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">16% Convertible Notes - Non-related parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,289,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,183,638</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesCEORelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zofSMdElpcl7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zx1BB1m5Gcfk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,414,595</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,308,638</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Other Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zcSwxQnMfaQb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCFOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zUIGsjFQ1hkg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term debt from CFO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">86,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zngpydE3T7pd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Autotelic Inc. – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,085,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCEOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zcIQlIiZjtyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short Term Debt from CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_zgIlIlObeISg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Short term debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,866,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,421,050</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DebenturesNotesAndOtherDebt_iI_zWw1IOxVrzY4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total of short-term convertible debentures & notes and other debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,870,344</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">13,088,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

35556

164444

200000

400000

137708

133958

323108

313733

322628

313253

105734

102659

216622

210322

1105800

1073925

301927

292552

451082

437075

90584

87770

843593

817397

143579

233687

4907562

4840247

788863

993130

400302

2289595

2183638

125000

2414595

2308638

210000

86050

76050

2520000

2085000

50000

2866050

2421050

13870344 13088074

670844

32772

704000

280000

400000

500000

1000000

250000

500000

250000

35000

27000

20000

168000

0.05

850000

10600

32000

1106000

1073900

2000000

0.02

1500000

0.02

500000

4500000

0.02

4900000

4800000

22700

67500

698500

691000

The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Common Stock, at a conversion price of $

0.18

<p id="xdx_892_ecustom--ScheduleOfConvertibleNotesNetOfDiscountTableTextBlock_gL3SOCNNODTTB-HLNID_z6ShY5gdC8k7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2025, and December 31, 2024, the August 2021 Notes, inclusive of accrued interest, consist of the following amounts: SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250930__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zbUyCxvMSyr7" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20241231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zJ2Mwa0vf516" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember_zWY9zQRFtU31" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Autotelic Related party convertible note, 5% coupon December 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">301,927</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,552</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFiveMember_zjwZIfpwWBMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accredited investors convertible note, 5% coupon December 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">451,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,075</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zdR2b2IQFjV9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">CFO Related party convertible note, 5% coupon December 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90,584</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,770</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_zU0mageELpff" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Convertible notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">843,593</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">817,397</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_300_134_zrr8a2TJMh8j" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250930__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_z17QiII3XlL3" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zv5MPkaH9gX4" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--SixteenPercentCouponMarchTwoThousandTwentyThreeMember_zd3bisVF7o9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">143,579</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">233,687</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_z53Dw4sUBLgb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_zg2nOWLv2Qmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,579</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">233,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" id="xdx_30D_134_ziMrP4YbuCzf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250930__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMastHillFunMember_zQowTPxMYAOa" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMastHillFunMember_zjrAUbYSkIma" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayableCurrent_iI_hdei--LegalEntityAxis__custom--MastHillMember_z1CIyMEktm3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, 12% coupon May 2025, inclusive of accrued interest and penalty</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">788,863</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">993,130</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleLongTermNotesPayable_iI_zRJcSsNvBD76" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">788,863</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">993,130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

301927

292552

451082

437075

90584

87770

843593

817397

8700

26200

4000

12190

145000

119000

250000

0.12

0.16

0.10

0.07

1250000

0.20

125000

0.20

143579

233687

143579

233687

62000

54100

1658914

1.25 70000

200000

1658914

45000

7100

23800

8400

25500

605000

0.12

0.16

0.10

0.07

3025000

0.20

302500

0.20

788863

993130

788863

993130

268400

3860000

82000

184000

388000

335000

0.12

0.16

0.10

837500

0.20

83750

531000

7605760

560000

0.12

0.18

0.07

2000000

0.15

P5Y

2250000

SCHEDULE OF NET OF DEBT DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250930__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_z7TvwknDorG8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20241231__srt--TitleOfIndividualAxis__custom--JulyTwoThousandAndTwentyFiveMastNoteMember_zB4AECa1I9a6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--OtherNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--TenPercentCouponAugustTwoThousandTwentySixMember_zULKQRjKFYR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, inclusive of accrued interest 10% coupon due August 2026</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">569,512</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right"> -</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherNotesPayable_iI_z5untKuGRK36" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible notes, gross</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">569,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_z5xRCfsrDCpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: debt discount recorded</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(203,834</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AmortizationOfDebtDiscount_iI_zbZa5lTTJL18" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Amortization of debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">34,624</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ConvertibleNotesPayableNet_iI_zlsrdlaMpLY" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">400,302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

569512

203834

34624 400302

9500

34600

As of September 30, 2025 compared to December 31, 2024, other short-term advances consist of the following amounts obtained from various employees and related parties: SCHEDULE OF SHORT-TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">Other Advances</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250930__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zugksRIpfvd2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--ShortTermDebtTypeAxis__custom--OtherShortTermAdvancesMember_zbj5Fz2bzdif" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zhv0650KFGRk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Short term advance from CFO – Related Party</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">86,050</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">76,050</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zqqrIRIoe7Zg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term advance from CEO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--BridgeInvestorMember_zcBysNwzaLpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term advances – bridge investors & others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AutotelicMember_zCqO1QAiXIL3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Short term advances – Autotelic Inc. – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,520,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,085,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_zTULriE4VOe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Short term advance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,866,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,421,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

86050

76050

50000

210000

2520000

2085000

2866050

2421050

1500000

600000

435000

2500000

35000

41000

10000

86000

50000

210000

NOTE 6 - JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT On March 31, 2022, the Company entered into (i) an agreement to form the JV with Dragon and GMP Bio, both affiliates of GMP, (ii) a license agreement for rights to OT-101for the territory within the United States of America with Sapu Holdings, LLC, a wholly owned subsidiary of GMP Bio and (iii) a license agreement for rights to OT-101 for the rest of the world with GMP Bio. For more information on the JV and the related agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. As of the effective date of the formation of the JV, the Company received a 45% ownership interest in the JV. The combined enterprise value of GMP Bio was approximately $50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $22.7 million and the total original capital contributions by Dragon Overseas of approximately $27.7 million. As of September 30, 2025, the JV had approximately $24.0 million in assets, recorded approximately $1.3 million in liabilities and incurred approximately $7.1 million and $4.9 million in operational expenses for the six months ended September 30, 2025 and 2024, respectively. Previously, GMP’s fiscal year commenced on April 1 and ended on March 31. Effective December 31, 2024, GMP Bio changed its fiscal year to a calendar year. The JV has initiated phase 2 and 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer. In late 2023, the JV initiated a plan to start evaluating various nanoparticles that could treat various cancers. In this regard, the JV identified a total of 4 compounds, in addition to OT-101, which had the potential of significant revenue generation for the JV. In the same year, the JV signed a lease agreement to set up a GMP manufacturing facility in San Diego (“SD”), California. The main purpose of this facility was to initially commence an aggressive formulation development of newly planned nanoparticle platform (“Nano Platform”). The GMP manufacturing facility was initiated in January 2024. Upon the initiation of this facility by the JV, the JV commenced the development work on two of the four identified compounds, as well as other activities, in tandem with the development of OT-101. The JV has since completed the formulation development of one of the products and is moving to complete the formulation development for the three additional products. The JV is also working on improved formulations for OT-101 with new nanoparticle sizes. The JV also has started clinical development for OT-101 for pancreatic cancer. Significant progress has been made in the development of the products and the JV anticipates to complete the formulation development work in 2025 and pushing to initiate clinical trials for the various compounds. In late 2024, the GMP facility in San Diego was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. Further, in late 2024, the JV identified a sixth candidate as a compound for development for the JV and has already started to work on the formulation development of that compound as well. All manufacturing including Phase 1 clinical trial materials will be performed at the SD site. In early 2025, the Company announced that it had entered into a strategic partnership with Shanghai Medicilon, Inc. (“Medicilon”) to access its industry-leading rapid investigational new drug (“IND”) development platform to support up to 20 IND projects, which the JV can also utilize to support their INDS. All six of our compounds the JV is developing are planned to be these INDs and are focused on becoming next-generation anticancer agents. The JV anticipates that all these six anticancer agents have the potential to become significant growth contributors to the JV, which in turn would add substantial value to the Company. The Company successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. The Company elected the fair value option under subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that it the most appropriate method to properly value the Company and record a change in value when and upon conducting a fair value assessment. During the year ended December 31, 2023, and based on the results of the valuation study and the 45% ownership of the Company in GMP Bio, the Company had reported a change in fair value of the Company’s investment in the JV of approximately $13,000 for the year December 31, 2023. As of September 30, 2025, as the operations of the JV are proceeding as planned, the Company assessed the fair value of its investment in the JV and determined that no change in the fair value is required until a triggering event has occurred, similar to, but not limited to, any fund raising event, entering into an IPO or any other major event enabling the Company to reassess the fair value of its investment in the JV. <p id="xdx_892_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_ztrN3NL90Waf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the change in fair value of our investment in GMP Bio, as of September 30, 2025 and December 31, 2024 is shown below: SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iS_c20250101__20250930_zcR3WTVd7Hog" style="width: 16%; text-align: right" title="Begining, investment">22,653,225</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iS_c20240101__20241231_z5nVVSu7xRJ5" style="width: 16%; text-align: right" title="Begining, investment">22,653,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Add: change in fair value of investment in GMP Bio</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_c20250101__20250930_zVEt9boC6ved" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--GainLossOnInvestments_c20240101__20241231_zjVs17h28vJc" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iE_c20250101__20250930_zolWAHWcazVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iE_c20240101__20241231_zzrRTWSbWgFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For information on the various notes from GMP, refer to Note 5 – GMP Notes of the Notes to the Consolidated Financial Statements above.

0.45

50400000

22700000

27700000

24000000.0

1300000

7100000

4900000

0.45

13000

<p id="xdx_892_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_ztrN3NL90Waf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the change in fair value of our investment in GMP Bio, as of September 30, 2025 and December 31, 2024 is shown below: SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance at January 1, 2025 and 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iS_c20250101__20250930_zcR3WTVd7Hog" style="width: 16%; text-align: right" title="Begining, investment">22,653,225</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iS_c20240101__20241231_z5nVVSu7xRJ5" style="width: 16%; text-align: right" title="Begining, investment">22,653,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Add: change in fair value of investment in GMP Bio</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--GainLossOnInvestments_c20250101__20250930_zVEt9boC6ved" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--GainLossOnInvestments_c20240101__20241231_zjVs17h28vJc" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at September 30, 2025 and December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iE_c20250101__20250930_zolWAHWcazVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iE_c20240101__20241231_zzrRTWSbWgFe" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

22653225

NOTE 7 – PRIVATE PLACEMENT -2 (PPM-2) AND JH DARBIE FUNDING During the period between July 2023 to January 2024, the Company entered into a series of subscription agreements with forty six accredited investors, whereby the Company issued and converted a total of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z72S4pjVB8F7">94 Units from a previous offering, which resulted in conversion of $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zZwbv9mkom7h">2.35 million of old debt into new debt to the Company (the “PPM-2 Financing”)The Company did not receive any cash proceeds through the PPM-2 Financing. Each of the new units under the PPM-2 Financing consisted of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">One <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zZyu0BfbNlW2">16% convertible unsecured promissory note of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zrczPjRgqtH5">25,000, convertible into up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zU3E9E4Yjx23">250,000 shares of the Company’s Common Stock, based on a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zsbvmfAClrZ">0.10 per share, subject to standard anti-dilution protection.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zchMQqUynkSi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000 warrants to purchase an equivalent number of shares of the Company’s Common Stock at a strike price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaa1EKL2z7w7">0.12 per share.</td></tr> </table> JH Darbie and the Company are parties to a March 2023 placement agent agreement (“Agreement”) pursuant to which DH Darbie had the right to sell a minimum of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MinimumMember_zKOU7dTvYamg">10 Units and a maximum of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zwZy1HIssGo8">200 Units on a best-efforts basis. For the 4 tranches of conversion related to PPM 2, placement agent fees of $377,500 were paid to JH Darbie. Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company provided warrant coverage equal to 13 % of all of the units sold by JH Darbie, resulting in the issuance of 3,055,000 warrants to JH Darbie, exercisable over a two-year period. A total of 5 unit holders under the PPM-1 opted not to participate in the PPM-2. In connection with the PPM-2 Financing, the Company entered into a Registration Rights Agreement granting certain registration rights with respect to the shares of the Company’s Common Stock issued in connection with the PPM-2 Financing. The issuance of the Units is exempt from the registration requirements of the Securities Act of 1933, as amended (“Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of common stock and warrants and any shares of common stock issuable upon exercise of the warrants, have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. <p id="xdx_89A_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscountTableTextBlock_zLVSPO4E3Rgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2025 and December 31, 2024, the PPM2 - JH Darbie Financing, net of debt discounts, consisted of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250930_zekiijfLYUV4" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zBpQ8RiZFJYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhI7ejoc0Hlf" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">PPM-2 Darbie Financing, inclusive of accrued interest, including related parties</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,414,595</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,308,638</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember_zaX48mkeENIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total PPM-2 Darbie Financing, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,414,595</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,308,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company incurred approximately $0.4 million of issuance costs under the PPM-2 and are incremental costs directly related to the issuance of the various instruments bundled in the offering. Concurrently with the sale of the Units, JH Darbie was granted a total of 3,055,000 stock warrants, exercisable over a two-year period. Management reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments and concluded that the terms of the agreements were substantially different and, accounted for the transaction as a debt extinguishment. The transaction related to T4 resulted in a loss from debt extinguishment of approximately $88,000, which is presented in other expense in the consolidated statements of operations for the year ended December 31, 2024. The estimated volume weighted grant date fair value of approximately $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfAZDo24GIH2">0.026 per share associated with the warrants to purchase up to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4tjcQnZxrma">3,390,000 shares of common stock issued in this offering, or a total of approximately $<span id="xdx_90B_eus-gaap--AdditionalPaidInCapital_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7umyf6PGAZ2">88,000 was recorded to additional paid-in capital. All warrants sold in this offering have an exercise price of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zljna3giDqq8">0.12 per share of the Company stock, subject to adjustment, are exercisable immediately and expire two years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values: <p id="xdx_891_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_ziuNvAnSfsZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify; text-indent: 0.5in; background-color: white">SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zi6pPWGL8FOj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">173</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table> The Company recorded approximately $318,000 as an initial debt discount related to the four tranches of PPM 2. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $19,900 and $101,000 for the three and nine months ended September 30, 2025. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $39,800 and $117,000 for the three and nine months ended September 30, 2024 During the nine months ended September 30, 2025, and 2024, the Company incurred approximately $<span id="xdx_907_eus-gaap--InterestExpense_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYk0a3phiQd8">276,000 and $<span id="xdx_903_eus-gaap--InterestExpense_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zmsKk9WX30s5">270,000 of interest expense related to the convertible notes, respectively.

2350000

0.16

25000

250000

0.10

250000

0.12

200

377500

Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company provided warrant coverage equal to 13 % of all of the units sold by JH Darbie, resulting in the issuance of 3,055,000 warrants to JH Darbie, exercisable over a two-year period. A total of 5 unit holders under the PPM-1 opted not to participate in the PPM-2.

<p id="xdx_89A_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscountTableTextBlock_zLVSPO4E3Rgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As of September 30, 2025 and December 31, 2024, the PPM2 - JH Darbie Financing, net of debt discounts, consisted of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20250930_zekiijfLYUV4" style="border-bottom: Black 1pt solid; text-align: center">September 30, 2025</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zBpQ8RiZFJYa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zhI7ejoc0Hlf" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 1pt">PPM-2 Darbie Financing, inclusive of accrued interest, including related parties</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,414,595</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">2,308,638</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember_zaX48mkeENIh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total PPM-2 Darbie Financing, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,414,595</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,308,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2414595

2308638

2414595

2308638

400000

3055000

88000

0.026

3390000

88000

0.12

<p id="xdx_891_eus-gaap--FairValueOptionQuantitativeDisclosuresTextBlock_ziuNvAnSfsZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify; text-indent: 0.5in; background-color: white">SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zi6pPWGL8FOj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">173</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table>

P2Y

173

4.29

0.00

318000

19900

101000

39800

117000

276000

270000

NOTE 8 - RELATED PARTY TRANSACTIONS Master Service Agreement with Autotelic Inc. In October 2015, Oncotelic entered into a Master Service Agreement (the “MSA”) with Autotelic Inc., a related party that is partly-owned by the Company’s CEO Vuong Trieu, Ph.D. Dr. Trieu, a related party, is a control person in Autotelic Inc. Autotelic Inc. currently owns less than 10% of the Company. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The Company had minimally used the services under the MSA since the formation of the JV with Dragon. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. Expenses related to the MSA were approximately $<span id="xdx_902_eus-gaap--OperatingCostsAndExpenses_c20250701__20250930__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zUl4QemERuce">500 and $<span id="xdx_90D_eus-gaap--OperatingCostsAndExpenses_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zq4I4tp0hONg">1,500 and for the three and nine months ended September 30, 2025 and 2024. License Agreement with Autotelic Inc. In September 2021, the Company entered into an exclusive License Agreement with Autotelic. For more information on the exclusive license Agreement with Autotelic, refer to our 2024 Annual Report on Form 10-K filed with SEC on April 15, 2025. Note Payable and Short-Term Loan – Related Parties In April 2019, the Company issued a convertible note to Dr. Trieu totaling $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z1ESuKFWBW5c">164,444, including OID of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXpvSXd7igd5">16,444, receiving net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_c20190401__20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zN1uQrq1e5kk">148,000, which was used by the Company for working capital and general corporate purposes. The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $250,000. Dr. Trieu also offset certain amounts due to him in the amount of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20190401__20190430__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandAndNineteenNoteMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_zOdJcbBFLJei">35,000 and was converted into the Fall 2019 debt. During the year ended December 31, 2020, Dr. Trieu purchased a total of 5 Units under the private placement for a gross total of $250,000. During the year ended December 31, 2023, Dr Trieu provided short term loan of $50 thousand to the Company. The balance due and payable to Dr. Trieu, as of September 30, 2025 and 2024, respectively, was $50,000. As of January 1, 2024, approximately $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20240101__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneNoteMember_zGJf9zM2HaT">1.5 million was outstanding and payable to Autotelic. During the year ended December 31, 2024 Autotelic Inc. provided additional short-term funding of approximately $0.6 million to the Company. In the nine months ended September 30, 2025 Autotelic Inc. provided additional short-term funding of $435,000 to the Company. As such, approximately $<span id="xdx_903_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20250930__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneNoteMember_zlGHsSitKTNc">2.5 million was outstanding and payable to Autotelic at September 30, 2025. In October 2025, Autotelic paid $162,500 to the ex-employee on behalf of the Company, in full and final settlement of the claim and counter claim to the ex-employee, with both parties not agreeing to any wrongdoing under both the claim and counter claim. Such amount was recorded as a short term loan payable to Autotelic. Artius Consulting Agreement In March 2020, the Company and Artius Bioconsulting, LLC (“Artius”), for which Mr. King is the Managing Member, entered into an amendment to an existing Consulting Agreement, under which Artius agreed to serve as a consultant to the Company for services related to the Company’s business from time to time. For more information on this Agreement, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. <span id="xdx_90A_eus-gaap--OperatingCostsAndExpenses_do_c20240101__20240930__us-gaap--TypeOfArrangementAxis__custom--ArtiusConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmD1N8xMMuLa" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No expense was recorded during the nine months ended September 30, 2025 and 2024, respectively, related to this Agreement. Maida Consulting Agreement Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020, under which Dr. Maida will assist the Company in providing medical expertise and advice from time to time in the design, conduct and oversight of the Company’s existing and future clinical trials. For more information on this Agreement, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. Effective April 1, 2022, Dr Maida’s compensation has been borne by the JV. No expense was recorded during the nine months ended September 30, 2025 and 2024, respectively, related to this Agreement. Mosaic ImmunoEngineering, Inc. In April 2024, the Company entered into a Term Sheet with Mosaic. For more information on the Term Sheet, refer to Note 1 of this Quarterly Report. Steven King, our Board member, is the CEO of Mosaic. The Company had advanced $<span id="xdx_907_eus-gaap--RepaymentsOfOtherDebt_pn6n6_c20240401__20240401__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenKingMember__us-gaap--TypeOfArrangementAxis__custom--TermSheetAgreementMember_zd8Oh1s2mXv3">40 thousand to Mosaic in accordance with the terms of the Term Sheet, and Mosaic has repaid the amount, with interest to the Company as of December 31, 2024. In addition, the Company, on behalf of our JV, had entered into an agreement with Mosaic to provide consulting services related to CMC activities for the JV. The expenses for these services have been paid for by the JV. As such, the Company has not recorded any expenses or accounts payable in this regard during the three and nine month periods ended September 30, 2025 or 2024.

500

1500

164444

16444

148000

250000

35000

250000

50000

1500000

600000

435000

2500000

162500

40000000

NOTE 9 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (PEAK ONE) On May 3, 2021, the Company entered into an Equity Purchase Agreement (“EPL”) and Registration Rights Agreement with Peak One Opportunity Fund LP (“Peak One” or the “Investor”). For further information on EPL, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The Company also filed a post-effective amendment to registration statement on Form S-1 with the Commission on April 12, 2024, and the Form S-1 was declared effective on April 21, 2025. The Company filed the prospectus under rule 424b3 with the SEC on April 29, 2025. During the nine months ended September 30, 2025 and 2024, the Company did not sell any shares of Common Stock under the EPL. NOTE 10 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (MAST HILL) On August 1, 2025, the Company entered into an Equity Purchase Agreement (“EPA”) and Registration Rights Agreement with Mast Hill Fund LP (“Mast Hill” or the “Investor”). Under the terms of the Equity Purchase Agreement, the Company issued warrants to purchase 3,350,000 shares of Common Stock to Mast Hill. Further, under the terms of the Equity Purchase Agreement, Mast Hill agreed to purchase from the Company up to $25,000,000 of the Company’s Common stock upon effectiveness of a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission and subject to certain limitations and conditions set forth in the Equity Purchase Agreement. The Registration Rights Agreement provided that the Company would (i) file the registration statement with the SEC by October 1, 2025: and (ii) use its best efforts to have the registration statement declared effective by the Commission at the earliest possible date (in any event, within 90 after days after the execution date of the definitive agreements). The Company intends to file the registration statement on Form S-1 with the SEC as soon as possible. Following effectiveness of the registration statement, and subject to certain limitations and conditions set forth in the Equity Purchase Agreement, the Company shall have the discretion to deliver put notices to the Investor and the Investor will be obligated to purchase shares of the Company’s Common Stock based on the investment amount specified in each put notice. The minimum amount that the Company shall be entitled to put to the Investor in each put notice is $<span id="xdx_908_eus-gaap--StockRepurchasedDuringPeriodValue_c20250801__20250831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zzyy0JoNwD8h">5,000 and the maximum amount is up to the lesser of $<span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodValue_pn5n6_c20250801__20250831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zCru9LHiEtYk">0.5 million or twenty percent (20%) of the average daily trading value of the Company’s Common stock. Pursuant to the Equity Purchase Agreement, the Investor will not be permitted to purchase, and the Company may not put shares of the Company’s Common Stock to the Investor that would result in the Investor’s beneficial ownership of the Company’s outstanding Common Stock exceeding 4.99%. The price of each put share shall be equal to the lesser of: <span id="xdx_90C_ecustom--VolumeWeightedAveragePrice_c20250801__20250831__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember_zLUAVFYFRbPg" title="Volume weighted average price">(i) 97% of the lowest VWAP during the two (2) trading days immediately following the Clearing Date associated with a Put Notice (the “Valuation Period”) or (ii) 102% of the lowest traded price during the Valuation Period (provided, however, that if a minimum price is specified and the common stock trades below the minimum price, then the purchase price under clause (ii) instead becomes equal to the minimum price specified in the relevant Put Notice). If a minimum price is specified by the Company in a Put Notice and the common stock trades at a price per share that is less than the minimum price during the Valuation Period then the number of shares with respect to such Put Notice shall automatically be reduced to the number of shares sold by the Selling Stockholder prior to the first time that the common stock traded below the minimum price during the Valuation Period. In connection with the Equity Purchase Agreement, the Company issued 3,350,000 warrants to Mast Hill and recorded a fair value deferred finance cost of approximately $122,000.

3350000

25000000

5000

500000

0.0499

(i) 97% of the lowest VWAP during the two (2) trading days immediately following the Clearing Date associated with a Put Notice (the “Valuation Period”) or (ii) 102% of the lowest traded price during the Valuation Period (provided, however, that if a minimum price is specified and the common stock trades below the minimum price, then the purchase price under clause (ii) instead becomes equal to the minimum price specified in the relevant Put Notice)

3350000

122000

NOTE 11 - STOCKHOLDERS’ EQUITY The following transactions affected the Company’s Stockholders’ Equity: Issuance of Common Stock during the nine months ended September 30, 2025 In March 2025, Fourth Man partially converted approximately $68,000 of their debt, including accrued interest. In connection with the partial Note conversion, the Company issued 1,002,832 shares of Common Stock to Fourth Man. In July 2025, the Company issued 2,250,000 shares of Common stock as commitment shares to Mast Hill as part of the secured convertible note purchase agreement. In August 2025, the Company issued 20,322,930 shares of Common stock as service fees to Jefferson Capital as part of the independent contractor agreement. A copy of the independent contractor agreement was submitted to the SEC on a Current Report on Form 8-K on August 12, 2025. In August 2025, the Company issued 4,064,586 shares of Common stock as service fee to Valor Nation as part of the independent contractor agreement. A copy of the independent contractor agreement was submitted to the SEC on a Current Report on Form 8-K on August 12, 2025. In August 2025, Mast Hill partially converted approximately $264,000 of accrued interest. In connection with the partial Note conversion, the Company issued 3,860,000 shares of Common Stock to Fourth Man. In September 2025, Fourth Man issued notice to the Company to partially convert approximately $44,000 of their debt, including accrued interest and fee of approximately $2,000. As the Company had received the request for conversion prior to close of business of the quarter ending September 30, 2025 and was obligated to issue such shares to Fourth Man, the Company recorded 656,082 shares of Common stock as ‘Equity to be issued” to Fourth Man. Issuance of Common Stock during the nine months ended September 30, 2024 In February 2024, Fourth Man partially converted $35,000 of their debt. In connection with the partial Note conversion, the Company issued 500,000 shares of Common Stock to Fourth Man. In May 2024, Blue Lake converted the balance of their $531,000 debt, inclusive of accrued interest and penalty, into 7,605,760 shares of Common Stock of the Company.

68000

1002832

2250000

20322930

4064586

264000

3860000

44000

2000

656082

35000

500000

531000

7605760

NOTE 12– STOCK-BASED COMPENSATION Options Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding options survived. The below information details the Company’s associated option activity. As of September 30, 2025, the Company had options to purchase Common Stock that were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). No further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms. Under the 2017 Plan, up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20250101__20250930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zaHDUM0nSFDj">2,000,000 shares of the Company’s Common Stock may be issued to directors, officers, employees or consultants pursuant to awards granted in the form of nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20250101__20250930__us-gaap--PlanNameAxis__custom--TwoThousandFifteenAndTwoThousandFiveEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zcvNlBRuM9Kl">27,250,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKULW7xCPhgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zOleMbgwlnA" style="width: 16%; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930_z1ooKuVjmCCb" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zIEIL3OSTU3h" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">(375,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zZBd41Ikkolc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zuJEsivhzObj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">23,802,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930_zhayBLyH6Xpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20250101__20250930_zUraoNjMzLj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,610,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930_zR7jlmw8JQy2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options exercisable">0.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zIAtDuzHzZy" style="width: 16%; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_zyQUlqBUEihb" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20240930_zqh2VUQEole6" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_z2cmlic2V3v8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_zMJKJ6S1S1z7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zhBFCaw8oUDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20240101__20240930_zc2Pu9GrDKpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,985,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zAouzUdQvX0c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options exercisable">0.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zb3IXm6R6cVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at September 30, 2025: SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise prices</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Options </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Life In Years </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zlSgxzlM83Gc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.1 to $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zqMIdK6ttVIe">0.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zoRwExrFQeV" style="width: 17%; text-align: right" title="Number of Outstanding Options">16,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkMd2dnF0qP9">6.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBzC9NOvTZw4" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price">0.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcUbPmzhYZP" style="width: 16%; text-align: right" title="Number Exercisable">6,057,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zRaKWwg4AG3c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zqRCuRARis7h">0.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zHSdFCgxESIc" style="text-align: right" title="Number of Outstanding Options">5,502,761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zeE6yHyMOgol">5.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztflqDJhOy44" style="text-align: right" title="Weighted-Average Exercise Price">0.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbohBFEsoAs9" style="text-align: right" title="Number Exercisable">5,502,761</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxdoVAD0fuD7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLWL7TfztDR4">0.37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zYQc1WryElH9" style="text-align: right" title="Number of Outstanding Options">1,550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z67qTaWc4zzb">2.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9Ynsmr9qutl" style="text-align: right" title="Weighted-Average Exercise Price">0.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zvWKdqt53jo1" style="text-align: right" title="Number Exercisable">1,550,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zj5U0dydUUl2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.38 to $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zEa1pAFusnWg">0.72</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zlEUdfIoO6z5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpgztA49jk4b">0.47</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zVENUPUBWvH2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price">0.73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z13tXwQgOpBj" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zX4siQYSyESd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">23,802,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930_zh3LcjyP5kPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price">0.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zVdbhi64EM6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">13,610,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The compensation expense attributed to the issuance of the options is recognized as they are vested. The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years. As of September 30, 2025, there was no unamortized stock compensation cost related to the stock options granted during the year as the stock options granted during the year ended December 31, 2023 are considered vested. Of the approximately 10 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements. For more information on the stock options, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. The Company amortized $0 stock compensation expense during the nine months ended September 30, 2025 and 2024 on previously issued grants. Warrants The Company has issued warrants in connection with the various financings conducted by the Company. For more information on the prior warrant issuances, refer our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. <p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJFBklFmQHY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of September 30, 2025 and 2024 are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zEqHinanjux9" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930_z6LQCblQzcNf" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Issued during the nine months ended September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_zO2bL6e9hD95" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Issued">5,350,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20250101__20250930_zvLE5J3GLpE7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Issued">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zXfuBJ8HjE0d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">37,240,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930_zrebjQBMGh3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240930_z9T9826yoh3a" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">61,500,355</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_zqw4ckDVREva" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during the nine months ended September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240930_zaGgFrHSpOz8" style="text-align: right" title="Number of Stock Options, Issued">3,390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20240930_ztWKmSbOSiOe" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised / cancelled during the nine months ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20240930_zXc5ZreR49m9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">(33,000,066</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zn7sQ1zC5DL6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240930_zgeegKJvZU82" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zYVht4VbMLN3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_895_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zjv4AaxECTOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about warrants outstanding and exercisable at September 30, 2025: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XzrGr7QEgb" style="width: 17%; text-align: right" title="Warrants Outstanding, Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEoVHRbchvmh" style="width: 17%; text-align: right" title="Warrants Outstanding, Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZHqLvJQI1V1">1.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z08OVI4PSjK8" style="width: 16%; text-align: right" title="Warrants Weighted- Average Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPiojiPTGkx6" style="width: 16%; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMkC65jbjfvd" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIRvzZoT8ooa" style="text-align: right" title="Warrants Outstanding, Number of Warrants">4,373,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFG9qbNFqhX2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51-<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z49O0kAMjPn1">1.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkywCE30hWFk" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTPeQWEPe4nd" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">4,373,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9IHl7yXk7h3" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zny0krRcvEP3" style="text-align: right" title="Warrants Outstanding, Number of Warrants">26,555,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zWnrQLAB9bUj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMO0k03MLctk" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU5zQCKN4Mt2" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">26,555,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqsk6vzLb757" style="padding-bottom: 1pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVIYvEQPT94" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Number of Warrants">5,350,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB43sz8sQQre">4.84</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTxAlDID64W" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Weighted- Average Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630_z5RkiYPGWZve" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Number of Warrants">37,240,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930_zd6ge0r7yTp" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Weighted Average Exercise Price">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930_z0mvaGnhT6Ag" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Number of Exercisable">37,240,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2000000

27250000

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKULW7xCPhgg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930_zOleMbgwlnA" style="width: 16%; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930_z1ooKuVjmCCb" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20250101__20250930_zIEIL3OSTU3h" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">(375,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930_zZBd41Ikkolc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930_zuJEsivhzObj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">23,802,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930_zhayBLyH6Xpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20250101__20250930_zUraoNjMzLj4" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,610,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930_zR7jlmw8JQy2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options exercisable">0.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240930_zIAtDuzHzZy" style="width: 16%; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_zyQUlqBUEihb" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20240930_zqh2VUQEole6" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_z2cmlic2V3v8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240930_zMJKJ6S1S1z7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zhBFCaw8oUDb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20240101__20240930_zc2Pu9GrDKpg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,985,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zAouzUdQvX0c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price options exercisable">0.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

24177761

0.21

375000

23802761

0.15

13610261

0.18

24177761

0.21

24177761

0.21

13985261

0.10

<p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zb3IXm6R6cVe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at September 30, 2025: SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise prices</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding Options </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Life In Years </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Exercise Price </td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zlSgxzlM83Gc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.1 to $<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zqMIdK6ttVIe">0.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zoRwExrFQeV" style="width: 17%; text-align: right" title="Number of Outstanding Options">16,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zkMd2dnF0qP9">6.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zBzC9NOvTZw4" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price">0.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zcUbPmzhYZP" style="width: 16%; text-align: right" title="Number Exercisable">6,057,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zRaKWwg4AG3c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.16 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zqRCuRARis7h">0.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zHSdFCgxESIc" style="text-align: right" title="Number of Outstanding Options">5,502,761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zeE6yHyMOgol">5.77</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_ztflqDJhOy44" style="text-align: right" title="Weighted-Average Exercise Price">0.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zbohBFEsoAs9" style="text-align: right" title="Number Exercisable">5,502,761</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zxdoVAD0fuD7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.22 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zLWL7TfztDR4">0.37</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zYQc1WryElH9" style="text-align: right" title="Number of Outstanding Options">1,550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z67qTaWc4zzb">2.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_z9Ynsmr9qutl" style="text-align: right" title="Weighted-Average Exercise Price">0.28</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zvWKdqt53jo1" style="text-align: right" title="Number Exercisable">1,550,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zj5U0dydUUl2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.38 to $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zEa1pAFusnWg">0.72</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zlEUdfIoO6z5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Outstanding Options">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zpgztA49jk4b">0.47</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zVENUPUBWvH2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price">0.73</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_z13tXwQgOpBj" style="border-bottom: Black 1pt solid; text-align: right" title="Number Exercisable">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20250930_zX4siQYSyESd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">23,802,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5.90</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20250930_zh3LcjyP5kPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price">0.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20250930_zVdbhi64EM6l" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">13,610,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.1

0.15

16250000

P6Y5M15D

0.12

6057500

0.16

0.21

5502761

P5Y9M7D

0.16

5502761

0.22

0.37

1550000

P2Y2M15D

0.28

1550000

0.38

0.72

500000

P0Y5M19D

0.73

500000

23802761

P5Y10M24D

0.15

13610261

P10Y

P3Y

Of the approximately 10 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements. For more information on the stock options, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025

<p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zJFBklFmQHY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, as of September 30, 2025 and 2024 are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2025</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20250101__20250930_zEqHinanjux9" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20250101__20250930_z6LQCblQzcNf" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.13</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Issued during the nine months ended September 30, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20250101__20250930_zO2bL6e9hD95" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Issued">5,350,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20250101__20250930_zvLE5J3GLpE7" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Issued">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20250101__20250930_zXfuBJ8HjE0d" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">37,240,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20250101__20250930_zrebjQBMGh3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240930_z9T9826yoh3a" style="width: 16%; text-align: right" title="Number of Stock Options Outstanding, Balance">61,500,355</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_zqw4ckDVREva" style="width: 16%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during the nine months ended September 30, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20240930_zaGgFrHSpOz8" style="text-align: right" title="Number of Stock Options, Issued">3,390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20240930_ztWKmSbOSiOe" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Exercised / cancelled during the nine months ended September 30, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20240930_zXc5ZreR49m9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">(33,000,066</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zn7sQ1zC5DL6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20240930_zgeegKJvZU82" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zYVht4VbMLN3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

31890289

0.13

5350000

0.15

37240289

0.13

61500355

0.15

3390000

0.12

33000066

0.15

31890289

0.13 <p id="xdx_895_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zjv4AaxECTOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about warrants outstanding and exercisable at September 30, 2025: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding and exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">in Years</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XzrGr7QEgb" style="width: 17%; text-align: right" title="Warrants Outstanding, Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEoVHRbchvmh" style="width: 17%; text-align: right" title="Warrants Outstanding, Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZHqLvJQI1V1">1.25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z08OVI4PSjK8" style="width: 16%; text-align: right" title="Warrants Weighted- Average Exercise Price">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPiojiPTGkx6" style="width: 16%; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">961,539</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMkC65jbjfvd" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIRvzZoT8ooa" style="text-align: right" title="Warrants Outstanding, Number of Warrants">4,373,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zFG9qbNFqhX2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51-<span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z49O0kAMjPn1">1.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkywCE30hWFk" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTPeQWEPe4nd" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">4,373,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9IHl7yXk7h3" style="text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zny0krRcvEP3" style="text-align: right" title="Warrants Outstanding, Number of Warrants">26,555,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zWnrQLAB9bUj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMO0k03MLctk" style="text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU5zQCKN4Mt2" style="text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">26,555,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqsk6vzLb757" style="padding-bottom: 1pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVIYvEQPT94" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Outstanding, Number of Warrants">5,350,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB43sz8sQQre">4.84</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTxAlDID64W" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Weighted- Average Exercise Price">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250630_z5RkiYPGWZve" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Number of Warrants">37,240,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20250930_zd6ge0r7yTp" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Weighted Average Exercise Price">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250930_z0mvaGnhT6Ag" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding, Number of Exercisable">37,240,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.13

961539

P1Y3M

0.13

961539

0.20

4373750

P1Y6M3D

P1Y8M23D

0.20

4373750

0.12

26555000

P0Y3M

0.12

26555000

0.15

5350000

P4Y10M2D

0.15

37240289

P1Y1M6D

0.13

37240289

NOTE 13 – COMMITMENTS AND CONTINGENCIES Leases Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. The Company believes the office is sufficient for its current operations. PointR Merger Contingent Consideration The total purchase price in the PointR Merger of $<span id="xdx_906_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--PointRMergerMember_zvSdSJsSZByc">17,831,427 included $<span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20250930__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--PointRMergerMember_zJFOkHJmFsel">2,625,000 of contingent consideration of shares issuable to PointR shareholders, upon achievement of certain milestones. For more information on the PointR Merger Contingent Consideration, refer to our 2024 Annual Report on Form 10-K filed with the SEC on April 15, 2025. Other claims From time to time, the Company may become involved in certain claims arising in the ordinary course of business. During the year ended December 2022, a former employee brought suit for breach of employment contract claim against the Company in Honorable Supreme Court of California. The Company filed a counter claim. A liability of $162,500 million was recorded related to this claim. The litigation was settled in October 2025. See Note 14.

17831427

2625000

162500

NOTE 14 – SUBSEQUENT EVENTS As previously disclosed in Note 13 above, in October 2025, the Company settled the outstanding litigation with the ex-employee. In connection with the settlement, Autotelic paid $162,500, for a complete release of claims, on behalf of the Company. The Company has recorded such payment as a debt from Autotelic. In October 2025, the Company partially converted approximately $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20251001__20251031__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zzneQx8MBKle">44,000 of their debt, including accrued interest, and fee of approximately $2,000 under the Fourth Man Note. In connection with the conversion, the Company issued <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20251001__20251031__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zq34ZecIZWf9">663,608 shares of its Common Stock to Fourth Man. In November 2025, the Company partially converted approximately $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20251101__20251130__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFLnkt0qRRg2">45,000 of their debt, including accrued interest, and fee of approximately $2,000 under the Fourth Man Note. In connection with the conversion, the Company issued <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20251101__20251130__srt--TitleOfIndividualAxis__custom--FourthManLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9q9aautQUM7">668,748 shares of its Common Stock to Fourth Man. On November 17, 2025, the Company entered into a restricted stock agreement with Dr. Trieu, our CEO and a related party, to provide incentive compensation for his extra-ordinary efforts and time to raise capital and successful achievement of certain milestones. The restricted stock agreement provides for a grant of up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20251117__20251117__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zTK6j4MR2DXh">24,387.516 shares of our unissued Series A Convertible Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20251117__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoTEPCjdcufb">0.01 (“Preferred Stock”), subject to achievement of certain milestones, namely (1) on the signing July 2025 Mast Note – 4,065 shares of Preferred Stock: (2) the Company achieving a market capitalization exceeding $100 million on any single trading day’s close – 8,131 shares of Preferred Stock; (3) the Company achieving a cumulative increase of at least $10 million in shareholder equity from the start of engagement (as reported in SEC filings ) - <span id="xdx_90C_eus-gaap--StockholdersEquityOtherShares_c20251117__20251117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zR7rCWlTQ2Sj">8,131,000 shares of Preferred Stock; and (4) a successful uplisting to a U.S. national exchange, with at least one full day of trading- <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20251117__20251117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zCMULK1x6hXg">4,062.516 Shares of Preferred Stock. Each share of Preferred Stock is convertible into <span id="xdx_90D_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20251117__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJ94bXxZXVZh">1,000 shares of the Company’s Common Stock, and votes with the Common Stock on an as converted basis. The Board of Directors has approved the entry into the restricted stock agreement, a copy of which is being filed as an exhibit to this report. On November 13, the Board approved a grant of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesOther_c20251113__20251113__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2UYb3zg7Hl1">1,818,182 shares of our Common Stock to Out the Box Capital, Inc. (“OTB”) in lieu of certain marketing services at a cost of $200,000. Such shares will be issued as unregistered shares.

162500

44000

2000

663608

45000

2000

668748

24387.516

0.01

4065

100000000

8131

10000000

8131000

4062.516

1000

1818182

200000

86128

170405

20000

18976

9107

62356

134211

271737

1101760

2788230

5988230

22653225

26677426

30014952

2437167

2437321

346057

344099

2625000

703616

423214

9790866

8066957

3297208

2608356

3297208

2608356

19199914

16504947

1898468

19199914

18403415

0.01

750000000

407289618

399184128

4072899

3991839

42219400

41655026

-38040668

-33516736

8251631

12130129

-774119

-518592

7477512

11611537

26677426

30014952

70000

61143

376013

573726

3200000

6083146

3576013

6718015

-3576013

-6648015

857723

1044786

-22937 -72246

12706

-280402

-225074

-88258

-373142

-1203446

-1558050

-4779459

-8206065

-255527

-302972

-4523932

-7903093

-0.01

-0.02

404396473

384075369

399184128

3991839

41655026

-33516736

-518592

11611537

8105760

81060

564374

645434

-4523932

-255527

-4779459

407289888

4072899

42219400

-38040668

-774119

7477512

391846880

3918469

41416632

-25926069

-215620

19193412

391846880

3918469

41416632

-25926069

-215620

19193412

521749 -312426 209323

7337248

73370

431559

504929

328584

-7903093

-302972

-8206065

399184128

3991839

41655026

-33516736

-518592

11611537

399184128

3991839

41655026

-33516736

-518592

11611537

-4779459

-8206065

3200000

6083146

122141

301917

12706

-88258

-373142

772

-280402

-225074

-53249

40392

293184

-72771

1958

26836

-740267

-1321047

125000

656000

1410000

35000

656000

1250000

-84267

-71047

190405

261452

106128

190405

365940

390561

1600

645434 504929

NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business Oncotelic Therapeutics, Inc. (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation; Pet2DAO, Inc (“Pet2DAO”) and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR, Pet2DAO and Edgepoint are collectively called the “Company” or “We”). The Company completed a reverse merger with Oncotelic Inc in April 2019, a merger with PointR in November 2019 and formed a subsidiary Edgepoint in February 2020. For more information on these mergers, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 14, 2024. The Company is currently developing OT-101, through its joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), both affiliates of Golden Mountain Partners (“GMP”), for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The JV is also developing 5 additional compounds, which if approved, are anticipated to be significant value contributors for the JV, as well as the Company. The Company is also, independently, planning to develop OT-101 for certain animal health indications and contemplating using crypto currencies for that platform. The Company has acquired apomorphine for Parkinson’s Disease, erectile dysfunction and female sexual dysfunction. In addition, the Company is evaluating the further development of its product candidates OXi4503 as a treatment for acute myeloid leukemia and myelodysplastic syndromes and CA4P in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. The Company is primarily a cancer immunotherapy company dedicated to the development of first in class self-immunization protocol (“SIP™”) candidates for difficult to treat cancers. The Company’s proprietary SIP™ candidates are expected to offer advantages over other immunotherapies because they do not require extraction of the tumor or isolation of the antigens, and they have the potential for broad-spectrum applicability for multiple cancer types. The Company’s proprietary product candidates have shown promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The Company aims to translate its unique insights, which span more than three decades of original work using RNA therapeutics, into the deployment of antisense as a RNA therapeutic for diseases which are caused by TGF-β overexpression, starting with cancer and expanding to Duchenne Muscular Dystrophy (“DMD”) and others. OT-101, is being developed as a broad-spectrum anti-cancer drug that can also be used in combination with other standard cancer therapies to establish an effective multi-modality treatment strategy for difficult-to-treat cancers. Further, The JV is also developing 5 additional compounds, which if approved, are anticipated to be significant revenue and value contributors for the JV as well as the Company. The JV plans to initiate phase 2 and 3 clinical trials for OT-101 in both high-grade glioma and pancreatic cancer, and any other indications that may evolve, for human pharmaceutical needs. The JV may also be sponsoring investigator-initiated studies for OT-101 for other oncology indications. The Company is evaluating the further development of its product candidates OXi4503, as a treatment for acute myeloid leukemia and myelodysplastic syndromes, and CA4P, in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. The JV is also developing OT-101 for the various epidemics and pandemics, similar to the corona virus (“COVID-19”) pandemic. In this connection, the Company entered into an agreement and supplemental agreement with GMP for a total of $<span id="xdx_908_eus-gaap--InvestmentCompanyRegistrationExpense_pn5n6_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--SupplementalAgreementMember__dei--LegalEntityAxis__custom--GoldenMountainPartnersLLCMember_zzcRBpp7vYl2">1.2 million to render services and was paid for the development of OT-101. For more information on GMP and Artemisinin, refer to our 2023 Annual report on Form 10- K filed with the SEC on April 12, 2024. Fundraising Private Placement 2 & JH Darbie Financing Between July 2023 and September 2023, the Company entered into a series of subscription agreements with 15 accredited investors which resulted in a conversion of a gross amount of $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20230901__20230930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zWOd3Kd8dKre">1.0 million, consisting of 40 notes, under the prior JH Darbie Financing into new debt to the Company. JH Darbie and the Company are parties to a March 2023 placement agent agreement (“Agreement”) pursuant to which <span id="xdx_907_eus-gaap--DebtConversionDescription_c20230901__20230930__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zaPottwm9uK1">JH Darbie has the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis. Further, in October 2023, the Company entered into a series of subscription agreements with 27 accredited investors which resulted in a conversion of a gross amount of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn4n6_c20231001__20231031__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zGZqRgGwdm3k">1.05 million, consisting of 42 notes, under the prior JH Darbie Financing into new debt to the Company. Additionally, in January 2024, Company entered into a series of subscription agreements with 4 accredited investors which resulted in a conversion of a gross amount of $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_pn5n6_c20240101__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AdditionallyAccreditedInvestorsMember_zDn9CrUfZ6W9">0.3 million, consisting of 12 notes. The July 2023, October 2023 and January 2024 conversions fully converted JH Darbie PPM-1 notes into PPM-2 notes. For more information on the new JH Darbie Financing, refer to Note 8 of these Notes to the Consolidated Financial Statements. J.H. Darbie Financing Notes & Issuance of Oncotelic Warrants In February 2022, the Company and 99 out of 100 of the Investors agreed to extend the maturity date of the notes connected to the Units from March 31, 2022 to March 31, 2023. In addition, the Company issued approximately 33 million warrants to purchase $50,000 of shares of common stock of the Company (“Common Stock’) in connection with agreeing to extend the maturity date by one year. The issuance of the additional warrants resulted in the Company recording an expense of approximately $2.9 million in the Company’s statement of operations during the year ended December 31, 2022. The approximately 33 million warrants to purchase shares of our Common Stock expired on March 31, 2024. For more information on the JD Darbie financing, refer to Note 7 of these unaudited Notes to the Consolidated Financial Statements. Equity Purchase Agreement In May 2021, the Company entered into an Equity Purchase Agreement (the “EPL”) and Registration Rights Agreement (the “Registration Rights Agreement”) with Peak One Opportunity Fund, L.P. (“Peak One”), pursuant to which the Company shall have the right, but not the obligation, to direct Peak One to purchase up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20210501__20210531__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--PeakOneOpportunityFundLPMember_zjAQUPvgWlci">10.0 million (the “Maximum Commitment Amount”) in shares of the common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20210531__us-gaap--TypeOfArrangementAxis__custom--EquityPurchaseAgreementMember__dei--LegalEntityAxis__custom--PeakOneOpportunityFundLPMember_zFiiYpzI9sNb">0.01 per share (“Common Stock”) in multiple tranches. The Company filed a post-effective amendment for the EPL on April 12, 2024 with the SEC and the SEC has made the post-effective amendment effective on April 22, 2024. The Company filed a prospectus under rule 424b3 with the SEC on April 26, 2024. For more information on the EPL, refer to Note 10 of the Notes to the Unaudited Consolidated Financial Statements. August 2021 Notes In August 2021, the Company issued Note Purchase Agreements with Autotelic Inc., the Company’s Chief Financial Officer (“CFO”), and certain other accredited investors. Under the terms of the Note Purchase Agreements, the Company issued an aggregate of $698,500 (the “Principal Amount”) in debt in the form of unsecured convertible promissory notes (collectively, the “Notes”). The Notes are unsecured, and provide for interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210831__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember_zYG5wuGfTxA2">5% per annum. Such Notes were issued against some of the short-term debt due as of June 30, 2021. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. November/December 2021 and March 2022 Notes In November / December 2021, the Company entered into various Securities Purchase Agreements with Talos Victory Fund, LLC (the (“Talos”), Mast Hill Fund, LP (“Mast”), FirstFire Global Opportunities Fund, LLC (“FirstFire”), Blue Lake Partners, LLC (“Blue Lake”) and Fourth Man, LLC (“Fourth Man”), pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.25 million each, aggregating gross $1.25 million (the “Notes”), and which Notes were convertible into shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). In June 2022, Mast fully converted their November 2021 Note, for which the company issued 4,025,000 shares of Common Stock. Further, during the year ended December 31, 2023, the Company fully converted the balance of Fourth Man convertible note of approximately $127,000 into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--FourthManLLCMember_zySOZkQCuDTj">1,820,395 shares of the Company’s common stock, which fully retired the convertible note as of December 31, 2024. In March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $0.25 million, which Note is convertible into shares of the Company’s Common Stock. As of December 31, 2024, this note is in default and available for conversion into the Company’s Common Stock due to cross default provision contained in November / December 2021 Notes. During the year ended December 31, 2024, Fourth Man converted a portion of the March 2022 debt, including interest, and conversion fee, of approximately $35,000 for 500,000 shares of the Company’s Common Stock. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. May 2022 Note In May 2022, the Company entered into a Securities Purchase Agreement with Mast, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.6 million, which note is convertible into shares of the Company’s Common Stock. In May 2024, the May 2022 Note was extended till May 2025, at a cost of 10% of the outstanding Note amount, including interest and penalty. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. June 2022 Note In June 2022, the Company entered into a Securities Purchase Agreement with Blue Lake, pursuant to which the Company issued convertible promissory notes in the aggregate principal amount of $0.34 million, which note is convertible into shares of the Company’s Common Stock. During the year ended December 31, 2024, Blue Lake converted the balance of their debt, including accrued interest and penalty, of approximately $531,000 for approximately 7.6 million shares of the Company’s Common Stock. For more information on the debt financing of the Company, refer to Note 5 of the Notes to the Consolidated Financial Statements. Forever Prosperity (previously GMP) Note purchase agreements and unsecured notes Between June 2020 and January 2022, the Company entered into various purchase agreements and promissory notes with GMP, cumulatively totaling $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementAndPurchaseAgreementMember__dei--LegalEntityAxis__custom--GoldenMountainPartnersMember_zKed5eXBSr9i">4.5 million. Such notes were assigned to Forever Prosperity, LLC, an affiliated entity of GMP. For more information on the GMP debt financing, refer to Note 5 of the Notes to the Consolidated Financial Statements. Joint Venture with GMP Bio In March 2022, the Company formalized a joint venture (“JV”) with Dragon Overseas Capital Limited (“Dragon”) and GMP Biotechnology Limited (“GMP Bio”), both affiliates of GMP. Although no assurances can be given, the Company and GMP currently intend to conduct an initial public offering of the JV, at a future date, on either the Hong Kong Exchange or other stock exchange. For more information on the JV, refer to Note 6 of the Notes to the Consolidated Financial Statements. Pet2DAO In November 2022, the Company formed a Decentralized autonomous organization (“DAO”) entity, Pet2DAO LLC (“Pet2DAO”), as a wholly owned subsidiary. For more information on Pet2DAO, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. Mosaic ImmunoEngineering, Inc. Term Sheet In April 2024, the Company entered into a binding term sheet (the “Term Sheet”) with Mosaic ImmunoEngineering, Inc. (“Mosaic”). For more information on the Term Sheet, refer to the Current Report on Form 8-K filed with the SEC on April 29, 2024. In August 2024, Mosaic and the Company mutually agreed to extend the date of the Term Sheet to expire at the earlier of (1) the signing of definitive agreements or (2) December 31, 2024. In December 2024, he Company and Mosaic further extended the term of the term-sheet to expire at the earlier of (1) the signing of definitive agreements or (2) June 30, 2025. This was to allow for both Companies to complete due diligence as well as agree and finalize the definitive agreements. The Company had advanced $40 thousand to Mosaic in accordance with the terms of the Term Sheet, and Mosaic has repaid the amount, with interest to the Company as of December 31, 2024. Licensing Agreement with Autotelic Inc. In September 2021, the Company entered into an exclusive License Agreement (the “Agreement”) with Autotelic, Inc. (“Autotelic”). For more information on the Agreement, refer to our 2023 10-K filed with the SEC on April 12, 2024. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Oncotelic, PointR and Edgepoint for which there are non-controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net losses of approximately $38 million since inception of Oncotelic Inc. as the Company’s historical financial statements before the Merger have been replaced with the historical financial statements of Oncotelic Inc. prior to the Merger in the financial statements and filings. The Company also has a negative working capital of approximately $19.1 million at December 31, 2024, of which approximately $2.6 million contingent liability of issuance of common shares of the Company to PointR shareholders upon achievement of certain milestones in accordance with the PointR Merger Agreement. The Company has negative cash flows from operations for the year ended December 31, 2024 of approximately $0.7 million. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of this filing. Management expects to incur significantly lower costs and losses in the foreseeable future, as a majority of the costs related with the development of OT-101 will be incurred by the JV, but the Company also recognizes the need to raise capital to remain viable. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The Company’s long-term plans include continued development of its current pipeline of products, in addition to continue the development of OT-101 which is exclusively out-licensed to the JV and the JV will be responsible for the funding required to support the development in entirety, to generate sufficient revenues, through either technology transfer or product sales, or raise additional financing to cover its anticipated expenses. Until the Company is able to generate sufficient revenues from its current pipeline, the Company plans on funding its operations through the sale of equity and/or the issuance of debt, combined with or without warrants or other equity instruments. The Company obtained short term loans of approximately $0.6 million from Autotelic Inc., a related party, during the year ended December 31, 2024. In addition, the Company obtained a short-term loan of $41 thousand from Amit Shah, it’s CFO during year ended December 31, 2024. Although no assurances can be given as to the Company’s ability to deliver on its revenue plans, or that unforeseen expenses may arise, management believes that the potential equity and debt financing or other potential financing will provide the necessary funding for the Company to continue as a going concern. Also, management cannot guarantee any potential debt or equity financing will be available on favorable terms or at all. As such, management does not believe the Company has sufficient cash for 12 months from the date of this report. If adequate funds are not available on acceptable terms, or at all, the Company will need to curtail operations, or cease operations completely.

1200000

1000000.0

JH Darbie has the right to sell/convert a minimum of 10 Units and a maximum of 200 Units on a best-efforts basis.

1050000.00

300000

33000000

50000 2900000

33000000

10000000.0

0.01

698500

0.05

250000

1250000

0.01

4025000

127000

1820395

250000

35000

500000

600000

340000

531000

7600000

4500000

40000

38000000

19100000 2600000

-700000

600000

41000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments. Cash As of December 31, 2024 and 2023, respectively, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2024 and 2023, respectively. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes. Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring. Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">●</td> <td style="text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">●</td> <td style="text-align: justify">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non- exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td>●</td> <td style="text-align: justify">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.</td></tr> </table> The Company did not have any Level 1 or Level 2 assets and liabilities at December 31, 2024 and 2023. Investment in equity securities The following table summarizes the cumulative gross unrealized gains and losses and fair values for long- term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of December 31, 2024 and 2023: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zsNaHjy4avG7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zNjI6gsFivy1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_ze6j6JDU9Pdj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zz9KBFPZoIGh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231_zfathUqgARsh" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231_zcc19pgzz8Nh" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231_zabuV4aVF4o6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231_z7lo2IEeZwX8" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--EquitySecuritiesInitialBookValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zbIBCjCvqyH2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, initial book value">22,640,519</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20230101__20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_z4ixTpxJna9h" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized gains">12,706</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20230101__20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zirabBcOxRT5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zWiGcOVKvFC4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--EquitySecuritiesInitialBookValue_iI_c20231231_zdoyM4zLpZD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,640,519</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20230101__20231231_zSnzCrhhGDNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">12,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20230101__20231231_ziqxdjBqieq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20231231_z0SLNFozd1u2" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of December 31, 2024 and 2023. During the year ended December 31, 2024, there have been no changes in the long-term value of the investment in equity securities of GMP Bio. Derivative Liability The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), consisted of conversion feature derivatives at December 31, 2024 and 2023, are Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of December 31, 2024 and 2023: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zH85noeXlQ0d" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">December 31, 2024 Conversion Feature</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_z9sEqykgHfCe" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">December 31, 2023 Conversion Feature</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zjQtEPB723Ei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">423,214</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zbAgL8N32Cg8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">423,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">198,140</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zEvgcY65UA19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280,402</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,074</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_z0SDncQox7ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423,214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zHnAIwgKKj2l" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423,214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At December 31, 2024 and 2023, respectively, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of December 31, 2024 and 2023: SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse"> <tr> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td style="white-space: nowrap; vertical-align: top; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">December 31, 2024</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">December 31, 2023</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Risk free interest</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z2W44sLKkVZ4" style="font-size: 10pt">3.98% - <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zzJPkGUGiD5d">5.09%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zDkHgrklv3yb" style="font-size: 10pt">4.64% - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7yo4Anc0vO7">5.40%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">Market price of share</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">$ <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zczzV6cTrwci">0.02 - <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zsGjqNQnZAk2">0.04</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">$ <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zq2Y2tsEzPm">0.03 - <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_z2cI4EF1JaVj">0.05</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 63%">Life of instrument in years</td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6rqFYQqIFW2" style="font-size: 10pt">0.01</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUOL70OAiS07" style="font-size: 10pt">0.01</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">Volatility</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zwAdjA5PrXHg" style="font-size: 10pt">138.38%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zdsFIuTtZqij">226.9</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z2cOk0eoo69e" style="font-size: 10pt">142.45%-<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zybUXGW7HLTh">236.86</td> <td style="vertical-align: bottom">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Dividend yield</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zbzbWwLN5B8l" style="font-size: 10pt">0</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGK2xfEwvUO9" style="font-size: 10pt">0</td> <td style="vertical-align: bottom">%</td></tr> </table> When the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the years ended December 31, 2024 and 2023, there were no transfers of financial assets or financial liabilities between the hierarchy levels. The $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMember_zgVCHolReKCb">2,625,000 of contingent consideration, of shares issuable to PointR shareholders which was recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic and other technologies being developed. As such, the Company did not record any change to the valuation during the years ended December 31, 2024 or 2023, respectively; and as of December 31, 2024 and 2023, respectively. Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted- average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. During the years ended December 31, 2024 and 2023, no equivalent shares of the Common Stock were included as the Company had incurred losses during this period and addition of such stock equivalents in the computation would have been anti-dilutive. Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and non-employees, including employee stock options, in the statements of operations. For stock options issued, the Company estimates the grant date fair value of each option using the Black- Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital. Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, there were no impairment losses recognized for long- lived assets. Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the years ended December 31, 2024 and 2023, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed. Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. The Company has always operated as a single unit. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed. For the years ended December 31, 2024 and 2023, we recorded an impairment loss of approximately $3.2 million and $6.1 million and, respectively, on our goodwill, based on the difference between the carrying value of our goodwill as against the market capitalization of the Company. For more information on goodwill and impairment, refer to Note 3 to these Notes to the Consolidated Financial Statements. Derivative Financial Instruments Indexed to the Company’s Common Stock We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Consolidated Statement of Income. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability. Variable Interest Entity (VIE) Accounting The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At December 31, 2024 and 2023, the Company identified EdgePoint to be the Company’s sole VIE. At December 31, 2024, and 2023, the Company’s ownership percentage of EdgePoint was 29% each, respectively. The VIE’s net assets were less than approximately $0.1 million at December 31, 2024 and 2023, respectively. Investments - Equity Method The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the Consolidated Financial Statements. Joint Venture agreement We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture. We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination. To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non- managing entity and the inability of the non-managing entity to remove us from our role as the managing entity. We use the equity method of accounting for those arrangements where we exercise significant influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our consolidated balance sheet. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss. When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value. The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the Company. Embedded debt costs in convertible debt instruments In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition was permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted no earlier than the fiscal year beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2023 and has removed the effects of any embedded conversion features from certain of our convertible instruments as of that date. Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company anticipates generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized. Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred. Recent Accounting Pronouncements In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition was permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption was permitted no earlier than the fiscal year beginning after December 15, 2020.The Company adopted ASU 2020-06 effective January 1, 2023 and recorded approximately $0.5 million as a reduction to the additional paid in capital and added approximately $0.3 million to the opening retained earnings in accordance with the authoritative guidance under ASU 2020-06. All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.

Cash As of December 31, 2024 and 2023, respectively, the Company held all its cash in banks in the United States of America. The Company considers investments in highly liquid instruments with a maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2024 and 2023, respectively. Restricted cash consists of certificates of deposits held at banks as collateral for various purposes.

Debt issuance Costs and Debt discount Issuance costs are specific incremental costs that are (1) paid to third parties and (2) directly attributable to the issuance of a debt or equity instrument. The issuance costs attributable to the initial sale of the instrument are offset against the associated proceeds in the determination of the instrument’s initial net carrying amount. Debt issuance costs and debt discounts are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs and discounts are presented as a reduction of the related debt in the accompanying balance sheets if related to the issuance of debt or presented as a reduction of additional paid in capital if related to the issuance of an equity instrument. The Company applies the relative fair value to allocate the issuance costs among freestanding instruments that form part of the same transaction. If the Company amends the terms of its convertible notes, the Company reviews and applies the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments, evaluates and concludes whether the terms of the agreements were or were not substantially different as of a particular reporting date and accounts the transaction as a debt modification or a troubled debt restructuring.

Fair Value of Financial Instruments The carrying value of cash, accounts payable and accrued expense approximate their fair values based on the short-term maturity of these instruments. As defined in ASC 820, “Fair Value Measurements and Disclosures,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement. The three levels of the fair value hierarchy defined by ASC 820 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">●</td> <td style="text-align: justify">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.5in">●</td> <td style="text-align: justify">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non- exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td>●</td> <td style="text-align: justify">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.</td></tr> </table> The Company did not have any Level 1 or Level 2 assets and liabilities at December 31, 2024 and 2023.

Investment in equity securities The following table summarizes the cumulative gross unrealized gains and losses and fair values for long- term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of December 31, 2024 and 2023: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zsNaHjy4avG7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zNjI6gsFivy1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_ze6j6JDU9Pdj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zz9KBFPZoIGh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231_zfathUqgARsh" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231_zcc19pgzz8Nh" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231_zabuV4aVF4o6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231_z7lo2IEeZwX8" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--EquitySecuritiesInitialBookValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zbIBCjCvqyH2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, initial book value">22,640,519</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20230101__20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_z4ixTpxJna9h" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized gains">12,706</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20230101__20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zirabBcOxRT5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zWiGcOVKvFC4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--EquitySecuritiesInitialBookValue_iI_c20231231_zdoyM4zLpZD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,640,519</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20230101__20231231_zSnzCrhhGDNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">12,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20230101__20231231_ziqxdjBqieq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20231231_z0SLNFozd1u2" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The table above sets forth a summary of the recording of the initial value of the long-term value of investment in equity securities of GMP Bio, based on a third-party valuation report, and changes in the fair value of such equity securities, if such change occurs, as a Level 3 fair value as of December 31, 2024 and 2023. During the year ended December 31, 2024, there have been no changes in the long-term value of the investment in equity securities of GMP Bio.

The following table summarizes the cumulative gross unrealized gains and losses and fair values for long- term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of December 31, 2024 and 2023: SCHEDULE OF UNREALIZED GAINS AND LOSSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zsNaHjy4avG7" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zNjI6gsFivy1" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_ze6j6JDU9Pdj" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zz9KBFPZoIGh" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquitySecuritiesInitialBookValue_iI_c20241231_zfathUqgARsh" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20240101__20241231_zcc19pgzz8Nh" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20240101__20241231_zabuV4aVF4o6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20241231_z7lo2IEeZwX8" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Initial Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Gains</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Gross Unrealized Losses</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-bottom: 1pt">Investment in GMP Bio (equity securities)</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--EquitySecuritiesInitialBookValue_iI_c20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zbIBCjCvqyH2" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, initial book value">22,640,519</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20230101__20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_z4ixTpxJna9h" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized gains">12,706</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20230101__20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zirabBcOxRT5" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20231231__us-gaap--AwardTypeAxis__custom--GMPBioMember_zWiGcOVKvFC4" style="border-bottom: Black 1pt solid; width: 12%; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--EquitySecuritiesInitialBookValue_iI_c20231231_zdoyM4zLpZD7" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, initial book value">22,640,519</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiUnrealizedGain_c20230101__20231231_zSnzCrhhGDNl" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized gains">12,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--EquitySecuritiesFvNiUnrealizedLoss_c20230101__20231231_ziqxdjBqieq4" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, unrealized losses">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--EquitySecuritiesFvNiCurrentAndNoncurrent_iI_c20231231_z0SLNFozd1u2" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment in equity securities, fair value">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 22653225

22653225

22640519

12706

22653225

22640519

12706

22653225

Derivative Liability The Company has certain derivative liabilities associated with its 2019 bridge financing Convertible Notes (see Note 5), consisted of conversion feature derivatives at December 31, 2024 and 2023, are Level 3 fair value measurements. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of December 31, 2024 and 2023: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zH85noeXlQ0d" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">December 31, 2024 Conversion Feature</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_z9sEqykgHfCe" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">December 31, 2023 Conversion Feature</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zjQtEPB723Ei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">423,214</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zbAgL8N32Cg8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">423,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">198,140</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zEvgcY65UA19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280,402</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,074</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_z0SDncQox7ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423,214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zHnAIwgKKj2l" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423,214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At December 31, 2024 and 2023, respectively, the Company estimated the fair value of the conversion feature derivatives embedded in the convertible debentures based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement dates. The Company used the following assumptions to estimate fair value of the derivatives as of December 31, 2024 and 2023: SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse"> <tr> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td style="white-space: nowrap; vertical-align: top; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">December 31, 2024</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">December 31, 2023</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Risk free interest</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z2W44sLKkVZ4" style="font-size: 10pt">3.98% - <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zzJPkGUGiD5d">5.09%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zDkHgrklv3yb" style="font-size: 10pt">4.64% - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7yo4Anc0vO7">5.40%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">Market price of share</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">$ <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zczzV6cTrwci">0.02 - <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zsGjqNQnZAk2">0.04</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">$ <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zq2Y2tsEzPm">0.03 - <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_z2cI4EF1JaVj">0.05</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 63%">Life of instrument in years</td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6rqFYQqIFW2" style="font-size: 10pt">0.01</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUOL70OAiS07" style="font-size: 10pt">0.01</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">Volatility</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zwAdjA5PrXHg" style="font-size: 10pt">138.38%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zdsFIuTtZqij">226.9</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z2cOk0eoo69e" style="font-size: 10pt">142.45%-<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zybUXGW7HLTh">236.86</td> <td style="vertical-align: bottom">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Dividend yield</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zbzbWwLN5B8l" style="font-size: 10pt">0</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGK2xfEwvUO9" style="font-size: 10pt">0</td> <td style="vertical-align: bottom">%</td></tr> </table> When the Company changes its valuation inputs for measuring financial liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the years ended December 31, 2024 and 2023, there were no transfers of financial assets or financial liabilities between the hierarchy levels. The $<span id="xdx_90D_eus-gaap--BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_c20240101__20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__dei--LegalEntityAxis__custom--PointRMember_zgVCHolReKCb">2,625,000 of contingent consideration, of shares issuable to PointR shareholders which was recorded and associated with the PointR Merger, is also classified as Level 3 fair value measurements. The Company initially recorded the contingency based on a valuation conducted by a third-party valuation expert. The valuation was based on a probability of the completion of certain milestones by PointR for the shareholders to earn additional shares. The Company evaluated the probability of the earning of the milestones and concluded that the probability of achievement of the milestones had not changed, primarily due to the shifting of focus by the Company to develop AI technologies for the COVID-19 pandemic and other technologies being developed. As such, the Company did not record any change to the valuation during the years ended December 31, 2024 or 2023, respectively; and as of December 31, 2024 and 2023, respectively. The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of December 31, 2024 and 2023: SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240101__20241231_zH85noeXlQ0d" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">December 31, 2024 Conversion Feature</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20230101__20231231_z9sEqykgHfCe" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">December 31, 2023 Conversion Feature</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zjQtEPB723Ei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">423,214</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">198,140</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zbAgL8N32Cg8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">423,214</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">198,140</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease_zEvgcY65UA19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">280,402</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,074</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_z0SDncQox7ph" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423,214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zHnAIwgKKj2l" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">703,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">423,214</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

423214

198140

423214

198140

280402

225074

703616

423214

703616

423214

SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse"> <tr> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td style="white-space: nowrap; vertical-align: top; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">December 31, 2024</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: bottom; text-align: center">December 31, 2023</td> <td style="white-space: nowrap; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Risk free interest</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z2W44sLKkVZ4" style="font-size: 10pt">3.98% - <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zzJPkGUGiD5d">5.09%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zDkHgrklv3yb" style="font-size: 10pt">4.64% - <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_z7yo4Anc0vO7">5.40%</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">Market price of share</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">$ <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zczzV6cTrwci">0.02 - <span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_zsGjqNQnZAk2">0.04</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">$ <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MinimumMember_zq2Y2tsEzPm">0.03 - <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__srt--RangeAxis__srt--MaximumMember_z2cI4EF1JaVj">0.05</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 63%">Life of instrument in years</td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span id="xdx_90D_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20240101__20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z6rqFYQqIFW2" style="font-size: 10pt">0.01</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 2%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span id="xdx_907_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUOL70OAiS07" style="font-size: 10pt">0.01</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom">Volatility</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zwAdjA5PrXHg" style="font-size: 10pt">138.38%-<span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zdsFIuTtZqij">226.9</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z2cOk0eoo69e" style="font-size: 10pt">142.45%-<span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zybUXGW7HLTh">236.86</td> <td style="vertical-align: bottom">%</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom">Dividend yield</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zbzbWwLN5B8l" style="font-size: 10pt">0</td> <td style="vertical-align: bottom">%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zGK2xfEwvUO9" style="font-size: 10pt">0</td> <td style="vertical-align: bottom">%</td></tr> </table>

3.98

5.09

4.64

5.40

0.02

0.04

0.03

0.05

P0Y3D P0Y3D

138.38

226.9

142.45

236.86

2625000

Net Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted- average number of common shares outstanding during the period. Diluted net income (loss) per share includes the effect of Common Stock equivalents (notes convertible into Common Stock, stock options and warrants) when, under either the treasury or if-converted method, such inclusion in the computation would be dilutive. During the years ended December 31, 2024 and 2023, no equivalent shares of the Common Stock were included as the Company had incurred losses during this period and addition of such stock equivalents in the computation would have been anti-dilutive.

Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and non-employees, including employee stock options, in the statements of operations. For stock options issued, the Company estimates the grant date fair value of each option using the Black- Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the Common Stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the Common Stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised. For warrants issued in connection with fund raising activities, the Company estimates the grant date fair value of each warrant using the Black-Scholes pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the warrant, the expected volatility of the Common Stock consistent with the expected life of the warrant, risk-free interest rates and expected dividend yields of the Common Stock. If the warrants are issued upon termination or cancellation of prior issued warrants, then the Company estimates the grant date fair value of the new warrants using the Black-Scholes pricing model and evaluates whether the new warrants are deemed as equity instruments or liability instruments. If the warrants are deemed to be equity instruments, the Company records stock compensation expense and an addition to additional paid in capital. If however, the warrants are deemed to be liability instruments, then the fair value is treated as a deemed dividend and credited to additional paid in capital.

Impairment of Long-Lived Assets The Company reviews long-lived assets, including definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of these assets is determined by comparing the forecasted undiscounted net cash flows of the operation to which the assets relate to the carrying amount. If the operation is determined to be unable to recover the carrying amount of its assets, then these assets are written down first, followed by other long-lived assets of the operation to fair value. Fair value is determined based on discounted cash flows or appraised values, depending on the nature of the assets. For the years ended December 31, 2024 and 2023, there were no impairment losses recognized for long- lived assets.

Intangible Assets The Company records its intangible assets at cost in accordance with ASC 350, Intangibles – Goodwill and Other. The Company reviews the intangible assets for impairment on an annual basis or if events or changes in circumstances indicate it is more likely than not that they are impaired. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. If the review indicates the impairment, an impairment loss would be recorded for the difference of the value recorded and the new value. For the years ended December 31, 2024 and 2023, there were no impairment losses recognized for intangible assets. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed.

Goodwill Goodwill represents the excess of the purchase price of acquired business over the estimated fair value of the identifiable net assets acquired. Goodwill is not amortized but is tested for impairment at least once annually, at the reporting unit level or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment test is applied by performing a qualitative assessment before calculating the fair value of the reporting unit. If, on the basis of qualitative factors, it is considered not more likely than not that the fair value of the reporting unit is less than the carrying amount, further testing of goodwill for impairment would not be required. Otherwise, goodwill impairment is tested using a two-step approach. The first step involves comparing the fair value of the reporting unit to its carrying amount. The Company has always operated as a single unit. If the fair value of the reporting unit is determined to be greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount is determined to be greater than the fair value, the second step must be completed to measure the amount of impairment, if any. The second step involves calculating the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit from the fair value of the reporting unit as determined in step one. The implied fair value of the goodwill in this step is compared to the carrying value of goodwill. If the implied fair value of the goodwill is less than the carrying value of the goodwill, an impairment loss equivalent to the difference is recorded. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed. For the years ended December 31, 2024 and 2023, we recorded an impairment loss of approximately $3.2 million and $6.1 million and, respectively, on our goodwill, based on the difference between the carrying value of our goodwill as against the market capitalization of the Company. For more information on goodwill and impairment, refer to Note 3 to these Notes to the Consolidated Financial Statements.

3200000

6100000

Derivative Financial Instruments Indexed to the Company’s Common Stock We have generally issued derivative financial instruments, such as warrants, in connection with our equity offerings. We evaluate the terms of these derivative financial instruments in order to determine their accounting treatment in our financial statements. Key considerations include whether the financial instruments are freestanding and whether they contain conditional obligations. If the warrants are freestanding, do not contain conditional obligations and meet other classification criteria, we account for the warrants as an equity instrument. However, if the warrants contain conditional obligations, then we account for the warrants as a liability until the conditional obligations are met or are no longer relevant. Because no established market prices exist for the warrants that we issue in connection with our equity offerings, we must estimate the fair value of the warrants based on the price of our Common Stock as of December 31 each year, which is as inherently subjective as it is for stock options, and for similar reasons as noted in the stock-based compensation section above. For financial instruments which are accounted for as a liability, we report any changes in their estimated fair values as gains or losses in our Consolidated Statement of Income.

Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815 “Derivatives and Hedging”. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur, and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.” The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with ASC 470-20 “Debt – Debt with Conversion and Other Options.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Original issue discounts (“OID”) under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying Common Stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815-40 “Derivatives and Hedging – Contracts in Entity’s Own Equity” provides that, among other things, generally, if an event occurs that is not within the entity’s control could or would require net cash settlement, then the contract shall be classified as an asset or a liability.

Variable Interest Entity (VIE) Accounting The Company evaluates its ownership, contractual relationships and other interests in entities to determine the nature and extent of the interests, whether such interests are variable interests and whether the entities are VIEs in accordance with ASC 810, Consolidations. These evaluations can be complex and involve Management judgment as well as the use of estimates and assumptions based on available historical information, among other factors. Based on these evaluations, if the Company determines that it is the primary beneficiary of a VIE, the entity is consolidated into the financial statements. At December 31, 2024 and 2023, the Company identified EdgePoint to be the Company’s sole VIE. At December 31, 2024, and 2023, the Company’s ownership percentage of EdgePoint was 29% each, respectively. The VIE’s net assets were less than approximately $0.1 million at December 31, 2024 and 2023, respectively.

0.29

100000

Investments - Equity Method The Company accounts for equity method investments at cost, adjusted for the Company’s share of the investee’s earnings or losses, which are reflected in the consolidated statements of operations. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Investment in GMP Bio represents the investment into equity securities for which the Company elected the fair value option pursuant to ASC 825-10-15 and subsequent fair value changes in the GMP Bio shares shall be included in the result from other income. Refer to Note 6 to these Notes to the Consolidated Financial Statements.

Joint Venture agreement We have equity interest in unconsolidated arrangement that is primarily engaged in the business of drug discovery, development, and commercialization, including but not limited to development and commercialization of TGF-beta therapeutics as well as establishing and operating contract development and manufacturing organization (“CDMO”) facilities and capabilities. The Company first reviews the arrangement to determine if it meets the definition of an accounting joint venture pursuant to ASC 323-10-20. In order to meet the definition of a joint venture, the arrangement must have all of the following characteristics, (i) the arrangement is organized within a separate legal entity, (ii) the entity is under the joint control of the venturers, (iii) the venturers must be able to exercise joint control through their equity investments, (iv) the qualitative characteristics of the entity, including its purpose and design must be consistent with the definition of a joint venture. We consolidate arrangements that are considered to be VIEs where we are the primary beneficiary. We analyze our investments in joint ventures to determine if the joint venture is considered a VIE and would require consolidation. We (i) evaluate the sufficiency of the total equity investment at risk, (ii) review the voting rights and decision-making authority of the equity investment holders as a group and whether there are limited partners (or similar owning entities) that lack substantive participating or kick out rights, guaranteed returns, protection against losses, or capping of residual returns within the group and (iii) establish whether activities within the venture are on behalf of an investor with disproportionately few voting rights in making this VIE determination. To the extent that we own interests in a VIE and we (i) have the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) have the obligation or rights to absorb losses or receive benefits that could potentially be significant to the VIE, then we would be determined to be the primary beneficiary and would consolidate the VIE. To the extent that we own interests in a VIE, then at each reporting period, we re-assess our conclusions as to which, if any, party within the VIE is considered the primary beneficiary. To the extent that our arrangements do not qualify as VIEs, they are consolidated if we control them through majority ownership interests or if we are the managing entity (general partner or managing member) and our partner does not have substantive participating rights. Control is further demonstrated by our ability to unilaterally make significant operating decisions, refinance debt, and sell the assets of the joint venture without the consent of the non- managing entity and the inability of the non-managing entity to remove us from our role as the managing entity. We use the equity method of accounting for those arrangements where we exercise significant influence but do not have control. Under the equity method of accounting, our investment in each arrangement is included on our consolidated balance sheet; however, the assets and liabilities of the joint ventures for which we use the equity method are not included on our consolidated balance sheet. When we sell or contribute properties to unconsolidated arrangements and retain a non-controlling ownership interest in such assets, we recognize the difference between the consideration received and the carrying amount of the asset sold or contributed when its derecognition criteria are met. The equity method investment we retain in such partial sale transactions is noncash consideration and is measured at fair value. As a result, the accounting for a partial sale will result in the recognition of a full gain or loss. When circumstances indicate there may have been a reduction in the value of an equity investment, we evaluate whether the loss in value is other than temporary. If we conclude it is other than temporary, we recognize an impairment charge to reflect the equity investment at fair value. The Company elected the fair value option under the fair value option Subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that the fair value option is most appropriate for a company in the biotechnology industry, The fair value option is more appropriate for companies that are involved in extensive and usually very expensive research and development efforts, which are not appropriately reflected in the market value or reflective of the true value of the development activities of the Company. Embedded debt costs in convertible debt instruments In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition was permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption was permitted no earlier than the fiscal year beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2023 and has removed the effects of any embedded conversion features from certain of our convertible instruments as of that date.

Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue when its customers obtain control of the promised good or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company applies the following five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the performance obligation(s) in the contract by assessing whether the goods or services promised within each contract are distinct. The Company then recognizes revenue for the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company anticipates generating revenues from rendering services to other third party customers for the development of certain drug products and/or in connection with certain out-licensing agreements. In the case of services rendered for development of the drugs, revenue is recognized upon the achievement of the performance obligations or over time on a straight-line basis over the extended service period. In the case of out-licensing contracts, the Company records revenues either (i) upon achievement of certain pre-defined milestones when there is no obligation of the Company achieve any performance obligations in connection with the said pre-defined milestones, or (ii) upon achievement of the performance obligations if the milestones require the Company to provide the performance obligations. The Company occasionally collects advance payments from customers toward commitments to provide services or performance obligations, in which case the advance payment is recorded as a liability until the obligations are fulfilled and revenue is recognized.

Research & Development Costs In accordance with ASC 730-10-25 “Research and Development”, research and development costs are charged to expense as and when incurred.

Recent Accounting Pronouncements In August 2020, the FASB issued “ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”) which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition was permissible for the adoption of this standard. Update No. 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption was permitted no earlier than the fiscal year beginning after December 15, 2020.The Company adopted ASU 2020-06 effective January 1, 2023 and recorded approximately $0.5 million as a reduction to the additional paid in capital and added approximately $0.3 million to the opening retained earnings in accordance with the authoritative guidance under ASU 2020-06. All other newly issued but not yet effective accounting pronouncements have been deemed to be not applicable or immaterial to the Company.

500000

300000

NOTE 3 – ACQUISITIONS, GOODWILL AND INTANGIBLE ASSETS INTANGIBLE ASSETS AND GOODWILL Goodwill from 2019 Reverse Merger with Oncotelic and Merger with PointR The Company completed the reverse merger with Oncotelic Inc. (“Merger”) in April 2019. The Company completed the merger with PointR Data Inc (“PointR Merger”) in November 2019. For more details on the two mergers, refer to our 2020 Annual Report on Form 10-K for the year ended December 31, 2020 filed by the Company on April 15, 2021. The Oncotelic merger gave rise to Goodwill of approximately $4.9 million. Upon the non-financial sale of our asset as contribution to our equity method investment, we derecognized the balance of the carrying value of our goodwill of approximately $4.9 million from the Oncotelic Merger in accordance with our policy and authoritative accounting guidance. Further, we added goodwill of $16,182,456 upon the completion of the Merger with PointR. We have one operating segment and reporting unit. Accordingly, our review of goodwill impairment indicators was performed at the entity-wide level. In performing our annual impairment assessment, we determined if we should qualitatively assess whether it was more likely than not the fair value of goodwill was less than its carrying amount (the qualitative impairment test). The factors we considered in the assessment included our market capitalization, general macroeconomic conditions, conditions specific to the industry and market and whether there had been sustained declines in our share price. If we concluded, it was more likely than not, the fair value of the reporting unit was less than its carrying amount, or elected not to use the qualitative impairment test, a quantitative impairment test would be performed. We used our market capitalization as an indicator of fair value. While we believe the fair value measurement need not be based solely on the quoted market price of an individual share of our Common Stock, and that we also could consider the impact of a control premium in measuring the fair value of its reporting unit. In the absence of any other valuation metrics, the Company believed using a control premium utilized would not be appropriate under the current circumstances. We also considered some other market comparables, trends in our stock price as well as the industry over a period of two successive quarters and prospective quarter to evaluate whether the fair value of our reporting unit was greater than our carrying amount. As such, we performed a quantitative impairment assessment of goodwill for our single reporting unit at the end of 2024 and 2023, due to a sustained change in our market capitalization and an increase in negative economic outlook for biotech markets. We estimated and reconciled the fair value of our reporting unit utilizing our market capitalization based on the stock price of our Common Stock as of December 31, 2024 and 2023. Before completing our goodwill impairment test, we first tested our indefinite-lived intangible asset then our remaining long-lived assets for impairment. We concluded our indefinite-lived intangible assets were not impaired. Based on the market capitalization, we further concluded the fair value of our single reporting unit was less than its carrying value and therefore recognized an impairment charge of approximately $3.2 million and approximately $6.1 million during the year ended December 31, 2024 and 2023. The calculation of the impairment charge included substantial fact-based determinations and estimates. The goodwill impairment charge is reflected as goodwill impairment in the consolidated statements of operations for the year ended December 31, 2024. A summary of our goodwill as of December 31, 2024 and 2023 is shown below: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zeJT69tqSKC" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zopDatTcJsmg" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iS_zOdVqBbDJGmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,988,230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,071,376</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Goodwill_iS_zumsIuqv5Vi2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,988,230</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,071,376</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillImpairmentLoss_iN_di_zHqpb6aVZsJe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Goodwill impairment due to market capitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,200,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,083,146</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iE_z3uoZCo57ybj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,988,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iE_zjX9TdeUs1Gk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,988,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In general, the goodwill is tested on an annual impairment date of December 31, unless we observe any further deterioration in our market capitalization, in which case we may, depending on the materiality of the impairment, record an impairment at the end of other reporting periods, as we have done during the course of the year ended December 31, 2024. In-Process Research & Development (“IPR&D”) Summary The IPR&D assets were acquired in the PointR Merger during the year ended December 31, 2019. Since January 2021, the Company has determined that the IPR&D should be reported as an indefinitely lived asset and therefore will evaluate, on an annual basis, for any impairment on the IPR&D and will record an impairment if identified. The balance of IPR&D as of December 31, 2024 and December 31, 2023 was $1,101,760. For more information on the IPR&D, please refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024.

4900000

16182456

3200000

6100000

A summary of our goodwill as of December 31, 2024 and 2023 is shown below: SCHEDULE OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20240101__20241231_zeJT69tqSKC" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230101__20231231_zopDatTcJsmg" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iS_zOdVqBbDJGmc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,988,230</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">12,071,376</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--Goodwill_iS_zumsIuqv5Vi2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,988,230</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,071,376</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--GoodwillImpairmentLoss_iN_di_zHqpb6aVZsJe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: Goodwill impairment due to market capitalization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,200,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,083,146</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iE_z3uoZCo57ybj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,988,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--Goodwill_iE_zjX9TdeUs1Gk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,788,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,988,230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5988230

12071376

5988230

12071376

3200000

6083146

2788230

5988230

2788230

5988230

1101760

NOTE 4 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expense consists of the following amounts: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zzOsfXdwZKSb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zmGiN4cJKqRi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzzKQ_z4Z0JsBFid18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,691,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,656,613</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALzzKQ_z0M1DjieqRv3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">745,442</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">780,708</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzzKQ_z2pyR9BotL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,437,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,437,321</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20241231_zKsnHIRtSnR3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20231231_zJH8f2DHEpkk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHDuD7Ts8qee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Accounts payable – related party</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">346,057</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">344,099</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

Accounts payable and accrued expense consists of the following amounts: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20241231_zzOsfXdwZKSb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zmGiN4cJKqRi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_maAPAALzzKQ_z4Z0JsBFid18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,691,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,656,613</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_maAPAALzzKQ_z0M1DjieqRv3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">745,442</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">780,708</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_mtAPAALzzKQ_z2pyR9BotL6b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Accounts payable and accrued liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,437,167</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,437,321</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20241231_zKsnHIRtSnR3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td> <td colspan="2" id="xdx_494_20231231_zJH8f2DHEpkk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; white-space: nowrap; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHDuD7Ts8qee" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Accounts payable – related party</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">346,057</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">344,099</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1691725

1656613

745442

780708

2437167

2437321

346057

344099

NOTE 5 – CONVERTIBLE DEBENTURES, NOTES AND OTHER DEBT As of December 31, 2024, special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts: SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_499_20241231_z2rRkosdk5T3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20231231_z6kd0RuEcShh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Current Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible debentures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zALO5SiZiP5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">10% Convertible note payable, due April 23, 2022 – Bridge Investor</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zvOWjl6xXDJc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">10% Convertible note payable, due April 23, 2022 – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zNYrPMkaltTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible note payable, due August 6, 2022 – Bridge Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zghOYTe5osJg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Fall 2019 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableStephenBoeschMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zkfCfS5Auo31" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Stephen Boesch</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,958</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z3ZLNfgcCqJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,733</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,233</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableDrSanjayJhaMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zkkCUgVb8Nth" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,253</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zy8TYUvXvdNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – CEO & CFO – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102,659</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,559</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zpS8uFZemRH" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note payable – Bridge Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">210,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">201,922</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zUj1viZskqN6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,073,925</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,031,425</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">August 2021 Convertible Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zaElt9B0ELEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note – Autotelic Inc– Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280,052</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zD9nLJmhDPu" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418,399</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_z8VpiJhrYJw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note – CFO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,770</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,018</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zDeWgeubANM1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">817,397</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">782,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">JH Darbie PPM Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMDebtMember_z0VEvpJPCpo5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">16% Convertible Notes – Non-related parties</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311,693</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPMDebtMember_zkPKDL4eo04a" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311,693</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">November/December 2021 & March 2022 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--NovemberDecemberTwoThousandTwentyOneAndMarchTwoThousandTwentyTwoNotesMember_zCVtVCshld7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233,687</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233,392</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Debt for Clinical Trials – Forever Prosperity ( Formerly GMP)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwoPercentageConvertibleNotesForeverProsperityMember__srt--TitleOfIndividualAxis__custom--DebtClinicalTrialsGMPMember_zZdMsejjFk23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2% Convertible Notes – Forever Prosperity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,840,247</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">May and June 2022 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MayAndJuneTwoThousandTwentyTwoNoteMember_zN47NenqlJL1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">993,130</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,401,284</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">JH Darbie PPM 2 Debt</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zCyyvC4z6ew7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">16% Convertible Notes - Non-related parties</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,183,638</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesCEORelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_z0P0itTZO9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">16% Convertible Notes – CEO – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">125,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_z2juLshXEjbg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible note payable</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,308,638</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left; width: 64%">Other Debt</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 14%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 14%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_402_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_ztNxdxmktu0h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCFOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zFKVD7MDv7O5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term debt from CFO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zTfaGIsgPzgh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Autotelic Inc. – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,085,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,470,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCEOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zkedfybhL0Th" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short Term Debt from CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_zdEt51mYUSgc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Short term debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,421,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,765,050</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DebenturesNotesAndOtherDebt_iI_zZr3UJvzwH7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total of short term convertible debentures & notes and other debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,088,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,675,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Long Term Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">JH Darbie PPM 2 Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM2DebtMember_zrfmjIs0caoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">16% Convertible Notes - Non-related parties</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,773,468</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesCEORelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM2DebtMember_zdo0ACoHuige" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPM2DebtMember_zh3fRR19GATa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,898,468</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Convertible Debentures As of December 31, 2024, the Company had a derivative liability of approximately $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20241231__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebenturesMember_zZKYeHVbwjRk">704,000 and recorded a change in fair value of approximately $280,000 during the year ended December 31, 2024, on the Convertible Debentures issued in 2019 to our CEO and a bridge investor. Bridge Financing Notes with Officer and Bridge Investor In April 2019, the Company entered into a Securities Purchase Agreement (the “Bridge SPA”) with our CEO (the “Trieu Note”) and a Bridge Investor with a commitment to purchase convertible notes in the aggregate of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20190430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zvYoTDPiTNgc">400,000. For more information on the Bridge SPA, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The issuance of the Trieu Note resulted in a discount from the beneficial conversion feature totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20190401__20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zh9bX5n9CCl5">131,555 related to the conversion feature. Total amortization of the OID and the discount totaled $<span id="xdx_902_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlWOyODm6oVa">0 and approximately for the years ended December 31, 2024, and 2023, respectively. Total unamortized discount on this note was approximately $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zj8aY6LZCWjh">0 as of December 31, 2024, and 2023, respectively. In April 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #1 (“Tranche #1”) with the Bridge Investor. For more information on Tranche #1, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The issuance of the note resulted in a discount from the beneficial conversion feature totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20190401__20190430__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zjVYy37Ek6d">28,445. Total amortization of the OID and discount totaled approximately $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zuKxIrWWCAE7">0 for the year ended December 31, 2024, and 2023, respectively. Total unamortized discount on this note was approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zASGXPiSQax6">0 as of December 31, 2024, and December 31, 2023. In August 2019, pursuant to the Bridge SPA the Company entered into Convertible Note Tranche #2 (“Tranche #2”) with the Bridge Investor. For more information on Tranche #2, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The issuance of the note resulted in a discount from the beneficial conversion feature totaling $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pp0p0_c20190801__20190831__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zayj5I7L5LI7">175,000. Total amortization of the OID and discount totaled approximately $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_pp0p0_c20230101__20231231__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zMKo0kDpasZh">0 for the years ended December 31, 2024, and 2023, respectively. Total unamortized discount on this note was $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20231231__srt--TitleOfIndividualAxis__custom--BridgeInvestorMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zUt9WA7XVLNh">0 as of December 31, 2024, and 2023. Fall 2019 Debt Financing In December 2019, the Company closed its Fall 2019 Debt Financing, raising an additional $500,000 bringing the gross proceeds of all debt financings under the Fall 2019 Debt Financing to $1,000,000. The Company entered into those certain Note Purchase Agreements (the “Fall 2019 Note Purchase Agreements”) with certain accredited investors and the officers of the Company for the sale of convertible promissory notes (the “Fall 2019 Notes”). The Company completed the initial closing under the Fall 2019 Note Purchase Agreements in November 2019. The Company issued Fall 2019 Notes in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_z0sRnTbpZQPe">250,000 to each of Dr. Vuong Trieu, the Company’s Chief Executive Officer, and Stephen Boesch, in exchange for gross proceeds of $<span id="xdx_90E_ecustom--ProceedsFromConvertibleDebtGross_pp0p0_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember_zLdaPEiFwuk5">500,000. In connection with the second and final closing of the Fall 2019 Debt Financing, the Company issued Fall 2019 Notes to additional investors including $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrSanjayJhaMember_zHq3xrox8K8e">250,000 to Dr. Sanjay Jha, through his family trust, the former CEO of Motorola and COO/President of Qualcomm. The Company also offset certain amounts due to Dr. Vuong Trieu, the Company’s Chief Executive Officer, Chulho Park, the Company’s then Chief Technology Officer, and Amit Shah, the Company’s Chief Financial Officer, all related parties as Officers of the Company, and converted such amounts due into the Fall 2019 Notes. $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--DrVuongTrieuMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zTQ9i2XnXTUg">35,000 due to Dr. Vuong Trieu, $<span id="xdx_90D_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--ChulhoParkMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z74mglOAFlZk">27,000 due to Chulho Park and $<span id="xdx_90B_eus-gaap--OtherLiabilities_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--AmitShahMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zgwPBLFNYFFi">20,000 due to Amit Shah were converted into convertible debt under the Fall 2019 Notes. The Company also issued the Fall 2019 Notes of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20191231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__srt--TitleOfIndividualAxis__custom--TwoAccreditedInvestorsMember_zttmKF97Ejse">168,000 to two accredited investors. All the Fall 2019 Notes provided for interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20241231__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember_zN1DBFEp6Cs8">5% per annum and are unsecured. For more information on the Fall 2019 Debt Financing, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. There was no activity during the year ended December 31, 2024 and 2023.The total unamortized principal amount of the Fall 2019 Notes was $850,000 as of December 31, 2024, and 2023. Further, the Company recorded interest expense of approximately $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zxJuBdBx8m06">42,500 on these Fall 2019 Notes for the years ended December 31, 2024, and 2023. The total amount outstanding under the Fall 2019 Notes, net of discounts and including accrued interest thereon, as of December 31, 2024, and 2023 was approximately $1,073,900 and $1,031,400 respectively. Forever Prosperity (Formerly GMP) Notes In June 2020, the Company secured $2 million in debt financing, evidenced by a one-year convertible note (the “GMP Note”) from GMP, to conduct a clinical trial evaluating OT-101 against COVID-19 bearing 2% annual interest, and is personally guaranteed by Dr. Vuong Trieu, the Chief Executive Officer of the Company. The GMP Note is convertible into the Company’s Common Stock upon the GMP Note’s maturity of the GMP Note, at the Company’s Common Stock price on the date of conversion with no discount. GMP has waived the default in the maturity of the GMP Note and as such there is no event of default and also agreed to extend the date of maturity of the GMP Note to December 31, 2024. GMP does not have the option to convert prior to the GMP Note’s maturity. Such financing will be utilized solely to fund the clinical trial. The Company’s liability under GMP Note commenced to accrue when GMP first began to pay for services related to the clinical trial to our third-party clinical research organization, up to a maximum of $<span id="xdx_909_ecustom--DebtFinancing_iI_pn6n6_c20241231__us-gaap--DebtInstrumentAxis__custom--GMPNoteMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__srt--RangeAxis__srt--MaximumMember_zXTNS7QlB1X">2 million. GMP has been invoiced by the clinical research organization for the full $2 million as of December 31, 2024, and as such the Company has recognized the liability as a convertible debt. In September 2021, the Company secured a further $1.5 million in debt financing, evidenced by a one-year convertible note (the “GMP Note 2”) from GMP, to fund the same clinical trial evaluating OT-101 against COVID- 19 bearing 2% annual interest. The GMP Note is convertible into the Company’s Common Stock upon the GMP Note 2’s maturity one year from the date of the GMP Note 2, at the Company’s Common Stock price on the date of conversion with no discount. GMP has waived the default in the maturity of the GMP Note and as such there is no event of default and also agreed to extend the date of maturity of the GMP Note to December 31, 2024. GMP does not have the option to convert prior to the GMP Note 2’s maturity at the end of one year. Such financing was to be utilized solely to fund the clinical trial. GMP was invoiced by the clinical research organization for $<span id="xdx_90D_eus-gaap--ProceedsFromLinesOfCredit_pn5n6_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--DebtFinancingMember__dei--LegalEntityAxis__custom--GoldenMountainPartnersLLCMember_zGbuI345nMOb">1.5 million. In October 2021, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “October Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pn5n6_c20211031__us-gaap--TypeOfArrangementAxis__custom--OctoberPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zaQ1yrXuMWrf">0.5 million (the “October 2021 Note”), which October 2021 Note is convertible into shares of the Company’s Common Stock. GMP has waived the default in the maturity of the GMP Note and as such there is no event of default and also agreed to extend the date of maturity of the GMP Note to December 31, 2024. In January 2022, the Company entered into an Unsecured Convertible Note Purchase Agreement (the “January Purchase Agreement”) with GMP, pursuant to which the Company issued a convertible promissory note in the aggregate principal amount of $<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_pn5n6_c20220131__us-gaap--TypeOfArrangementAxis__custom--JanuaryPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zdP9SNNuU9Pj">0.5 million (the “January 2022 Note”), which January 2022 Note is convertible into shares of the Company’s Common Stock. GMP agreed to extend the date of maturity of the January 2022 Note to December 31, 2024. Cumulatively, the GMP Note, GMP Note 2, October 2021 Note and the January 2022 Notes are referred to as the “GMP Notes”. The GMP Notes carry an interest rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220131__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JanuaryPurchaseAgreementMember_zng5KLMKbDY1">2% per annum and mature on the earlier of (a) the one- year anniversary of the date of the Purchase Agreement, or (b) the acceleration of the maturity by GMP upon occurrence of an Event of Default (as defined below). All Notes contain a voluntary conversion mechanism whereby GMP may convert the outstanding principal and accrued interest under the terms of all the GMP Notes into shares of Common Stock (the “Conversion Shares”), at the consolidated closing bid price of the Company’s Common Stock on the applicable OTC Market as of the date the Company receives a Notice of Conversion from GMP. Prepayment of the GMP Notes may be made at any time by payment of the outstanding principal amount plus accrued and unpaid interest. The October Note contained customary events of default (each an “Event of Default”). If an Event of Default occurred, at GMP’s election, the outstanding principal amount of the GMP Notes, plus accrued but unpaid interest, would become immediately due and payable in cash. The October Purchase Agreement required the Company to use of the proceeds received under the October 2021 Note to support the clinical development of OT-101, including payroll and had been made in continuation of the relationship between the Company and GMP. All the GMP notes were assigned to Forever Prosperity, LLC, an affiliated entity of GMP. As of January 1, 2025, the GMP Notes are in default. The total principal outstanding on all the GMP notes, inclusive of accrued interest, was approximately $4.8 million as of December 31, 2024 and 2023, respectively. During the years ended December 31, 2024 and 2023, the Company incurred approximately $90,000 of interest expense. August 2021 Convertible Notes In August 2021, the Company entered into Note Purchase Agreements with Autotelic - a related party, our CFO – a related party, and certain accredited investors (the “August 2021 investors”), whereby the Company issued four convertible notes in the aggregate principal amount of $698,500 convertible into shares of common stock of the Company for net proceeds of approximately $691,000. The convertible notes carry a five (5%) percent coupon and mature one year from issuance. The majority of the August 2021 investors have the right, but not the obligation, not more than five days following the maturity date, to convert all, but not less than all, the outstanding and unpaid principal plus accrued interest into the Company’s common stock, at a conversion price of $0.18. The August 2021 Note Holders has waived the default in the maturity of the August 2021 Notes and as such there is no event of default and also agreed to extend the date of maturity of the August 2021 Notes to December 31, 2025. The Company determined that the economic characteristics and risks of the embedded conversion option are not clearly and closely related to the economic characteristics and risks of the debt host instrument. Further, the Company determined that the embedded conversion feature meets the definition of a derivative but met the scope exception to the derivative accounting required under ASC 815 for certain contracts involving a reporting entity’s own equity. <p id="xdx_89B_ecustom--ScheduleOfConvertibleNotesNetOfDiscountTableTextBlock_gL3SOCNNODTTB-MREJ_zIXe67wIW36c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023, the August 2021 convertible notes, net of debt discount, consist of the following amounts: SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20241231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zl5yfuwCoofc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20231231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zQ8gHJmTkXnc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zWTzy32ntJX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Autotelic Related party convertible note, 5% coupon December 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">292,552</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">280,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zkC815SX8dT2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CFO Related party convertible note, 5% coupon December 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,770</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zTbVfoewgfa7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accredited investors convertible note, 5% coupon December 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">437,075</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">418,399</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_zXfTgaOUQWd7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Convertible notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">817,397</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">782,469</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the years ended December 31, 2024 and 2023 the Company recognized approximately $35,000 of interest expense on the August 2021 Investors notes of which approximately $<span id="xdx_907_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--AugustTwoThousandTwentyOneInvestorsNotesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znamfeLDIJV4">16,000 are attributable to related parties. At December 31, 2024, and 2023, accrued interests on these convertible notes totaled approximately $119,000 and $84,000, respectively. The outstanding balance on the note for the year ended December 31, 2024 was approximately $817,000 including related party balance of approximately $<span id="xdx_908_eus-gaap--NotesPayable_iI_pn3d_c20241231__srt--TitleOfIndividualAxis__custom--FivePercentConvertibleNoteMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zEyWJKHGaum9">380,000. The outstanding balance on the note for the year ended December 31, 2023 was approximately $782,000 including related party balance of $<span id="xdx_90C_eus-gaap--NotesPayable_iI_pn3d_c20231231__srt--TitleOfIndividualAxis__custom--FivePercentConvertibleNoteMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zGwmjMOA2iM3">364,000. November – December 2021 Financing In November / December 2021, the Company entered into securities purchase agreement with five institutional investors, whereby the Company issued five convertible notes in the aggregate principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zhtGAteXwnkd">1,250,000 convertible into shares of common stock of the Company. The convertible notes carry a twelve (<span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zsWn07P7VqP5">12%) percent coupon and a default coupon of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zQXQmbDJhM3">16% and mature at the earliest of one year from issuance or upon event of default. Investors has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_z7b1VNrrRGi8">0.07. The Company granted a total number of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zXRXcbepSUp5">9,615,385 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_za2SWQnr6NYe">0.13 up to five years after issuance. The Placement agent was also granted a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20211201__20211231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zR0FEtHX67mi">961,540 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--PlacementAgentMember_zwQ5vpMThRB">0.13 up to five years after issuance, as part of a finder’s fee agreement. Further, in March 2022, the Company entered into a Securities Purchase Agreement with Fourth Man, pursuant to which the Company issued convertible promissory note in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn4n6_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zhBthe5ct1w3">0.25 million, convertible into shares of common stock of the Company. The convertible notes carry a twelve (<span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_z7UxocVfZOkb">12%) percent coupon and a default coupon of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20220331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FiveInstitutionalInvestorsMember_zdyE3als0Fsc">16% and mature at the earliest of one year from issuance or upon event of default. As of December 31, 2022, this note is in Investors have the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s Common Stock at a conversion price established at a fixed rate of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zJuivu1WDsS2">0.10. The Company granted a total number of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zVqNCSHoG4Bi">1,250,000 warrants convertible into an equivalent number of the Company common shares at a strike price of $0.20 up to five years after issuance. The Placement agent was also granted a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zoDHFjUf7fYi">125,000 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--FourthManLLCMember_zZIuk83U402d">0.20 up to five years after issuance, as part of a finder’s fee agreement. During the year ended December 31, 2023, the Company converted the balance of approximately $243,000 of Blue Lake convertible note, inclusive of accrued interest, into 3,466,583 shares of the Company’s Common Stock, which fully retired the convertible note as of December 31, 2023. Further, during the year ended December 31, 2023, the Company fully converted the balance of Fourth Man convertible note of approximately $127,000 into 1,820,395 shares of the Company’s common stock, which fully retired the convertible note as of December 31, 2023. As of December 31, 2024, all of the November- December 2021 notes and any accrued interest, are fully converted. <div id="xdx_C02_gL3SOCNNODTTB-MREJ_zkkt9LlxV9Vk">As of December 31, 2024, and December 31, 2023, the Fourth Man convertible note, net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_307_134_zwVRnEWHpyuc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--ShortTermDebtTypeAxis__custom--MarchTwoThousandTwentyTwoMember_zANbgCggtmsh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231__us-gaap--ShortTermDebtTypeAxis__custom--MarchTwoThousandTwentyTwoMember_zjWGyECBwGni" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--SixteenPercentCouponMarchTwoThousandTwentyThreeMember_zZkCkFnkkxqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">233,687</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">233,392</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_zNXG9NBfGB9g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_zoUfg00wPpve" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">233,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">233,392</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The March 2022 Fourth Man Financing principal balance was approximately $142,000 and $162,000 as of December 31, 2024, and December 31, 2023, respectively. During the year ended December 31, 2024, the Company converted approximately $35,000 in principal, accrued interest and legal fees into 500,000 shares of common stock. The note includes a default amount calculated at <span id="xdx_90D_ecustom--DebtDefaultPrincipalAndAccruedInterestPercentage_iI_pid_dp_uPure_c20241231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--BlueLakeMember_zPFpkzKGYkQ2">125% of the unpaid principal and accrued interest. As the Company failed to repay the note at the original maturity date, The Company has recorded an estimated default penalty of approximately $70,000. As of December 31, 2024, the balance includes the remaining principal of $142,000 and $70,000 of accrued default penalty pursuant to the terms of the underlying agreement. The Company recognized approximately $34,000 and $25,000 of interest during the years ended December 31, 2024 and 2023. As of December 31, 2024 and 2023, the balance of the unamortized debt discount was $0. The Company adopted ASU 2020-06 on January 1, 2023, which resulted in the reversal of the original BCF amount to additional paid in capital for $109,349, reversal of the unamortized debt discount related to the BCF for $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member_z9e2vzxNoIre">25,489 with the balance being recorded through retained earnings for $78,460. May 2022 Mast Financing In May 2022, the Company entered into a securities purchase agreement with one institutional investor, whereby the Company issued one convertible note in the aggregate principal amount of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zSBOjGX5tR2k">605,000 convertible into shares of common stock of the Company (“May 2022 Mast Note”). The convertible notes carry a twelve (<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_z7H53y5WviM4">12%) percent coupon and a default coupon of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zPCTGloNQiJ2">16% and mature at the earliest of one year from issuance or upon event of default. Investor has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zCvQ1XGG2rvb">0.10. The Company granted a total number of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zL5VxoTqkhn4">3,025,000 warrants convertible into an equivalent number of Company common shares at a strike price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_ztUdAs82Ojp7">0.20 up to five years after issuance. The Placement agent was also granted a total of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220501__20220531__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zt7uhziB46jd">302,500 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_z457WcFnDeK4">0.20 up to five years after issuance, as part of a finder’s fee agreement. A portion of the proceeds were used to retire some of the November/December 2021 notes. <div id="xdx_C0B_gL3SOCNNODTTB-MREJ_zSbwcZ0pmf5k">As of December 31, 2024, and December 31, 2023, convertible note under the May 2022 Mast Financing, net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_30C_134_z9TzoI9Ui0w3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zfJa0reiJ4Bh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_z34SVPyEkC5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_hdei--LegalEntityAxis__custom--MastHillMember_z80eed5oPBLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, 12% coupon May 2025, inclusive of accrued interest and penalty</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">993,130</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">905,484</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleLongTermNotesPayable_iI_zpQ7FgAIIjC" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">993,130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">905,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The Mast Hill Note of $<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember__dei--LegalEntityAxis__custom--MastHillFundLPMember_zGBVzp4N2Dlf">993,130 as of December 31, 2024 includes $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember__dei--LegalEntityAxis__custom--MastHillFundLPMember_zDf9CTJ8wlLl">605,000 of principal, $<span id="xdx_900_ecustom--DefaultPenaltyOnAcrruedInterest_iI_pp0p0_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember__dei--LegalEntityAxis__custom--MastHillFundLPMember_z9wyblxWQHaj">169,400 in default penalty, and approximately $<span id="xdx_90B_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember__dei--LegalEntityAxis__custom--MastHillFundLPMember_z4YVPmKeSmB7">219,000 in accrued interest. Accrued interest was approximately $219,000 and $131,000 as of December 31, 2024 and 2023, respectively. The May 2022 Mast Note was extended through May 2025 at a cost of approximately $<span id="xdx_905_eus-gaap--ConvertibleDebt_iI_pn3n3_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zBAtTT9EWBub">82 thousand, and which is included in the amount outstanding and payable to Mast as of December 31, 2024. The Company recognized approximately $0 and approximately $146,000 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants during the years ended December 31, 2024 and 2023, respectively. Effective January 1, 2023, the Company adopted ASU 2020-06, which resulted in the reversal of the original BCF amount to additional paid in capital for approximately $<span id="xdx_906_eus-gaap--AdditionalPaidInCapital_iI_pn5n6_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember_zaMxpEwP5sbe">0.2 million, a reversal of the unamortized debt discount related to the BCF for approximately $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn5n6_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember_zDvByT4yrN4c">0.1 million, with the balance of approximately $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyThreeMember_zgDlo0zwknZc">0.1 million being recorded through retained earnings. June 2022 Blue Lake Financing In June 2022, the Company entered into a securities purchase agreement with one institutional investor, whereby the Company issued one convertible note in the aggregate principal amount of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zPTSiMK2rFoh">335,000 convertible into shares of common stock of the Company (“June 2022 Blue Lake Note”). The convertible notes carry a twelve (<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zZ5SrOYARbFj">12%) percent coupon and a default coupon of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zfXqJIrFM5o2">16% and mature at the earliest of one year from issuance or upon event of default. The investor has the right at any time following issuance date to convert all or any part of the outstanding and unpaid amount of the note into the Company’s common stock at a conversion price established at a fixed rate of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zh2GpKDhnrOb">0.10. The Company granted a total number of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zJ1VJkQdOeod">837,500 warrants convertible into an equivalent number of the Company common shares at a strike price of $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20220630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zqHQoP0YKjh7">0.20 up to five years after issuance. The Placement agent was also granted a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220601__20220630__srt--TitleOfIndividualAxis__custom--PlacementAgentMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztgXNKvkLqYb">83,750 warrants convertible into an equivalent number of the Company Common Stock at a strike price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zLLz9rHpmzc1">0.20 up to five years after issuance, as part of a finder’s fee agreement. A portion of the proceeds were used to retire some of the November/December 2021 notes. In May 2024, Blue Lake converted the balance of their note of approximately $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20240531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zLA1JVinGrt7">531,000 including principal, accrued interest and default penalty, into <span id="xdx_909_eus-gaap--ConversionOfStockSharesIssued1_c20240531__20240531__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OneInstitutionalInvestorsMember_zvd63w9uJxT6">7,605,760 common shares of the Company <div id="xdx_C0F_gL3SOCNNODTTB-MREJ_zLJINGEHapEh">As of December 31, 2024 and 2023, convertible note under the June 2022 Blue Lake Financing, net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_305_134_zbFTcRnNNt4h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyTwoMember_zL8PgYu8aaIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20231231__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyTwoMember_z71N9VgN31A5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iI_hdei--LegalEntityAxis__custom--BlueLakePartnersLLCMember_z2Xwk50tVDT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Blue Lake Convertible note, 16% coupon June 2023, inclusive of accrued interest</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">495,800</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleLongTermNotesPayable_iI_zeqhRQGFUcM8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">495,800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> </div> The Company recognized approximately $35,000 and $88,400 of interest expense attributable to interest, amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants and the beneficial conversion feature during the years ended December 31, 2024 and 2023, respectively. The Company recognized approximately $0 and approximately $62,000 of interest expense attributable to the amortization of the debt discount from the original debt discount, deferred financing costs, fair value allocated to the warrants and BCF during the years ended December 31, 2024 and 2023. The Company recognized $35,000 and approximately $40,200 of interest expense related to the guaranteed coupon for the years ended December 31, 2024 and 2023, respectively. The Company adopted ASU 2020-06 effective January 1, 2023, which resulted in the reversal of the original BCF amount to additional paid in capital of approximately $<span id="xdx_902_eus-gaap--AdditionalPaidInCapital_iI_pn5n6_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyThreeMember_zaCGXcewNxNc">0.2 million, reversal of the unamortized debt discount of approximately $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_pn5n6_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyThreeMember_zGzsKp2BFBt4">0.1 million related to the BCF and the balance of $<span id="xdx_90B_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pn5n6_c20230101__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate202006Member__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyThreeMember_zSIhDK0x3KBj">0.1 million being recorded through retained earnings. Other short-term advances As of December 31, 2024, other short-term advances consist of the following amounts obtained from various employees and related parties: SCHEDULE OF SHORT-TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold">Other Advances</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_z9dNAjHjuvd9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zjjljtp6gkY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zKZEEphAA09g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Short term advance from CFO – Related Party</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">76,050</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35,050</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWHDmVD8jVai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term advance from CEO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--BridgeInvestorMember_zXzxow1ToBM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term advances – bridge investors & others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AutotelicMember_z8XoflL4n6id" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Short term advances – Autotelic Inc. – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,085,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,470,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_zyyPwNLYgN04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Short term advance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,421,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,765,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In May 2021, Autotelic provided an additional short-term funding of approximately $<span id="xdx_905_eus-gaap--OtherLiabilities_iI_pn5n6_c20210531__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znFWKMzt6OPa">0.3 million to the Company, which was converted into the August 2021 Notes. Autotelic provided an additional $0.1 million short term loan to the Company during the year ended December 31, 2022. During the year ended December 31, 2023, Autotelic provided $1.4 million in various short-term loans to the Company. During the year ended December 31, 2024 Autotelic Inc. provided additional short-term funding of $614,000 to the Company. As such, approximately $2.1 million was outstanding and payable to Autotelic at December 31, 2024. The Company’s CFO was owed approximately $25 thousand at December 31, 2022. During the year ended December 31, 2023, the company’s CFO provided additional short-term advance of $10 thousand. During the year ended December 31, 2024, the CFO provided additional short-term funding of $41 thousand. As such, approximately $76 thousand was outstanding from the Company’s CFO at December 31, 2024. In December 2023, the Company received $50 thousand from the company’s CEO. As such, $50 thousand was outstanding to the Company’s CEO at December 31, 2024. As of December 31, 2024 and December 31, 2023, respectively, approximately $210,000 was outstanding as short-term advances from certain bridge investors.

As of December 31, 2024, special purchase agreements (SPAs) with convertible debentures and notes, net of debt discount and including accrued interest, if any, consist of the following amounts: SCHEDULE OF CONVERTIBLE DEBENTURES AND NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_499_20241231_z2rRkosdk5T3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20231231_z6kd0RuEcShh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Current Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible debentures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zALO5SiZiP5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">10% Convertible note payable, due April 23, 2022 – Bridge Investor</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35,556</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAprilTwentyThreeTwoThousandTwentyTwoRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zvOWjl6xXDJc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">10% Convertible note payable, due April 23, 2022 – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,444</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TenPercentageConvertibleNotesPayableDueAugustSixTwoThousandTwentyTwoBridgeInvestorMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zNYrPMkaltTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">10% Convertible note payable, due August 6, 2022 – Bridge Investor</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">200,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--ConvertibleDebenturesMember_zghOYTe5osJg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">400,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Fall 2019 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableStephenBoeschMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zkfCfS5Auo31" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Stephen Boesch</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,958</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,958</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_z3ZLNfgcCqJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,733</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">301,233</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableDrSanjayJhaMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zkkCUgVb8Nth" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note payable – Dr. Sanjay Jha (Through his family trust)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">313,253</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">300,753</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableCEOAndCFORelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zy8TYUvXvdNj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note payable – CEO & CFO – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102,659</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,559</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNotePayableBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zpS8uFZemRH" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note payable – Bridge Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">210,322</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">201,922</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--FallTwoThousandNineteenNotesMember_zUj1viZskqN6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,073,925</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,031,425</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">August 2021 Convertible Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zaElt9B0ELEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">5% Convertible note – Autotelic Inc– Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">292,552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">280,052</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zD9nLJmhDPu" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">5% Convertible note – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,075</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418,399</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--FivePercentConvertibleNoteChiefFinancialOfficerRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_z8VpiJhrYJw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">5% Convertible note – CFO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">87,770</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">84,018</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--AugustTwentyTwentyOneConvertibleNotesMember_zDeWgeubANM1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">817,397</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">782,469</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">JH Darbie PPM Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMDebtMember_z0VEvpJPCpo5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: left">16% Convertible Notes – Non-related parties</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311,693</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPMDebtMember_zkPKDL4eo04a" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">311,693</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">November/December 2021 & March 2022 Notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--NovemberDecemberTwoThousandTwentyOneAndMarchTwoThousandTwentyTwoNotesMember_zCVtVCshld7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233,687</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">233,392</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Debt for Clinical Trials – Forever Prosperity ( Formerly GMP)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--TwoPercentageConvertibleNotesForeverProsperityMember__srt--TitleOfIndividualAxis__custom--DebtClinicalTrialsGMPMember_zZdMsejjFk23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2% Convertible Notes – Forever Prosperity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,840,247</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,750,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold">May and June 2022 Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesAccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--MayAndJuneTwoThousandTwentyTwoNoteMember_zN47NenqlJL1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – Accredited Investors</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">993,130</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,401,284</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%">JH Darbie PPM 2 Debt</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 14%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_zCyyvC4z6ew7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">16% Convertible Notes - Non-related parties</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,183,638</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesCEORelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_z0P0itTZO9Xb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">16% Convertible Notes – CEO – Related Party</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">125,000</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPMTwoDebtMember_z2juLshXEjbg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Convertible note payable</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,308,638</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left; width: 64%">Other Debt</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 14%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 14%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_402_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtBridgeInvestorsMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_ztNxdxmktu0h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Bridge investors</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCFOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zFKVD7MDv7O5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term debt from CFO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtAutotelicIncRelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zTfaGIsgPzgh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term debt – Autotelic Inc. – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,085,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,470,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_hus-gaap--ShortTermDebtTypeAxis__custom--ShortTermDebtFromCEOMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_zkedfybhL0Th" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Short Term Debt from CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OtherShortTermBorrowings_iI_pp0p0_zdEt51mYUSgc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Short term debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,421,050</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,765,050</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DebenturesNotesAndOtherDebt_iI_zZr3UJvzwH7g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total of short term convertible debentures & notes and other debt</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,088,074</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">10,675,313</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Long Term Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-weight: bold; text-align: left">JH Darbie PPM 2 Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesNonRelatedPartiesMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM2DebtMember_zrfmjIs0caoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">16% Convertible Notes - Non-related parties</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,773,468</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SixteenPercentageConvertibleNotesCEORelatedPartyMember__us-gaap--DebtInstrumentAxis__custom--JHDarbiePPM2DebtMember_zdo0ACoHuige" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">16% Convertible Notes – CEO – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--JHDarbiePPM2DebtMember_zh3fRR19GATa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Convertible note payable</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,898,468</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

35556

164444

200000

400000

133958

128958

313733

301233

313253

300753

102659

98559

210322

201922

1073925

1031425

292552

280052

437075

418399

87770

84018

817397

782469

311693

233687

233392

4840247

4750000

993130

1401284

2183638

125000

2308638

210000

76050

35050

2085000

1470000

50000

2421050

1765050

13088074 10675313

1773468

125000

1898468

704000

280000

400000

131555

28445

175000

500000

1000000

250000

500000

250000

35000

27000

20000

168000

0.05

850000

42500

1073900

1031400

2000000

0.02

2000000 2000000 1500000

0.02

1500000

500000

0.02

4800000

90000

698500

691000

0.18

<p id="xdx_89B_ecustom--ScheduleOfConvertibleNotesNetOfDiscountTableTextBlock_gL3SOCNNODTTB-MREJ_zIXe67wIW36c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023, the August 2021 convertible notes, net of debt discount, consist of the following amounts: SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20241231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zl5yfuwCoofc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20231231__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneMember_zQ8gHJmTkXnc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--RelatedPartiesConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zWTzy32ntJX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Autotelic Related party convertible note, 5% coupon December 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">292,552</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">280,052</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--ChiefFinancialOfficerConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zkC815SX8dT2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CFO Related party convertible note, 5% coupon December 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,770</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,018</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleNotesPayable_iI_hsrt--TitleOfIndividualAxis__custom--AccreditedInvestorsConvertibleNoteFivePercentageCouponDecemberTwoThousandTwentyFourMember_zTbVfoewgfa7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Accredited investors convertible note, 5% coupon December 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">437,075</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">418,399</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleNotesPayable_iI_zXfTgaOUQWd7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Convertible notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">817,397</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">782,469</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2024, and December 31, 2023, the Fourth Man convertible note, net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_307_134_zwVRnEWHpyuc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--ShortTermDebtTypeAxis__custom--MarchTwoThousandTwentyTwoMember_zANbgCggtmsh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231__us-gaap--ShortTermDebtTypeAxis__custom--MarchTwoThousandTwentyTwoMember_zjWGyECBwGni" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ConvertibleNotesPayable_iI_hus-gaap--DebtInstrumentAxis__custom--SixteenPercentCouponMarchTwoThousandTwentyThreeMember_zZkCkFnkkxqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Fourth Man Convertible note, 16% coupon March 2023 inclusive of accrued interest and default provision</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">233,687</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">233,392</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_di_zNXG9NBfGB9g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Unamortized debt discount</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ConvertibleNotesPayable_iI_zoUfg00wPpve" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">233,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">233,392</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2024, and December 31, 2023, convertible note under the May 2022 Mast Financing, net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_30C_134_z9TzoI9Ui0w3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_zfJa0reiJ4Bh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20231231__us-gaap--ShortTermDebtTypeAxis__custom--MayTwoThousandAndTwentyTwoMember_z34SVPyEkC5a" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayableCurrent_iI_hdei--LegalEntityAxis__custom--MastHillMember_z80eed5oPBLh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Mast Hill Convertible note, 12% coupon May 2025, inclusive of accrued interest and penalty</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">993,130</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">905,484</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ConvertibleLongTermNotesPayable_iI_zpQ7FgAIIjC" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">993,130</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">905,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2024 and 2023, convertible note under the June 2022 Blue Lake Financing, net of debt discount, consist of the following amounts: <table cellpadding="0" cellspacing="0" id="xdx_305_134_zbFTcRnNNt4h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF CONVERTIBLE NOTES, NET OF DISCOUNT (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyTwoMember_zL8PgYu8aaIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20231231__us-gaap--ShortTermDebtTypeAxis__custom--JuneTwoThousandAndTwentyTwoMember_z71N9VgN31A5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleNotesPayableCurrent_iI_hdei--LegalEntityAxis__custom--BlueLakePartnersLLCMember_z2Xwk50tVDT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Blue Lake Convertible note, 16% coupon June 2023, inclusive of accrued interest</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">-</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">495,800</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ConvertibleLongTermNotesPayable_iI_zeqhRQGFUcM8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible notes, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">495,800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

292552

280052

87770

84018

437075

418399

817397

782469

35000

16000

119000

84000

817000

380000

782000

364000

1250000

0.12

0.16

0.07

9615385

0.13

961540

0.13

250000

0.12

0.16

0.10

1250000

0.20

125000

0.20

243000

3466583

127000

1820395

233687

233392

233687

233392

142000

162000

35000

500000

1.25 70000

142000

70000

34000

25000

109349

25489

78460

605000

0.12

0.16

0.10

3025000

0.20

302500

0.20

993130

905484

993130

905484

993130

605000

169400

219000

131000

82000

146000

200000

100000

335000

0.12

0.16

0.10

837500

0.20

83750

0.20

531000

7605760

495800

35000

88400

62000

35000

40200

200000

100000

As of December 31, 2024, other short-term advances consist of the following amounts obtained from various employees and related parties: SCHEDULE OF SHORT-TERM LOANS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold">Other Advances</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_z9dNAjHjuvd9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231_zjjljtp6gkY1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zKZEEphAA09g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Short term advance from CFO – Related Party</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">76,050</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">35,050</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWHDmVD8jVai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short term advance from CEO – Related Party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--BridgeInvestorMember_zXzxow1ToBM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term advances – bridge investors & others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShortTermBorrowings_iI_hsrt--TitleOfIndividualAxis__custom--AutotelicMember_z8XoflL4n6id" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Short term advances – Autotelic Inc. – Related Party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,085,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,470,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_zyyPwNLYgN04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Short term advance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,421,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,765,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

76050

35050

50000

210000

2085000

1470000

2421050

1765050

300000

100000

1400000

614000

2100000

25000

10000

41000

76000

50000

210000

NOTE 6 - JOINT VENTURE WITH GMP BIO AND AFFILIATES, EQUITY METHOD INVESTMENT On March 31, 2022, the Company entered into (i) a joint venture (the “JV”) agreement with Dragon and GMP Bio, both affiliates of GMP, (and the Company, Dragon and GMP Bio are collectively called the “Parties”) (the “JVA”), (ii) a license agreement for rights to OT-101 (the “US License Agreement”) for the territory within the United States of America (the “US”) with Sapu Holdings, LLC, a subsidiary of GMP Bio and (iii) a license agreement for rights to OT-101 for the rest of the world with GMP Bio (the “Ex-US Rights Agreement”, and the US License Agreement and the Ex-US License Agreement are collectively called the “Agreements”). For more information on the JV, JVA, and Agreements, refer to our 2022 Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. As of the effective date of the formation of the JV, the combined enterprise value of GMP Bio was approximately $50.4 million, comprising of the fair value of the Company’s investment in GMP Bio of approximately $22.7 million and the total original capital contributions by Dragon Overseas of approximately $27.7 million. As of December 31, 2024, the JV had approximately $24.4 million in assets, recorded approximately $1.2 million in liabilities and incurred approximately $9.2 million and $6.5 million in operational expenses for the years ended December 31, 2024 and 2023, respectively. While GMP’s fiscal year commences on April 1 and ends on March 31, the Company has reported the operational expenses for the same fiscal period as the Company. The JV has determined to changing the fiscal year to an annual year and plans to do it soon. In late 2023, the JV initiated a plan to start evaluating various nanoparticles that could treat various cancers. In this regard, the JV identified a total of 4 compounds, in addition to OT-101, which had the potential of significant revenue generation for the JV. In the same year, the JV signed a lease agreement to set up a GMP manufacturing facility in San Diego (“SD”), California. The main purpose of this facility was to initially commence an aggressive formulation development of newly planned nanoparticle platform (“Nano Platform”). The GMP manufacturing facility was initiated in January 2024. Upon the initiation of this facility by the JV, the JV commenced the development work on two of the four identified compounds, as well as other activities, in tandem with the development of OT-101. The JV has since completed the formulation development of one of the products and is moving to complete the formulation development for the three additional products. The JV is also working on improved formulations for OT-101 with new nanoparticle sizes. The JV also has started clinical development for OT-101 for pancreatic cancer. Significant progress has been made in the development of the products and the JV anticipates to complete the formulation development work in 2025 and pushing to initiate clinical trials for the various compounds. In late 2024, the GMP facility in San Diego was issued a Drug Manufacturing License by the State of California Department of Public Health and Food and Drug Branch. Further, in late 2024, the JV identified a sixth candidate as a compound for development for the JV and has already started to work on the formulation development of that compound as well. All manufacturing including Phase 1 clinical trial materials will be performed at the SD site. Further, in late 2024, the JV identified a sixth candidate as a compound for development for the JV and has already started to work on the formulation development of that compound as well. In early 2025, the Company announced that it had entered into a strategic partnership with Shanghai Medicilon, Inc. (“Medicilon”) to access its industry-leading rapid investigational new drug (“IND”) development platform to support up to 20 IND projects, which the JV can also utilize to support their INDS. All six of our compounds the JV is developing are planned to be these INDs and are focused on becoming next-generation anticancer agents. The JV anticipates that all these six anticancer agents have the potential to become significant growth contributors to the JV, which in turn would add substantial value to the Company. The Company successfully completed a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, Oncotelic plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers. The Company elected the fair value option under subsection of Section 825-10-15 to account for its equity-method investment as the Company believes that it the most appropriate method to properly value the Company and record a change in value when and upon conducting a fair value assessment. During the year ended December 31, 2023, and based on the results of the valuation study and the 45% ownership of the Company in GMP Bio, the Company had reported a change in fair value of the Company’s investment in the JV of approximately $13,000 for the year December 31, 2023. As of December 31, 2024, as the operations of the JV are proceeding as planned, the Company assessed the fair value of its investment in the JV and determined that no change in the fair value is required until a triggering event has occurred, similar to, but not limited to, any fund raising event, entering into an IPO or any other major event enabling the Company to reassess the fair value of its investment in the JV. <p id="xdx_892_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_zTkzQjccOyx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the change in fair value of our investment in GMP Bio, as of December 31, 2024 and 2023 is shown below: SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iS_c20240101__20241231_zoxxSl7tkwb9" style="width: 14%; text-align: right" title="Begining, investment">22,653,225</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iS_c20230101__20231231_zIrtJSd2Syph" style="width: 14%; text-align: right" title="Begining, investment">22,640,519</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Add: change in fair value of investment in GMP Bio</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--GainLossOnInvestments_c20240101__20241231_zdYuzoGo6xKb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--GainLossOnInvestments_c20230101__20231231_zY6hPAL0AVL1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">12,706</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iE_c20240101__20241231_zP45b8rlRXx1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iE_c20230101__20231231_zDc6axtAJPS1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For information on the various notes from GMP, refer to Note 5 – GMP Notes of the Notes to the Consolidated Financial Statements above.

50400000

22700000

27700000

24400000

1200000

9200000

6500000

0.45

13000

<p id="xdx_892_eus-gaap--FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock_zTkzQjccOyx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A summary of the change in fair value of our investment in GMP Bio, as of December 31, 2024 and 2023 is shown below: SCHEDULE OF CHANGE IN FAIR VALUE OF OUR INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Balance at January 1, 2024 and 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iS_c20240101__20241231_zoxxSl7tkwb9" style="width: 14%; text-align: right" title="Begining, investment">22,653,225</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--InvestmentsFairValueDisclosure_iS_c20230101__20231231_zIrtJSd2Syph" style="width: 14%; text-align: right" title="Begining, investment">22,640,519</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Add: change in fair value of investment in GMP Bio</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--GainLossOnInvestments_c20240101__20241231_zdYuzoGo6xKb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--GainLossOnInvestments_c20230101__20231231_zY6hPAL0AVL1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of investment">12,706</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at December 31, 2024 and 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--InvestmentsFairValueDisclosure_iE_c20240101__20241231_zP45b8rlRXx1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsFairValueDisclosure_iE_c20230101__20231231_zDc6axtAJPS1" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending, investment">22,653,225</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

22653225

22640519

12706

22653225

NOTE 7 - PRIVATE PLACEMENT (PPM-1) AND JH DARBIE FINANCING During the period from July 2020 to March 2021, the Company entered into subscription agreements with certain accredited investors pursuant to the JH Darbie Financing, whereby the Company issued and sold a total of 100 Units, for total gross proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zqHsT80p3E59">5 million, pursuant to the JH Darbie Placement Agreement, with each Unit consisting of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">■</td> <td style="text-align: justify"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_z1ALI0pNST6" style="font-size: 10pt">25,000 shares of Edgepoint Common Stock for a price of $1.00 per share of Edgepoint Common Stock.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>■</td> <td style="text-align: justify">One convertible promissory note, convertible into up to <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_ziyvqcuLbg9e">25,000 shares of Edgepoint Common Stock, at a conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zdAqjvXZ7J9i">1.00 per share or up to <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zXi0mILMIRU">138,889 shares of the Company’s Common Stock, at a conversion price of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_ziV3TqrwGNz3">0.18 per share.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>■</td> <td style="text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zXDibuRVSsnb" style="font-size: 10pt">50,000 warrants to purchase an equivalent number of shares of Edgepoint Common Stock at $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zLiUZdsTsc8e">1.00 per share or an equivalent number of shares of the Company’s Common Stock at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zEfFgxONL3Be">0.20 per share with a three-year expiration date. Either the Edgepoint or the Company’s warrants would be exercised.</td></tr> </table> During the period between July 2023 and January 2024, the Company converted the debt of forty six accredited investors from the JH Darbie Financing (now referred to as “PPM-1”) into the new subscription agreements under the new financing (“PPM-2”- See Note 8 below), which resulted in conversion of $<span id="xdx_90A_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zndTF2A7vj72">2.35 million of old debt into new debt to the Company. <p id="xdx_899_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementConvertedDebtDiscountTableTextBlock_zisH8bHw5Vl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, and 2023, funds received under the JH Darbie Financing, net of debt discounts, consist of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zqNeemX93P65" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zwLtD5rReQZf" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zdd1qq0scxTk" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Subscription agreements - accredited investors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,693</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--RelatedPartyMember_zjybtYeQVKU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Subscription agreements – related party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zOKjXCasodVb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible promissory notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">311,693</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company incurred approximately $0.64 million of issuance costs, including legal costs of approximately $39,000, that are incremental costs directly related to the issuance of the various instruments bundled in the offering. As of the date of this Report, the PPM notes are in default. Concurrently with the sale of the Units, JH Darbie was granted, for nominal consideration, a warrant, exercisable over a five-year period, to purchase 10% of the number of Units sold in the JH Darbie Financing. As such, the Company granted 10 Units to JH Darbie pursuant to the JH Darbie Placement Agreement. The terms of convertible notes are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">■</td> <td style="text-align: justify">Term: Through March 31, 2023.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>■</td> <td style="text-align: justify">Coupon: 16%.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>■</td> <td style="text-align: justify">Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common Stock.</td></tr> <tr style="vertical-align: top"> <td> </td> <td>■</td> <td style="text-align: justify">The conversion price is initially set at $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zbG5dR3nUXkf">0.18 per share for the Company’s Common Stock or $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zva2fprVKAWj">1.00 for Edgepoint Common Stock, subject to adjustment.</td></tr> </table> In February 2022, the Company and all except one of the Investors agreed to extend the maturity date of the Notes from March 31, 2022, to March 31, 2023. In consideration for the extension of the Notes, the Company issued to the Investors an aggregate of 33,000,066 Oncotelic Warrants at a price of $0.15 per share of Company’s Common Stock. Each Investor will be entitled to receive 333,334 Oncotelic Warrants for each Unit purchased. Upon the amendment of the terms of the convertible notes under the private placement memorandum. As incentive to extend the maturity date, approximately 33 million warrants were issued to the Unit Holders who participated in the amendment, the Company repaid the 1-unit holder who did not participate in the amendment shortly after March 31, 2022. Further, during the year ended December 31, 2023, the Company repaid two of the unit holders, who held 5 units and opted not to participate in the new JH Darbie financing. While the Company had been in default under the PPM-1 since April 2023, as of the date of this Annual Report, with the conversion of the rest of the Note Holders under the PPM-1, the event of default has been addressed. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $0 and 8,400 for the years ended December 31, 2024 and 2023, respectively, which is included in interest expense in the statements of operations.

5000000

25000

1.00

25000

1.00

138889

0.18

50000

1.00

0.20

2350000

<p id="xdx_899_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementConvertedDebtDiscountTableTextBlock_zisH8bHw5Vl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, and 2023, funds received under the JH Darbie Financing, net of debt discounts, consist of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20241231_zqNeemX93P65" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20231231_zwLtD5rReQZf" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zdd1qq0scxTk" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Subscription agreements - accredited investors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,693</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__us-gaap--RelatedPartyMember_zjybtYeQVKU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Subscription agreements – related party</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zOKjXCasodVb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible promissory notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">311,693</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

311693

640000

39000

0.10

0.16

0.18

1.00

33000066

0.15

333334

Upon the amendment of the terms of the convertible notes under the private placement memorandum. As incentive to extend the maturity date, approximately 33 million warrants were issued to the Unit Holders who participated in the amendment, the Company repaid the 1-unit holder who did not participate in the amendment shortly after March 31, 2022. Further, during the year ended December 31, 2023, the Company repaid two of the unit holders, who held 5 units and opted not to participate in the new JH Darbie financing.

8400

NOTE 8 – PRIVATE PLACEMENT -2 (PPM-2) AND JH DARBIE FUNDING During the period between July 2023 to January 2024, the Company entered into a series of subscription agreements with forty six accredited investors (the “Financing”) whereby the Company issued and converted a total of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z4PHkrSL76H2">94 Units from the previous PPM (“PPM -1”- See Note 7 above) into the current subscription agreements under the PPM-2, which resulted in conversion of $<span id="xdx_904_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20240131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zDBovbGsFCZd">2.35 million of old debt into new debt to the Company; and the Company did not receive any cash proceeds through the July 2023 through January 2024 conversions., with each Unit consisting of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify">●</td> <td style="text-align: justify">One <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zYQexEZ7k0A">16% convertible unsecured promissory note (the “Note”) of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zIwDfWol2KJ2">25,000, convertible into up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zWWy6LATANbd">250,000 shares of the Company’s common stock (par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zAl3FpkX2rk6">0.01) based on a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember_zM5nvXNzgBC2">0.10 per share.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"> </td> <td style="width: 0.25in; text-align: justify">●</td> <td style="text-align: justify"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEL8ViyBqkck" style="font-size: 10pt">250,000 warrants to purchase an equivalent number of shares of the Company’s common stock at a strike price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH4bVWW3jDq9">0.12 per share (“Oncotelic warrant”).</td></tr> </table> JH Darbie and the Company are parties to a March 2023 placement agent agreement (“Agreement”) pursuant to which DH Darbie had the right to sell a minimum of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MinimumMember_zVLn5fCwjNs6">10 Units and a maximum of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20230701__20240131__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zy3toFI9M6Cd">200 Units on a best-efforts basis. For the 4 tranches of conversion related to PPM 2, placement agent fees of $377,500 were paid to JH Darbie. Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company provided warrant coverage equal to 13 % of all of the units sold to JH Darbie. As the Company converted an aggregate of 94 units, JH Darbie was entitled to earn a total of 3,055,000 warrants. A total of 5 unit holders under the PPM-1 opted not to participate in the PPM-2. In connection with the consummation of Tranche 1, 2 and 3 and 4 of the July 2023 PPM, the Company entered into a Registration Rights Agreement granting certain registration rights with respect to the shares of the Company’s Common Stock issued in connection with the financing, as well as the shares of the Company’s Common Stock issuable upon exercise of the Warrants. The issuance of the Units is exempt from the registration requirements of the Securities Act of 1933, as amended (“Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of common stock and warrants and any shares of common stock issuable upon exercise of the warrants, have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act. <p id="xdx_89A_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscountTableTextBlock_zSPLe678wdQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, and December 31, 2023, debt recorded under PPM-2, net of debt discounts and including accrued interest, consist of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zSzMpp4XpLob" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_zy6nvI6n0tEk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z8CVdaK40vJc" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Subscription agreements - accredited investors</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">2,308,638</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,898,468</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember_z8dEvDYyAb5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible promissory, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,308,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,898,468</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company incurred approximately $0.4 million of issuance costs under the PPM-2 and are incremental costs directly related to the issuance of the various instruments bundled in the offering. Concurrently with the PPM- 2, JH Darbie was granted a total of 3,055,000 stock warrants, exercisable over a two-year period. The terms of convertible notes are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td>Term: through December 31, 2025</td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Coupon: 16%</td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Convertible at the option of the holder at any time into the Company’s common stock</td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Conversion price is set at $0.10 per share subject to standard anti-dilution provision.</td></tr> </table> Management reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt- Modifications and Extinguishments and concluded that the terms of the agreements were substantially different and, accounted for the transaction as a debt extinguishment. The transaction related to T4 during the year ended December 31, 2024 resulted in a loss from debt extinguishment of approximately $88,000, which is presented in other expense in the consolidated statements of operations for the year ended December 31, 2024. The estimated volume weighted grant date fair value of approximately $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8ctU93lxJE8">0.026 per share associated with the warrants to purchase up to <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8XqmOoQ6lGg">3,390,000 shares of common stock issued in this offering, or a total of approximately $<span id="xdx_903_eus-gaap--AdditionalPaidInCapital_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuGpvrsgLY5">88,000, was recorded to additional paid-in capital. All warrants sold in this offering have an exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_iI_c20241231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zguuBNGHhral">0.12 per share of the Company stock, subject to adjustment, are exercisable immediately and expire two years from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values: SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 82%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">173</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table> The Company recorded approximately $318,000 as an initial debt discount related to the four tranches of PPM 2. The Company recognized amortization expense related to the debt discount and debt issuance costs of approximately $157,000 and $50,000 for the years ended December 31, 2024 and 2023, respectively, which is included in interest expense in the statements of operations During the years ended December 31, 2024 and 2023, the Company incurred approximately $<span id="xdx_90C_eus-gaap--InterestExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwoQkB5xz8bb">363,000 and $<span id="xdx_90D_eus-gaap--InterestExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z2wMuqQjA036">122,000 of interest expense related to the convertible notes.

2350000

0.16

25000

250000

0.01

0.10

250000

0.12

200

377500

Based on the placement agent agreement, JH Darbie was entitled to a non-refundable $25,000 fee to start the due diligence process and 2% due diligence fees and 13% commissions on all subsequent conversions or new funding. In addition, the Company provided warrant coverage equal to 13 % of all of the units sold to JH Darbie. As the Company converted an aggregate of 94 units, JH Darbie was entitled to earn a total of 3,055,000 warrants. A total of 5 unit holders under the PPM-1 opted not to participate in the PPM-2.

<p id="xdx_89A_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscountTableTextBlock_zSPLe678wdQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, and December 31, 2023, debt recorded under PPM-2, net of debt discounts and including accrued interest, consist of the following amounts: SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zSzMpp4XpLob" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20231231_zy6nvI6n0tEk" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z8CVdaK40vJc" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left; padding-bottom: 1pt">Subscription agreements - accredited investors</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">2,308,638</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,898,468</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsTwoMember_z8dEvDYyAb5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible promissory, net of discounts</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,308,638</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,898,468</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2308638

1898468

2308638

1898468

400000

3055000

0.16

0.10

88000

0.026

3390000

88000

0.12

SCHEDULE OF FAIR VALUE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2 years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 82%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">173</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.29</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> </table>

P2Y

173

4.29

0.00

318000

157000

50000

363000

122000

NOTE 9 - RELATED PARTY TRANSACTIONS Master Service Agreement with Autotelic Inc. In October 2015, Oncotelic Inc. entered into a Master Service Agreement (the “MSA”) with Autotelic Inc. (“Autotelic”), a related party that is partly owned by Dr. Trieu. Dr. Trieu, a related party, is a control person in Autotelic. Autotelic currently owns less than 10% of the Company. The MSA stated that Autotelic will provide business functions and services to the Company and allowed Autotelic to charge the Company for these expenses paid on its behalf. The MSA includes personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA requires a 90-day written termination notice in the event either party requires to terminate such services. Expenses related to the MSA were $<span id="xdx_907_eus-gaap--OperatingCostsAndExpenses_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z65qvQWhQBl3">2,000 and approximately $<span id="xdx_902_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAgreementMember__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2ujraqEeQFe">12,000 for the years ended December 31, 2024 and 2023, respectively. The Company owed Autotelic, Inc. approximately $<span id="xdx_90E_eus-gaap--OperatingCostsAndExpenses_pn5n6_c20230101__20231231__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zFMCpVBWbt2e">0.3 million at December 31, 2024 and December 31, 2023 respectively. License Agreement with Autotelic Inc. In September 2021, the Company entered into an exclusive License Agreement with Autotelic. For more information on the exclusive license Agreement with Autotelic, refer to our 2023 Annual Report on Form 10-K filed with SEC on April 12, 2024. Notes Payable and Short-Term Loan – Related Party In April 2019, the Company issued a convertible note to Dr. Trieu totaling $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7O2u03uQsf">164,444, including OID of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1XvuKHXNqo1">16,444, receiving net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromConvertibleDebt_c20190401__20190430__srt--TitleOfIndividualAxis__custom--VuongTrieuMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxbO7KPJxnh3">148,000, which was used by the Company for working capital and general corporate purposes. The Company issued a Fall 2019 Note to Dr. Trieu in the principal amount of $250,000. Dr. Trieu also offset certain amounts due to him in the amount of $<span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20190401__20190430__us-gaap--DebtInstrumentAxis__custom--FallTwoThousandAndNineteenNoteMember__srt--TitleOfIndividualAxis__custom--VuongTrieuMember_zvo414lBqdvj">35,000 and was converted into the Fall 2019 debt. During the year ended December 31, 2020, Dr. Trieu purchased a total of 5 Units under the private placement for a gross total of $250,000. During the year ended December 31, 2023, Dr Trieu provided short term loan of $50 thousand to the Company. The balance due and payable to Dr. Trieu, as of December 31, 2024 and 2023, respectively, was $50,000. In May 2021, Autotelic provided an additional short-term funding of $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210501__20210531__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneNoteMember_zZIaLJDfveye">250,000 to the Company, which was converted into the August 2021 Notes. Autotelic provided an additional $120,000 short-term loan to the Company during the year ended December 31, 2022. During the year ended December 31, 2023, Autotelic provided $1.4 million in short term advances to the Company. During the year ended December 31, 2024, Autotelic provided and additional $0.7 million. As such, approximately $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn4n6_c20241231__dei--LegalEntityAxis__custom--AutotelicIncMember__us-gaap--ShortTermDebtTypeAxis__custom--AugustTwoThousandAndTwentyOneNoteMember_z8zvsMWMX2A6">2.1 million was outstanding and payable to Autotelic at December 31, 2024. Artius Consulting Agreement In March 2020, the Company and Artius Bioconsulting, LLC (“Artius”), for which Mr. King is the Managing Member, entered into an amendment to the Consulting Agreement dated December 1, 2018, under which Artius agreed to serve as a consultant to the Company for services related to the Company’s business from time to time, effective December 1, 2019 (the “Effective Date”) (the “Artius Agreement”). For more information on this Agreement, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. <span id="xdx_903_eus-gaap--OperatingCostsAndExpenses_do_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ArtiusConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zrPLTCKmmmo9">No expense was recorded during the year ended December 31, 2024, or 2023, respectively, related to this Agreement. Mosaic Consulting Agreement In July 2024, the Company and Mosaic, for which Mr. King is the Chief Executive Officer, entered into an consulting agreement (“Mosaic Agreement”), under which Mosaic agreed to serve as a consultant to the Company for services related to the JV’s chemistry, manufacturing and controls for the San Diego site on a month to month basis at a rate of $<span id="xdx_90F_eus-gaap--OfficersCompensation_c20240701__20240731__us-gaap--TypeOfArrangementAxis__custom--MosaicConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zUj1myuCIeRk">7,000 per month. This cost was entirely borne by the JV. <span id="xdx_90F_eus-gaap--OperatingCostsAndExpenses_do_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--MosaicConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVnMTstMBuh5">No expense was recorded during the year ended December 31, 2024, related to the Mosaic Agreement. Maida Consulting Agreement Effective May 5, 2020, the Company and Dr. Maida entered into an independent consulting agreement, commencing April 1, 2020 (the “Maida Agreement”), under which Dr. Maida will assist the Company in providing medical expertise and advice from time to time in the design, conduct and oversight of the Company’s existing and future clinical trials. For more information on this Agreement, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 15, 2022. The Company recorded an expense of $<span id="xdx_901_eus-gaap--OperatingCostsAndExpenses_c20230101__20231231__srt--TitleOfIndividualAxis__custom--DrMaidaMember__us-gaap--TypeOfArrangementAxis__custom--MaidaConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zfmkif2g6qn3">0 during the years ended December 31, 2024 and 2023, respectively, related to this Agreement. Effective April 1, 2022, Dr Maida’s compensation is being borne by the JVA with GMP Bio.

2000

12000

300000

164444

16444

148000

250000

35000

250000

50000

250000

120000

1400000

700000

2100000

7000

NOTE 10 - EQUITY PURCHASE AGREEMENT AND REGISTRATION RIGHTS AGREEMENT On May 3, 2021, the Company entered into an Equity Purchase Agreement (“EPL”) and Registration Rights Agreement with Peak One Opportunity Fund LP (“Peak One” or the “Investor”). For further information on EPL, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The Company also filed a post-effective amendment registration statement on Form S-1 with the Commission on April 12, 2024, and the Form S-1 was declared effective on April 22, 2024. The Company filed the prospectus under rule 424b3 with the SEC on April 26, 2024. During year ended December 31, 2024 and 2023, the Company did not sell any shares of Common Stock under the EPL.

NOTE 11 – STOCKHOLDERS’ EQUITY The following transactions affected the Company’s Stockholders’ Equity: Issuance of Common Stock during the year ended December 31, 2024 In February 2024, Fourth Man partially converted $35,000 of their debt. In connection with the partial Note conversion, the Company issued 500,000 shares of Common Stock to Fourth Man. In May 2024, Blue Lake converted the balance of their $531,000 debt, inclusive of accrued interest and penalty, into 7,605,760 shares of Common Stock of the Company. Issuance of Common Stock during the year ended December 31, 2023 In February 2023, Fourth Man partially converted $71,750 of their debt. In connection with the partial Note conversion, the Company issued 1,025,000 shares of Common Stock to Fourth Man. In June 2023, Blue Lake converted the full remainder of their $181,750 debt, accrued interest and penalty. In connection with this Note conversion, the Company issued 3,466,853 shares of Common Stock to Blue Lake. In May and June 2023, Fourth Man converted $50,000 in principal and $30,000 in accrued interest into 1,192,857 shares of Common Stock. In July 2023, Fourth Man converted approximately $43,000 balance in principal and accrued interest into 627,538 shares of Common Stock. In October 2023, Fourth Man converted approximately $72,000 in principal, accrued interest and legal fees into 1,025,000 shares of Common Stock. For further information on Common Stock issuance, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024.

35000

500000

531000

7605760

71750

1025000

181750

3466853

50000

30000

1192857

43000

627538

72000

1025000

NOTE 12 – STOCK-BASED COMPENSATION Options Pursuant to the Merger, the Company’s Common Stock and corresponding outstanding options survived. The below information details the Company’s associated option activity pre and post-merger. As of December 31, 2024, the Company had options to purchase Common Stock that were outstanding under three stock option plans – the 2017 Equity Incentive Plan (the “2017 Plan”), the 2015 Equity Incentive Plan (the “2015 Plan”) and the 2005 Stock Plan (the “2005 Plan”). Under the 2017 Plan, up to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zJ3cth9BdTkb">2,000,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Under the 2015 and 2005 Plans, taken together, up to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenAndTwoThousandFiveEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zgLbPV7koiM3">27,250,000 shares of the Company’s Common Stock may be issued pursuant to awards granted in the form of incentive stock options, nonqualified stock options, restricted and unrestricted stock awards, and other stock-based awards. Employees, consultants, and directors are eligible for awards granted under the 2017 and 2015 Plans. Since the adoption of the 2015 Plan, no further awards may be granted under the 2005 Plan, although options previously granted remain outstanding in accordance with their terms. <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zDvR2FGLxaD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zY44hMlSfYn" style="width: 14%; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_z3cibdRg7EJg" style="width: 14%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zHgBtu5IAPUb" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zDYgLfkdXcle" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zj5WKnk0BG32" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zR4lWKHCkJE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20240101__20241231_zMKnRom6Mgck" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,985,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z6h5wE7aVVak" style="width: 14%; text-align: right" title="Options outstanding, Balance">25,690,261</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zRQa5fAp9sSc" style="width: 14%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zARFOUuUhLAi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">(1,512,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z7Sk4AYKodK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">0.46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z6Mv3yN34dn9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zVTm305o7xZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20230101__20231231_zwdujn0Nztp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,985,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zQ9vdHVnjqgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at December 31, 2024: SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise prices </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Outstanding Options </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Remaining Life In Years </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Exercise Price </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Number Exercisable </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; padding-bottom: 1.5pt">$</td> <td style="width: 20%; padding-bottom: 1.5pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRK9VFCq8vNj" style="font-size: 10pt">0.1 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zETXA4zszBQ">0.15</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z7IOwe2sfxJa" style="width: 16%; padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">16,250,000</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 16%; padding-bottom: 1.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z9VCChbUsi49" style="font-size: 10pt">7.2</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt">$</td> <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zfwmKXMnL8fd" style="width: 15%; padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.12</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnJMJKC02C8" style="width: 15%; padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">6,057,500</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsQNLHMn95U7" style="font-size: 10pt">0.16 to $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmiWEUsxrcb4">0.21</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrohMeWgDHu9" style="padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">5,502,761</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z0qjGzXONcZ5" style="font-size: 10pt">6.5</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zPCCv2nEJvy1" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.16</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zj1VuxYFULRg" style="padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">5,502,761</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zhgNfihXYmv3" style="font-size: 10pt">0.22 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_ziJutXjL1Dz3">0.37</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zAJsm3mqmC41" style="padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">1,550,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zisbx9mwznDb" style="font-size: 10pt">3.0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zU3bqiOFlnNe" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.28</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwnVe6mSWq96" style="padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">1,550,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeyEY66cwdQ9" style="font-size: 10pt">0.38 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zRuVZMOdAv0a">0.72</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAe7idmUXEkf" style="padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">500,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zY7dOmoNRTYb" style="font-size: 10pt">1.2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zVOoIuQcoB48" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.73</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_ztCwH6bfHLUc" style="padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">500,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFDapgVmw3Lg" style="font-size: 10pt">0.73 to $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFyzbz1C5xCh">15.0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z1AOREz1K04i" style="border-bottom: black 1pt solid; text-align: right" title="Number of Outstanding Options">375,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zOzRjGW9Snug" style="font-size: 10pt">0.4</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z3TSvEDf4Gfk" style="border-bottom: black 1pt solid; text-align: right" title="Weighted-Average Exercise Price">4.14</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4KPbKmM2seh" style="border-bottom: black 1pt solid; text-align: right" title="Number Exercisable">375,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zjMfTawgkfAf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">24,177,761</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zWgKcoZnXQS5" style="font-size: 10pt">6.5</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231_z6G1d0OELWkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price">0.21</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zLLkd8ygsMni" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">13,985,261</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> The compensation expense attributed to the issuance of the options is recognized as they are vested. The employee stock option plan stock options are generally exercisable for ten years from the grant date and vest over various terms from the grant date to three years. As of December 31, 2024, there was no unamortized stock compensation cost related to the stock options granted during the year ended December 31, 2022. Of the approximately 10 million unvested stock options, the vesting criteria for 7.3 million options is still being evaluated as on the date of this Report, as those options are subject to individual milestone achievements. For more information on the stock options, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The Company amortized $0 stock compensation expense during the years ended December 31, 2024 and 2023, respectively on the 2021 and 2022 grants. Warrants The Company has issued warrants in connection with the various financings conducted by the Company. For more information on the warrant issuances, refer to our 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024. The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, for the years ended December 31, 2024 and 2023, respectively are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Exercise Price </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231_z18V1yAwTo4e" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Balance">61,500,355</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zodRbGtSQVgh" style="width: 14%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during the year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231_z2MnDqyIHLu6" style="text-align: right" title="Number of Stock Options, Issued">3,390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20241231_zDQNuI3NwWXj" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Exercised / cancelled during the year ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231_zFVb8mm6kh9d" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">(33,000,066</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zLL212Yj1Pqf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231_zeXwvN0iCqE8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z25PK3X99kk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Exercise Price </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zkRzHSE5GCtl" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Balance">81,072,855</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zWBJtKAjvmM9" style="width: 14%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during the year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zV6FUNYQ3UU2" style="text-align: right" title="Number of Stock Options, Issued">23,165,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20230101__20231231_zg8AseuWzQmg" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Exercised / cancelled during the year ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231_zNhgYkQPKFV9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">(42,737,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z8JbE0s4RIHh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">0.20</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_zLl6FZwKO92f" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">61,500,355</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_z3qGAopX37fb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table summarizes information about warrants outstanding and exercisable at December 31, 2024: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">Outstanding and exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Number Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Remaining Life in Years </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Exercise Price </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Number Exercisable </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; padding-bottom: 1.5pt">$</td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1xGekJzUJ49" style="width: 16%; padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.13</td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWVZiybwjwMf" style="width: 17%; padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">961,539</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 17%; padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9EgtHCtEpXh" style="font-size: 10pt">2.00</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_988_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkkss8wVG3ik" style="width: 17%; padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.13</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwdRvtLOiCIh" style="width: 15%; padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">961,539</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh2OJoAe5gfi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.20</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJiiTbmEcGM4" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">4,373,750</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z1kYaFF76zi3" style="font-size: 10pt">2.26-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z7AL3Z5qjbCc">2.47</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCsRF4iv3Eed" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.20</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ecvR0JjDyj" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">4,373,750</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWAb7khi0Mbi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6p0PVahHAi4" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">11,300,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8rss6ekJP45" style="font-size: 10pt">0.51</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6YTRAJ2VU1" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Hg79yR9FJi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">11,300,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNv77Al7dQS2" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF026kNs0wY" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">11,865,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zomEgFhkMOO9" style="font-size: 10pt">0.81</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_982_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicorN7gfshj" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr2cj9QPbdFf" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">11,865,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX4pQ3DKN0nb" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTb92C1VfM0a" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Outstanding, Number of Warrants">3,390,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO9DK7e6Mc" style="font-size: 10pt">1.08</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98D_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqfTXt1RA68" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYiS55HXHbGl" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">3,390,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_z3Gpjog6InAe" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding, Number of Warrants">31,890,289</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.99</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_984_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231_zNRQ2ANiMtTk" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Weighted Average Exercise Price">0.13</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231_zJRsgyMqFU9d" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding, Number of Exercisable">31,890,289</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

2000000

27250000

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zDvR2FGLxaD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Compensation based stock option activity for qualified and unqualified stock options are summarized as follows: SCHEDULE OF COMPENSATION BASED STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231_zY44hMlSfYn" style="width: 14%; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_z3cibdRg7EJg" style="width: 14%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20240101__20241231_zHgBtu5IAPUb" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zDYgLfkdXcle" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231_zj5WKnk0BG32" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_zR4lWKHCkJE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20240101__20241231_zMKnRom6Mgck" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,985,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_z6h5wE7aVVak" style="width: 14%; text-align: right" title="Options outstanding, Balance">25,690,261</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zRQa5fAp9sSc" style="width: 14%; text-align: right" title="Weighted average exercise price outstanding, Balance">0.23</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Expired or cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zARFOUuUhLAi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding, expired or cancelled">(1,512,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z7Sk4AYKodK2" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price outstanding, Expired or Cancelled">0.46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_z6Mv3yN34dn9" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, Balance">24,177,761</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zVTm305o7xZk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price outstanding, Balance">0.21</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iE_pid_c20230101__20231231_zwdujn0Nztp5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, Balance">13,985,261</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

24177761

0.21

24177761

0.21

13985261

25690261

0.23

1512500

0.46

24177761

0.21

13985261

<p id="xdx_89D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zQ9vdHVnjqgh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table summarizes information about options to purchase shares of the Company’s Common Stock outstanding and exercisable at December 31, 2024: SCHEDULE OF OPTIONS TO PURCHASE SHARES OF COMMON STOCK OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise prices </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Outstanding Options </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Remaining Life In Years </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Exercise Price </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Number Exercisable </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; padding-bottom: 1.5pt">$</td> <td style="width: 20%; padding-bottom: 1.5pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zRK9VFCq8vNj" style="font-size: 10pt">0.1 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zETXA4zszBQ">0.15</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z7IOwe2sfxJa" style="width: 16%; padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">16,250,000</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 16%; padding-bottom: 1.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_z9VCChbUsi49" style="font-size: 10pt">7.2</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt">$</td> <td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zfwmKXMnL8fd" style="width: 15%; padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.12</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zxnJMJKC02C8" style="width: 15%; padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">6,057,500</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zsQNLHMn95U7" style="font-size: 10pt">0.16 to $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zmiWEUsxrcb4">0.21</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrohMeWgDHu9" style="padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">5,502,761</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_z0qjGzXONcZ5" style="font-size: 10pt">6.5</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zPCCv2nEJvy1" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.16</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zj1VuxYFULRg" style="padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">5,502,761</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zhgNfihXYmv3" style="font-size: 10pt">0.22 to $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_ziJutXjL1Dz3">0.37</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zAJsm3mqmC41" style="padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">1,550,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zisbx9mwznDb" style="font-size: 10pt">3.0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zU3bqiOFlnNe" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.28</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zwnVe6mSWq96" style="padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">1,550,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zeyEY66cwdQ9" style="font-size: 10pt">0.38 to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zRuVZMOdAv0a">0.72</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zAe7idmUXEkf" style="padding-bottom: 1.5pt; text-align: right" title="Number of Outstanding Options">500,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zY7dOmoNRTYb" style="font-size: 10pt">1.2</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zVOoIuQcoB48" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-Average Exercise Price">0.73</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_ztCwH6bfHLUc" style="padding-bottom: 1.5pt; text-align: right" title="Number Exercisable">500,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFDapgVmw3Lg" style="font-size: 10pt">0.73 to $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zFyzbz1C5xCh">15.0</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z1AOREz1K04i" style="border-bottom: black 1pt solid; text-align: right" title="Number of Outstanding Options">375,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zOzRjGW9Snug" style="font-size: 10pt">0.4</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z3TSvEDf4Gfk" style="border-bottom: black 1pt solid; text-align: right" title="Weighted-Average Exercise Price">4.14</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z4KPbKmM2seh" style="border-bottom: black 1pt solid; text-align: right" title="Number Exercisable">375,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20241231_zjMfTawgkfAf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Outstanding Options">24,177,761</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231_zWgKcoZnXQS5" style="font-size: 10pt">6.5</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td id="xdx_988_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_c20241231_z6G1d0OELWkl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price">0.21</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20241231_zLLkd8ygsMni" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable">13,985,261</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

0.1

0.15

16250000

P7Y2M12D

0.12

6057500

0.16

0.21

5502761

P6Y6M

0.16

5502761

0.22

0.37

1550000

P3Y

0.28

1550000

0.38

0.72

500000

P1Y2M12D

0.73

500000

0.73

15.0

375000

P0Y4M24D

4.14

375000

24177761

P6Y6M

0.21

13985261

P10Y

P3Y

The issuance of warrants to purchase shares of the Company’s Common Stock, including those attributed to debt issuances, for the years ended December 31, 2024 and 2023, respectively are summarized as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Exercise Price </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20241231_z18V1yAwTo4e" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Balance">61,500,355</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20241231_zodRbGtSQVgh" style="width: 14%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.15</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during the year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20240101__20241231_z2MnDqyIHLu6" style="text-align: right" title="Number of Stock Options, Issued">3,390,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20240101__20241231_zDQNuI3NwWXj" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Exercised / cancelled during the year ended December 31, 2024</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20240101__20241231_zFVb8mm6kh9d" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">(33,000,066</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20241231_zLL212Yj1Pqf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">0.15</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20240101__20241231_zeXwvN0iCqE8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">31,890,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20241231_z25PK3X99kk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.13</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">For the year ended December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Exercise Price </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zkRzHSE5GCtl" style="width: 14%; text-align: right" title="Number of Stock Options Outstanding, Balance">81,072,855</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zWBJtKAjvmM9" style="width: 14%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, beginning balance">0.18</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued during the year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zV6FUNYQ3UU2" style="text-align: right" title="Number of Stock Options, Issued">23,165,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedInPeriodWeightedAverageExercisePrice_c20230101__20231231_zg8AseuWzQmg" style="text-align: right" title="Weighted-Average Exercise Price, Issued">0.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Exercised / cancelled during the year ended December 31, 2023</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_iN_pid_di_c20230101__20231231_zNhgYkQPKFV9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Stock Options, Expired / cancelled">(42,737,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z8JbE0s4RIHh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired / cancelled">0.20</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_zLl6FZwKO92f" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Stock Options Outstanding, Balance">61,500,355</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_z3qGAopX37fb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, outstanding, Balance">0.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

61500355

0.15

3390000

0.12

33000066

0.15

31890289

0.13

81072855

0.18

23165000

0.12

42737500

0.20

61500355

0.15 The following table summarizes information about warrants outstanding and exercisable at December 31, 2024: SCHEDULE OF WARRANTS OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">Outstanding and exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Number Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Remaining Life in Years </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted- Average Exercise Price </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Number Exercisable </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; padding-bottom: 1.5pt">$</td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1xGekJzUJ49" style="width: 16%; padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.13</td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWVZiybwjwMf" style="width: 17%; padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">961,539</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 17%; padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9EgtHCtEpXh" style="font-size: 10pt">2.00</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_988_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkkss8wVG3ik" style="width: 17%; padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.13</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwdRvtLOiCIh" style="width: 15%; padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">961,539</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh2OJoAe5gfi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.20</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJiiTbmEcGM4" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">4,373,750</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z1kYaFF76zi3" style="font-size: 10pt">2.26-<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z7AL3Z5qjbCc">2.47</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCsRF4iv3Eed" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.20</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7ecvR0JjDyj" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">4,373,750</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWAb7khi0Mbi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6p0PVahHAi4" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">11,300,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8rss6ekJP45" style="font-size: 10pt">0.51</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_987_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA6YTRAJ2VU1" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Hg79yR9FJi" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">11,300,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNv77Al7dQS2" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF026kNs0wY" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Number of Warrants">11,865,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zomEgFhkMOO9" style="font-size: 10pt">0.81</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_982_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zicorN7gfshj" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr2cj9QPbdFf" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">11,865,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zX4pQ3DKN0nb" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Outstanding, Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTb92C1VfM0a" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Outstanding, Number of Warrants">3,390,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO9DK7e6Mc" style="font-size: 10pt">1.08</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_98D_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlqfTXt1RA68" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Weighted- Average Exercise Price">0.12</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYiS55HXHbGl" style="border-bottom: black 1pt solid; text-align: right" title="Warrants Exercisable, Exercisable Number of Warrants">3,390,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20241231_z3Gpjog6InAe" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding, Number of Warrants">31,890,289</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.99</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td id="xdx_984_ecustom--ClassOfWarrantWeightedAverageExercisePriceOfWarrants_iI_c20241231_zNRQ2ANiMtTk" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Weighted Average Exercise Price">0.13</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241231_zJRsgyMqFU9d" style="border-bottom: black 2.25pt double; text-align: right" title="Warrants Outstanding, Number of Exercisable">31,890,289</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

0.13

961539

P2Y

0.13

961539

0.20

4373750

P2Y3M3D

P2Y5M19D

0.20

4373750

0.12

11300000

P0Y6M3D

0.12

11300000

0.12

11865000

P0Y9M21D

0.12

11865000

0.12

3390000

P1Y29D

0.12

3390000

31890289

P0Y11M26D

0.13

31890289

NOTE 13 – INCOME TAXES Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes as of December 31, 2024 and 2023 are as follows in thousands: SCHEDULE OF COMPONENTS OF NET DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20241231_zkLbQDERqsCc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20231231_ztbKZE3IeGrj" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzGLT_zLRznv18jCC5" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Stock-based compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,438</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzGLT_zXWDbsfhiMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,304</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzGLT_zVJZLYfrXQPf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Liability accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">324</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzGLT_z0Pq6tvnemZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">R&D Credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,372</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,372</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_maDTAGzGLT_z36k9vipZn0h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Capital Loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--IncomeTaxReconciliationStateAndLocalIncomeTax_iI_pn3n3_maDTAGzGLT_zwQSvboDVs5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred state tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,087</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,065</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzGLT_z2vuAU7d9Jc4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net operating loss carry forward</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,489</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzGLT_maDTANzNCY_zApxU5oLpVAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,760</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,390</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzNCY_z1rblL4yvjV9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less - valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,760</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,390</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzNCY_z4g1gsArotL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The Company had gross deferred tax assets, which primarily relate to net operating loss carryforwards. As of December 31, 2024, the Company had gross federal and state net operating loss carryforwards, which are available to offset future taxable income, if any. The Company recorded a valuation allowance in the full amount of its net deferred tax assets since realization of such tax benefits has been determined by our management to be less likely than not. Portions of these carryforwards will expire through 2038, if not otherwise utilized. The Company’s utilization of net operating loss carryforwards could be subject to an annual limitation. as a result of certain past or future events, such as stock sales or other equity events constituting a “change in ownership” under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations could result in the expiration of net operating loss carryforwards and tax credits before they can be utilized. We have not performed a formal analysis, but we believe our ability to use such net operating losses and tax credit carryforwards will be subject to annual limitations, due to change of ownership control provisions under Section 382 and 383 of the Internal Revenue Code, which would significantly impact our ability to realize these deferred tax assets.

Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes as of December 31, 2024 and 2023 are as follows in thousands: SCHEDULE OF COMPONENTS OF NET DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20241231_zkLbQDERqsCc" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20231231_ztbKZE3IeGrj" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzGLT_zLRznv18jCC5" style="vertical-align: bottom; background-color: White"> <td style="width: 64%; text-align: left">Stock-based compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,438</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,438</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzGLT_zXWDbsfhiMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,304</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pn3n3_maDTAGzGLT_zVJZLYfrXQPf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Liability accruals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">324</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pn3n3_maDTAGzGLT_z0Pq6tvnemZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">R&D Credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,372</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,372</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_iI_pn3n3_maDTAGzGLT_z36k9vipZn0h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Capital Loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">528</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--IncomeTaxReconciliationStateAndLocalIncomeTax_iI_pn3n3_maDTAGzGLT_zwQSvboDVs5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred state tax</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,087</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,065</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzGLT_z2vuAU7d9Jc4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net operating loss carry forward</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,024</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,489</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzGLT_maDTANzNCY_zApxU5oLpVAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,760</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,390</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANzNCY_z1rblL4yvjV9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less - valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,760</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,390</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANzNCY_z4g1gsArotL8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

1438000

1174000

1304000

311000

324000

1372000

528000

-2087000 -2065000

10024000

10489000

12760000

13390000

12760000

13390000

Portions of these carryforwards will expire through 2038, if not otherwise utilized.

NOTE 14 – COMMITMENTS AND CONTINGENCIES Leases Currently, the Company is leasing the office located at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 on a month-to-month basis until such time a new office is identified. The Company believes the office is sufficient for its current operations. PointR Merger Consideration The total purchase price in the PointR Merger of $<span id="xdx_90B_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--PointRMergerMember_z3AJPjj2EInc">17,831,427 included $<span id="xdx_902_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pp0p0_c20241231__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__dei--LegalEntityAxis__custom--PointRMergerMember_zCzHxKi2UcE1">2,625,000 of contingent consideration of shares issuable to PointR shareholders, upon achievement of certain milestones. For more information on the PointR Merger Contingent Consideration, refer to our 2021 Annual Report on Form 10-K filed with the SEC on April 12, 2024. Third Party Service Provider Claim The Company had disputed a judgement of $20,000 for a non-payment to a third service provider. The Company considered the claim to be immaterial to the financial position of the Company. The Company had filed a counter claim on the third-party service provider as the Company believed the claim to be false and malicious to the interests of the Company. In March 2024, The Honorable Court overruled the previous judgement and ruled in favor of the Company. Other claims From time to time, the Company may become involved in certain claims arising in the ordinary course of business. One of the Company’s ex-employees has made a breach of employment contract claim against the Company. The Company and its legal counsel are evaluating the validity of the claim, as the Company believes that such claim has limited merits and is hopeful to attain a positive outcome for such claim. Since the Company and its legal counsel are still evaluating the claim, we are unable to quantify the amount such claim would be settled at, if at all settled.

17831427

2625000

20000

NOTE 15 – SUBSEQUENT EVENTS In March 2025, the Company announced of successfully completing a Phase 1 clinical trial evaluating OT-101, in combination with IL-2 for advanced or metastatic solid tumors, on behalf of the JV. These results set the stage for new studies that combine OT-101, an antisense therapeutic targeting Transforming Growth Factor Beta 2 (TGFβ2), with checkpoint inhibitors (“CKIs”) and recombinant IL-2 (aldesleukin) (“IL-2”). The Phase 1 trial (ClinicalTrials.gov ID: NCT04862767) investigated the safety and tolerability of OT-101 in combination with recombinant IL-2 in patients with advanced or metastatic solid tumors. The combination showed a tolerable safety profile at the planned dosing schedule, with no unexpected safety signals identified. Based on the favorable safety data, the JV, through the Company, plans to advance OT-101 plus IL-2 into further clinical studies, exploring synergies with CKIs such as PD-1 blockers.